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Cataracts are the leading cause of blindness and low vision throughout the
world.  Millions of people suffer as a result of this debilitating disease, and millions of
dollars are spent annually on cataract removal surgery, which is the only cure.  Genes
have been identified which cause cataracts when mutated in man and/or mouse.
Understanding the functions of these genes, as well as the mechanisms involved in
cataract formation may help us to develop ways to prevent, delay, or cure cataracts.
Animal models have contributed significantly to our understanding of normal lens
development, as well as abnormal development and cataract formation.  With the
recent advances in canine genomics, the dog has become a promising model for
studying the molecular aspects of ocular diseases.  Furthermore, inherited cataracts
occur in over 20 breeds of dog.
The chromosomal locations of 21 genes known to cause cataracts in man,
and/or mouse were determined in the canine genome using a Radiation-Hybrid
mapping technique.  This created a tool which could facilitate association and linkage
analysis in canine pedigrees with inherited cataracts.  Next, the canine homologue of
the cataract-associated gene PAX6 was selected for cloning and characterization, and
was found to have remarkable homology with the human gene.  Finally, canine PAX6
was evaluated for mutations causing cataract, aniridia, persistent pupillary membranes,
sclero-cornea, and choroidal hypoplasia.  Direct sequence analysis of PAX6 in affected
dogs revealed only single nucleotide polymorphisms and microsatellite changes.
However, further pedigree information and analysis is needed to definitively rule out
PAX6’s involvement in these ocular diseases.
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INTRODUCTION
Approximately half of all human blindness is caused by cataracts, making
them the most significant cause of visual impairment worldwide (1).  The cure for
cataracts is surgical removal of the opacified lens and its replacement with an artificial
intra-ocular lens (IOL).  Approximately 1.4 million cataract surgeries are performed
annually in the United States (2).  Both the public health, and economics of our society
will greatly benefit from identification of the etiologies and mechanisms of cataract
formation.
A cataract is any opacity of the normally transparent ocular lens, or its
surrounding capsule.  Cataracts may be caused by injury or trauma to the lens or lens
capsule, infection (e.g. rubella), systemic disease (e.g. diabetes mellitus), drugs (e.g.
steroids), heredity, or age-related changes in the lens.  Cataracts are described by their
location within the lens, their morphology or physical characteristics, their disease
progression, and when in the patient’s life they occur.  Nuclear cataracts occur in the
center, or nucleus of the lens, while cortical cataracts occur in the outer area
surrounding the nucleus (Figure 1.1).  Capsular cataracts occur in the lens capsule
which surrounds the entire lens, and subcapsular opacities occur just under the
capsule. Opacities associated with the anterior or posterior lens sutures are referred to
as sutural cataracts, and those present at the lens periphery where the zonular fibers
connect the lens to the ciliary body, are considered equatorial or zonular.  Polar
opacities occur at the center (pole) of the anterior or posterior lens surface, while axial
opacities go through the central pole of the lens.
In addition to their location, cataracts are described by their morphology,
which varies greatly.  Punctate cataracts are small opaque specks while pulverulent
2Figure 1.1. Lens diagram.  Cataracts occur in different locations
within the lens including the central nucleus, outer cortex, or in
association with the lens capsule.  In addition, lens opacities may be
associated with the anterior or posterior Y-sutures.  Cataract
locations are further described as anterior, posterior, polar or
zonular depending on their position within the lens.
3cataracts have multiple specks that appear like dust, and can be fine (tiny) or coarse
(large) in texture.  Cuneiform cataracts look like cones, wedges or spikes, and
coraliform cataracts resemble sea coral with finger-like extensions.  There are also
stellate or star-like opacities as well as other shapes.  In addition to morphology, some
cataracts reflect different wavelengths of light and appear brunescent (brown) or
cerulean (blue) in color.
Along with location in the lens and morphology, cataracts are described by
their stage of development.  Cataracts can remain stagnant or progress in their
maturity.  Early or incipient cataracts usually involve less than 15% of the lens and
may not affect vision.  A cataract may grow from this stage into an immature cataract
involving more than 15% of the lens.  Immature cataracts usually compromise vision
to some degree.  Mature cataracts are those which involve the entire lens and cause
blindness.  These often result in swelling of the lens which may in turn, result in
degeneration of the zonular fibers, lens subluxation, or luxation, impingement upon
the ciliary body, obstruction of aqueous humor outflow and the development of
secondary glaucoma.  A hypermature cataract is one in which the cortex of the lens
has liquified resulting in a decrease in the total lens size. The liquified cortex may
escape into the anterior or posterior ocular chambers causing inflammation and lens-
induced uveitis. The final stage of cataract progression is known as the Morgagnian
stage in which the integrity of the cortex is so compromised that it can no longer
support the solid nucleus, causing it to sink ventrally.  All cataracts do not necessarily
proceed through all 5 stages of progression. A cataract may arrest in one stage
indefinitely or progress to some degree and then remain stagnant.
Cataracts can be present at birth (congenital), or occur at any time throughout
life.  Cataracts occur most commonly in the elderly and over half of the population
aged 80 and older have evidence of cataract formation, or have had cataract surgery
4(3).  The etiology of age-related cataracts is not fully understood, however, the
interaction between an individual’s genetic background and exposure to certain
environmental risk factors suggests the importance of heredity in the development of
senile cataracts.  Factors such as UV light exposure (4), alcohol consumption (5), and
cigarette smoking (6), are associated with an increased risk of cataract formation,
while several nutrients have been associated with a decreased risk of cataract
formation (7, 8).
Although age-related cataracts are more common, congenital cataracts are an
important disease in children, and represent the most common cause of treatable
childhood blindness in the United States and in Europe (9, 10).  Approximately 33%
of all congenital cataracts are inherited (11), but as more cataract genes are identified,
this percentage will likely increase.  The study of congenital cataracts has contributed
significantly to our understanding of the molecular bases of inherited cataracts because
of the early manifestation of the phenotype, and the ease of diagnosis, both of which
facilitate molecular genetic studies.  Cataracts may be inherited as autosomal
dominant (12-14) , autosomal recessive (15-17) or X-linked (18, 19) traits.
The identification of genes involved in cataract formation has advanced our
understanding of normal lens biology, and the factors that regulate both lens
transparency, and pathology.  In addition, the identification of cataract genes and
mutations has revealed both genetic and phenotypic heterogeneity.  The occurrence of
the same cataract phenotypes in patients with mutations in different genes is an
example of genetic heterogeneity.  For example, in man, pulverulent nuclear cataracts
may result from mutations in crystallin genes; CRYBB1 (20), CRYBB2 (21), or
CRYGC (22), as well as gap junction proteins; connexin 46 (23), and connexin 50
(24).  Alternatively, the occurrence of different cataract phenotypes in patients with
mutations in the same gene reveals phenotypic heterogeneity.  For example, in man,
5mutations in CRYGC can cause either pulverulent nuclear cataracts (22), or lamellar
cataracts (25).  Molecular genetic studies are needed to increase our understanding of
the relationship between cataract phenotypes and their corresponding genetic
mutations, which will help to explain the genetic and phenotypic heterogeneity
observed. Such heterogeneity however, makes it difficult to perform direct linkage
studies in man, and to combine linkage data from different families in order to obtain
statistically significant logarithm of odds (LOD) scores.  The use of animal models has
helped to overcome this difficulty.
Animal models
There are many benefits to using animal models in molecular genetic studies.
Laboratory animals can be readily examined for phenotypic evaluation, and they can
be examined often and over long periods of time to follow disease progression.  They
can also be housed in regulated environments with controlled exposure to risk factors
such as diet and ultraviolet light. The typically shorter life-span and generation
interval of animal models also facilitates the observation of disease progression, and
allows the generation of large pedigrees which can provide statistically significant data
for association and linkage studies.  Increased progeny numbers, and planned
breedings, also help in determining the mode of inheritance for a particular disease.  In
addition, animal models provide ready access to blood, and tissue samples necessary
for DNA analysis, as well as RNA and protein expression studies.  Animal models are
also important in determining the efficacy and safety of gene therapy protocols before
using them in people.
6Mouse models
Both normal and pathological development of ocular structures, and the
corresponding genes involved, have been attained through the study of mouse
embryos (26).  The molecular and developmental pathology of mouse cataract models
has been instrumental in advancing our knowledge of the mechanisms underlying
cataract formation (27).  There are over 60 inherited cataracts described in the mouse
(11).  In addition, there are over 35 cataract loci, from which mutations have been
identified in at least 19 genes that cause cataracts as a primary phenotype (28).
Although mouse models have been used extensively to study the genetics of
human diseases, they can have some limitations.  For example, mutations in the same
genes can result in different phenotypes in the mouse versus man.  Mutations in PAX6
cause aniridia in man, a disease characterized by partial to complete absence of the iris
(29, 30).  However, spontaneous Pax6 mutations in the mouse result in the “small eye”
phenotype, which is characterized by microphthalmia, cataracts and small body size
(31, 32).  Similarly, mutations in PITX3 cause cataracts and anterior segment
mesenchymal dysgenesis in man (33, 34), but cause aphakia (absence of the lens) in
the mouse (35, 36).
Another limitation in mouse models is the lack of certain phenotypes which
occur in man. This may result from the lack of naturally occurring mutations in
homologous genes, or from the lack of anatomical structures in the mouse which are
present in man. For example, mice do not have a macula and therefore cannot be used
as direct anatomical models for diseases affecting the macula such as age-related
macular degeneration (AMD) and Stargardt’s disease, a recessive form of macular
degeneration (37) (38). Similarly, mice do not have a fovea and cannot anatomically
replicate diseases such as foveal hypoplasia (39, 40). Since only primates have
maculas and foveas they would make ideal animal models for these diseases.
7In an effort to overcome the lack of naturally occurring mouse mutations,
genetic engineering techniques have been used to generate new  phenotypes in hope of
creating diseases in the mouse that resemble those seen in man. These techniques
include the use of radiation, or chemicals like ethylnitrosourea (ENU), to induce
mutations, as well as transgenic, and targeted gene knockout techniques.  Such genetic
engineering projects may generate artificial mutations in mice, but again, the
phenotypes seen may not be similar to those in man. Furthermore, transgenic
techniques often randomly insert foreign DNA into the mouse genome using non-
homologous recombination techniques.  The foreign DNA or gene is then subject to
the promoters, enhancers, and regulators present at its new location in the mouse
genome.  This new environment may affect the temporal-spatial expression of the
inserted fragment in such a way that it fails to recreate the desired molecular and
phenotypic characteristics. Targeted gene knockout techniques also have tremendous
variability depending on the strain of mouse used and the corresponding genetic
background.  Hence, a gene knockout may be lethal in one mouse strain but not in
another.
Today, there are a variety of animal models to choose from for molecular
studies, including: insects, fish, amphibians, birds, and mammals.  Each model has
strengths and weaknesses, and the anatomical and physiological properties of one
model may be more appropriate than another in studying a particular disease, or a
specific aspect of a particular disease.  Historically, the mouse model has been used
extensively, and as a result, has well developed genetic tools and documented genetic
engineering techniques.  However, as genetic resources develop for other species, and
genomic sequences become available, opportunities will emerge to choose new animal
models based on how well their anatomy, physiology, and phenotypes match the
8diseases of man. Given this choice, a canine model for human ocular diseases becomes
desirable.
Canine models
The dog model has many of the same benefits as other animal models
including access for phenotypic evaluation, and a short life-span which facilitates the
manifestation of age-related phenotypes earlier than would be achieved in man.  The
short generation interval, along with the use of selective mating, allows production of
informative progeny, determination of disease mode of inheritance, and the generation
of large pedigrees for association and linkage analysis with increased statistical power.
Canine models, as other models, also provide ready access to tissue samples for
histopathology, DNA, RNA, and protein analysis.  However, dogs have additional
advantages in that there are over 300 different dog breeds which exhibit great
interbreed phenotypic variation while exhibiting minimal intrabreed differences (41-
44).  In this way, individual dog breeds function as genetic isolates which often show
increased frequency of certain genetic disorders (45).  For example, autosomal
recessive diseases are seen with increased frequency in genetically isolated breed
populations, thus creating unique opportunities for genetic study. The tremendous
natural genetic variation of dog breeds also provides a large reservoir of allelic
differences which can be used to study genetic diseases and traits (41, 46).
Additionally, dogs can be selectively inbred to eliminate heterogeneous genetic
background, and selectively outbred to reveal genetic background effects on
phenotypic expression (41). Furthermore, the dog is physiologically similar to man,
and suffers from many naturally occurring diseases which are biologically,
histologically, and clinically similar to their human counterparts (41, 47). These
qualities make the dog an ideal model for the study of human diseases.  Finally, the
9dog also represents a large animal model intermediate between the mouse and man
that can be used for in vivo testing of gene therapy techniques.
Progress in canine genetics has created the genetic basis on which to study
inherited diseases in dogs, and has made this species a viable option for phenotypic
evaluation and gene discovery (48). Resources for molecular studies using canine
models include somatic cell (49) and bacterial artificial chromosome (BAC) libraries
(50), canine linkage maps (51-53), a cytogenic map characterized by fluorescent in
situ hybridization (FISH) (54), canine-rodent somatic cell hybrid lines for radiation
hybrid (RH) mapping (55), and RH-maps of the canine genome (56-58).  Additional
resources include integrated RH/linkage maps (59, 60), and an integrated 4249 marker
FISH/RH map of the canine genome (61).  Comparative maps of canine and human
chromosomes reveal homologous segments between both species allowing
comparative genetic studies (54, 62, 63).  The creation of Minimal Screening Sets
(MSS), consisting of subsets of microsatellite markers dispersed over the entire canine
genome, facilitate genome wide scans for candidate genes on chromosomes linked to
disease phenotypes (64-66).  Finally, the 1.5X (poodle) (67), and 7.5X (boxer) (68)
genomic sequences have been tremendous assets in advancing the use of canine
models in molecular biology.
Canine genetic resources have already been used successfully to map
homologous human disease-associated genes (e.g. TSC2- tuberous sclerosis 2, PKD1-
polycystic kidney disease 1, and CLN3- ceroid lipofuscinosis neuronal 3) in the dog
(CFA6) and show that there is often greater homology between human and dog
chromosomes than between human and mouse chromosomes (69).   These resources
were also instrumental in mapping canine early retinal degeneration (erd) to
chromosomal segments homologous to HSA12 (70), progressive rod-cone
degeneration (prcd) to CFA9 (71, 72), and hereditary renal carcinoma to CFA 5 (73).
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Linkage analysis and positional cloning led to the identification of a mutation in the
canine hypocretin-2 receptor gene in a family of Doberman pinschers with inherited
narcolepsy (74).  This finding was pivotal in establishing the subsequent identification
of hypocretin mutations in human narcolepsy patients (75-77).
Progress in canine genomics has also helped to identify canine models of
human ocular diseases.  For example, the locus for recessively inherited, human
achromatopsia or colorblindness (ACHM3) links to HSA8q21-22 (78, 79) and is
caused by mutations in the cyclic nucleotide-gated channel beta-subunit gene
(CNGB3) (80).  Similarly, naturally occurring, recessively inherited retinal cone
degeneration (cd) in Alaskan malamutes and German shorthaired pointers, links to
CFA29 in a region homologous to HSA8, and is caused by mutations in the same
gene; CNGB3 (81).  Cone degeneration in dogs is homologous to achromatopsia in
man at both the phenotypic and molecular levels making the dog an excellent model
for this disease.
Retinitis pigmentosa (RP) in man is a heterogeneous group of inherited
diseases characterized by the loss of photoreceptors and progressive retinal
degeneration.  RP can have a recessive, dominant or X-linked mode of inheritance.  A
subset of autosomal dominant forms of RP are caused by mutations in the rhodopsin
gene which codes for the light absorbing pigment found in rod photoreceptors (82-84).
Naturally occurring rhodopsin mutations in English mastiff dogs also result in
dominantly inherited retinal degeneration, making these dogs excellent canine models
for rhodopsin RP in man (85-87).
Human X-linked retinitis pigmentosa 3 (XLRP3) is caused by mutations in the
retinitis pigmentosa GTPase regulator (RPGR) gene (88).  X-linked progressive
retinal atrophy (XLPRA) in Siberian huskies was the first X-linked retinal
degeneration in animals ever reported and the first canine retinal degeneration disease
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assigned to a chromosome (89, 90).  Like the human disease, canine XLPRA is also
caused by mutations in the RPGR gene, creating yet another canine model which is
homologous with the human disease phenotypically, genetically, and with regard to
mode of inheritance (91).
Autosomal recessive congenital stationary night blindness (csnb) and retinal
dystrophy in the briard dog are caused by naturally occurring mutations in the RPE65
gene (92-94).  These diseases are homologous to Leber’s congenital amaurosis type 2
(LCA2) and autosomal recessive retinitis pigmentosa in man (respectively), and both
of these disorders are also caused by RPE65 mutations (95-98).  The briard has been
used successfully as the first large animal model to test gene therapy for LCA (99-
101).
Canine cataracts
The advances in canine genetics, identification of homologous canine models
for human diseases, and the successful use of dogs in translational and gene therapy
studies encourages the development of canine models for molecular studies of
cataract. Primary or isolated cataracts, which occur without other ophthalmic or
systemic diseases, occur in 164 of the approximately 300 recognized dog breeds
worldwide (102).   Over 20 dog breeds have naturally occurring inherited cataracts,
and an additional 40 breeds have a high incidence of breed-related cataracts which are
suspected of being inherited (102, 103).  Inherited cataracts have been documented in
Labrador (104, 105), golden (104, 106, 107), and Chesapeake Bay (108) retrievers,
Bishon Frise (109, 110), standard poodles (111, 112), American cocker spaniels (113,
114), German shepherds (115), German Pinschers (116), Rottweilers (117), Tibetan
terriers (118), Afghan hounds (119), dachshunds (120), Leonbergers (121), and
Entlebucher mountain dogs (122-124).
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Congenital, inherited cataracts have been described in the miniature schnauzer
(125-129), Welsh springer spaniel (130), cocker spaniels (131), West Highland white
terrier (132), old English sheepdog (133), chow chow (134), Norwegian buhund (135),
akita (136), and English cocker spaniel breeds (137). Recently, cataract-associated
mutations in the heat shock factor 4 (HSF4) gene were identified in Staffordshire bull
terriers, Boston terriers, and Australian shepherds, making these 3 breeds the first with
cataracts described at the molecular level (138).
Normal lens development
To begin to understand how, when, and why cataracts develop, one must first
understand normal lens development.   In the early embryo, the prosencephalon
evaginates to form the optic vesicle day 9.5 in the mouse (139), day 15-17 in the dog
(140, 141), and day 24 (Carnegie stage 11) in man (142). This optic vesicle induces
the overlying surface ectoderm to thicken and form the lens placode which will
invaginate and pinch off to form the lens vesicle, day 10-12 in the mouse (139), day
25 in the dog (140, 141), and day 33 (Carnegie stage 13) in man (142).  Initially, the
lens vesicle is a hollow sphere surrounded by a single layer of epithelial cells.
However, the posterior cells of the vesicle are induced by the developing retina to
elongate and form primary lens fibers.  The elongating primary lens fibers fill the
cavity of the lens vesicle, and produce crystallin proteins which fill the cells as they
lose their nuclei and organelles (26).  These primary lens fiber cells form the nucleus
of the lens.  Secondary lens fibers originate from the germinal epithelium of the
anterior lens vesicle.  These anterior epithelial cells divide and produce new cells
which migrate toward the lens vesicle equator, where they elongate and form
secondary lens fibers.  Like primary lens fibers, the secondary fibers lose their nuclei,
and organelles, but unlike primary fibers, they are produced throughout life and
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continue to elongate and pack around the core of primary lens fibers repeatedly
(Figure 1.2).
The function of the lens is to refract light rays, and to focus them on to the
retina. To accomplish this task, the lens must be transparent.  The normal transparency
of the lens is dependent upon many factors. 1) The structural proteins of the lens
including the intermediate filaments which are part of the cytoskeleton, as well as cell
matrix proteins must be organized in a precise network which allows light to pass
through.  Also, the soluble crystallin proteins which comprise over 90% of the proteins
in the lens, are essential for normal lens development and transparency.  2) Lens
membrane proteins form intercellular junctions, and channels between cells which are
critical for maintaining ionic homeostasis, necessary for lens clarity.  3) Finally,
transcription factors are critical for regulating the temporal-spatial gene expression
necessary for normal lens morphogenesis.  Because lens transparency is dependent
upon structural proteins, membrane proteins, and transcription factors, the genes
which encode these proteins are key candidate genes for cataract phenotypes.
1. Lens structural proteins
a. Intermediate filaments
The cytoskeleton of lens cells, like other cells, is made up of microtubules,
actin filaments, and intermediate filaments, which determine cell size, shape, and
motility, and which organize and support the cytoplasm.  During lens fiber cell
differentiation, however, crystallins are produced, and the cytoskeleton is altered as
the cell loses its nucleus and membranous organelles, and drastically elongates (143,
144).  The type III intermediate filament, vimentin, is expressed in lens epithelial cells,
and in early, differentiating lens fiber cells, but it is lost in mature lens fiber cells
(145).  However, beaded filament structural protein 1 (BFSP1, filensin, CP115) and
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Figure 1.2. Developing canine eye from an approximately 30 day-old fetus,
with structures labeled.
Eyelid
Cornea
Lens
Eyelid
Retinal pigment epithelium
Neural retina
Anterior lens epithelium
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BFSP2 (phakinin, CP49) are lens-specific intermediate filaments (146), which are not
expressed in lens epithelial cells, but are expressed in the plasma membrane of young
differentiating fiber cells, and in the cytoplasm of older, more mature fiber cells which
have lost their nuclei (145).  These two intermediate filaments heterodimerize, and
form a special beaded filament structure in the lens (147).  Alpha crystallins may also
be required for the assembly of beaded filament (148), and their function as molecular
chaperones may in turn, be facilitated by their incorporation in this cytoskeletal
structure (149).  BFSP1 and  2, and their assembly into beaded filament, are not
required for normal lens development, but are required to maintain lens clarity (150,
151).
Mutations in BFSP1 (152),and BFSP2 (153-155) cause non-congenital cataract
in man.  Similarly, a progressive increase in light scatter, and decrease in lens optical
clarity, are observed in Bfsp1 (150), and Bfsp2 (151, 156) knockout mice.  In addition,
the organization of the lens fiber cell plasma membrane is altered in Bfsp2 knockout
mice, which suggests that the plasma membrane and its interaction with the
cytoskeleton, play a role in lens clarity (156).  Furthermore, strains  of mice have been
identified with naturally occurring Bfsp2 mutations, and these mice also show
increased light scatter which progresses with age (157-159).
b. Cell matrix glycoprotein
Another structural protein of the lens is secreted protein, acidic, cysteine-rich
(SPARC), also known as osteonectin.  SPARC is a calcium-binding, glycoprotein that
interacts with collagen, and other extra-cellular matrix proteins, and regulates cell-
matrix interactions (160-162).   It also determines the production and deposition of the
basement membrane protein laminin-1, in lens epithelial cells (163, 164).  In addition,
SPARC regulates cellular adhesions (163, 164) (160, 162), as well as cell shape and
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morphology (161, 162, 165, 166).  SPARC is important in maintaining lens cell
osmotic homeostasis by regulating cell size, shape, and water content (165).  It is
required for normal differentiation and elongation of lens fiber cells, and normal lens
function (167, 168).
SPARC is widely expressed in both embryonic and adult tissues including the
lens, and is important for cellular proliferation and turnover (166, 169).  In the human
eye, SPARC is expressed in lens epithelial cells, and lens capsule, but not in the
differentiated lens fiber cells of the nucleus or cortex (170, 171).  In addition, SPARC
is expressed in the aqueous humor, vitreous, cornea, ciliary epithelium, and retina
(170).  Similarly, in rodent eyes, Sparc is expressed in lens epithelial cells, lens
capsule epithelia, cornea, sclera, ciliary body, choroid and retina (163, 172).  The
expression of SPARC is increased in human senile cataract (171, 173), and mice with
targeted disruption of the Sparc gene appear normal at birth but developed lens
vacuoles, cataract, and ruptured lens capsule (167, 168, 174). This suggests that
SPARC is not required for the initial development of a normal lens, but is required for
maintenance of lens clarity, and lens capsule integrity.
c. Soluble structural proteins: crystallins
Crystallins are divided into three main classes based on their molecular weight.
These including alpha, beta, and gamma crystallins, which together, make up 90% of
the soluble protein of the lens (175).  Crystallin proteins form dimers, trimers, or
oligomers with themselves and other crystallins, which are important in maintaining
both crystallin stability and solubility, which in turn are necessary for lens
transparency (175-177).  As well, crystallins contribute to lens transparency through
their unique spatial order and arrangement in the lens, as well as their refractive index
gradient (175).  The formation of cataracts is associated with the unfolding of
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crystallins and formation of insoluble aggregates that often associate with membrane
proteins (175).  Primary and secondary lens fiber cells synthesize crystallin proteins
that fill the cell and contribute to the loss of cell nuclei and organelles (26).  Since the
lens fiber cells are continuously added to the lens, but never lost, the crystallins must
be stable enough to last throughout life.  The expression of crystallin genes in the lens
is regulated by transcription factors including Maf (178-180) Prox1 and Six3 (181),
Pax6 (178, 182, 183) and, Sox 1 (184).
Alpha crystallins are important for normal lens development, and are the first
crystallins to be expressed during lens development, in the lens vesicle and lens
epithelial cells (175).  Alpha crystallins function as small heat shock proteins, and
molecular chaperones which stabilize lens proteins and prevent protein aggregation
(185).  The formation of protein aggregates in the lens is thought to contribute to the
loss of lens clarity.  Alpha crystallins also interact with other crystallins, as well as
with the cytoskeleton and beaded filament, and these interactions are thought to be
crucial for their normal function as heat shock proteins and molecular chaperones
(186).  There are two types of alpha crystallins; acidic alpha crystallin (CRYAA), and
basic alpha crystallin (CRYAB).  Mutations in alpha crystallins cause cataracts in man
(13, 15, 187-191), and mouse (192, 193).
Beta and gamma crystallins are both part of a superfamily of proteins which
contain four Greek key motifs.  However, beta crystallins form dimers, while the
gamma crystallins form monomers, and are particularly stable in dehydrated
environments (175).  The Greek key motifs are important in calcium binding, and in
interactions with other proteins (194, 195). Thus, mutations which disrupt the Greek
key motif may interfere with calcium binding and disturb normal lens ionic
homeostasis, which in turn, could alter lens transparency.  Likewise, disruption of the
Greek key motifs may interfere with the ability of beta, and gamma crystallins to bind
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or interact with other proteins, to form monomers, dimers and other aggregates
important in maintaining lens clarity.  Beta, and gamma crystallins are expressed in
the lens fiber cells during development and are required for normal differentiation and
elongation of the lens fiber cells (179, 180, 186).
Beta crystallins are divided into two groups; CRYBA and CRYBB.  There are
four CRYBA crystallin genes (CRYBA1, CRYBA2, CRYBA3, CRYBA4), and three
CRYBB crystallin genes (CRYBB1, CRYBB2, CRYBB3).  Mutations in the beta
crystallins cause cataracts in man (196) (20, 21, 197, 198)  and in mouse (199-201).
There are at least seven gamma crystallins in mammals including CRYGA, B, C, D, E,
F, and S, where CRYGE, and F are pseudogenes (202).  Mutations in gamma
crystallins cause cataract in man (25, 203-205), and mouse (206-210).
2. Membrane proteins
Because the lens is avascular and does not contain blood vessels, the transport
system created by membrane proteins is critical for supplying nutrients throughout the
lens, especially to the centrally located lens fiber cells.  This transport system must
also remove waste products. Membrane proteins are also critical for maintaining the
osmotic homeostasis within the lens fiber and epithelial cells.  Abnormalities in
osmotic gradients in the lens can alter the solubility of proteins, causing them to
aggregate and precipitate, resulting in refractive index changes, light scatter, and
cataract.
The connexin family of transmembrane proteins form gap junctions between
cells which allow passage of ions and small molecules.  These intercellular channels
are composed of six connexin units arranged in a hexamer to form a pore in the cell
membrane which unites with that of an adjacent cell (211).  Connexins are expressed
in the developing blastomere, and throughout life, and are important for maintaining
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ionic gradients within the cell (211).  Connexins can open and close in response to pH
and ionic gradients across cells, and are important for maintaining osmotic
homeostasis which is necessary for normal lens clarity.  While there are at least 20
different connexins in man, only Connexins 43, 46, and 50 are expressed in the lens
(212).  These connexins are expressed during development in the embryonic lens
vesicle, and later in the lens epithelial and fiber cells, and are important in the
development and elongation of lens fibers (213, 214).   Connexin 46 (Cx46) and
Connexin 50 (Cx50) knockout mice show loss of solubility and abnormal precipitation
of crystallins, and the development of nuclear cataract (215, 216).  Mutations in CX50,
also known as gap junction protein alpha 8 (GJA8), cause cataract in man (24, 217-
221), and mouse (222-225).  And mutations in CX46 (GJA3) cause cataract in man
(23, 226-231).
Lens membrane proteins form transport channels between cells important in
regulating and maintaining osmotic homeostasis.  These channels transport water,
ions, and molecules between communicating cells.  Major intrinsic protein of lens
fiber 26 (MIP26), also known as lens instrinsic membrane protein1 (LIM1), or
aquaporin 0 (AQP0), is the most abundant membrane protein in the lens, and is a
member of the aquaporin family of water transport proteins (232) (233).   This
membrane protein allows transport of water molecules between cells, and helps to
maintain normal ionic homeostasis in lens cells (232, 233).  In turn, the function of the
MIP26 water channel is regulated by calcium and hydrogen ions in the cell (234).
MIP26 is expressed during embryogenesis in the differentiating primary lens fiber
cells, and continues to be expressed in adult secondary lens fibers (235, 236).
Mutations in MIP26 cause cataract in man (236, 237), and mouse (238-240).
Lens intrinsic membrane protein 2 (LIM2), also called membrane protein 19
(MP19), is the second most abundant lens membrane protein.  It is expressed during
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embryogenesis (241) and plays a role in the development of lens fiber cells, forming
intercellular channels between lens fiber and epithelial cells (186).  Mutant Lim2
proteins fail to localize to cell membranes in mice with cataracts (242), suggesting that
the presence of Lim2 in the membrane is necessary for normal lens transparency.
LIM2 mutations cause cataract in man (16), and mouse (243-245).
3. Transcription factors
Transcription factors bind to specific DNA sequences and can promote or
inhibit gene expression. When transcription factors bind to gene promoters they
initiate gene transcription, while binding to gene enhancers, or silencers, can increase
or decrease transcription respectively.  In addition to binding to target DNA
sequences, transcription factors can bind to, and interact with other transcription
factors.  They regulate the temporal, and spatial expression of genes and are important
in lens development, growth, and maintenance.  As a result, abnormalities in
transcription factors which are involved in eye and lens morphogenesis can affect the
time and location of the expression of critical genes during lens development, growth
and maintenance, and adversely affect lens transparency.  Mutations in a number of
transcription factors are associated with cataracts in man and mouse.
The transcription factors; CEH10 homeodomain-containing homolog
(CHX10), eyes absent 1 (EYA1), forkhead box E3 (FOXE3), and paired box 6
(PAX6) are all expressed during embryogenesis, and are important regulators for
ocular development.  CHX10 is expressed in the progenitor cells of the fetal retina,
and in the inner nuclear layer of the adult retina (246). Although CHX10 is only
expressed in the retina, mutations in CHX10 cause microphthalmia, cataracts and iris
abnormalities (246). This suggests that the developing retina is correlated to the
development of the rest of the eye.
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EYA1 is expressed in the developing CNS, and eye, including the lens placode,
corneal ectoderm, iris, ciliary body, retinal pigment epithelium (RPE), and optic nerve
(247).  Expression of Eya1 in the lens placode requires Pax6 (247).  EYA1 functions
as both a transcription factor (248) as well as a protein-tyrosine phosphatase enzyme
(249).  The transcription factor EYA1 binds to and interacts with other transcription
factors including SIX1 and SIX2 (250).  Mutations in EYA1 cause congenital cataracts
and anterior segment abnormalities in man (251).
FOXE3 is a member of the forkhead box (FOX) family of genes.  It is
expressed in the developing eye, in the lens placode, lens vesicle, and undifferentiated
anterior lens epithelial cells (252).  FOXE3 is a transcription factor which regulates
lens development, and in particular the closing of the lens vesicle and its pinching off
from the surface ectoderm (252).  Also, within the lens epithelium, FOXE3 regulates
cell proliferation and differentiation (252).  Mutations in FOXE3 cause anterior
segment dysgenesis and cataract (253), and aphakia (254) in man, and dysgenetic lens
in mouse, characterized by cataract and fusion of the lens and cornea (252).
Paired box 6 (PAX6) is one of nine transcription factors in the PAX family
(255). It has both homeo, and paired domains which bind to DNA target sequences.
This transcription factor is the master control gene for eye development and is
essential for normal eye formation.  It is required for the differentiation of the surface
ectoderm into lens placode (256), and targeted expression of Pax6 produces ectopic
eyes in Xenopus (257) and Drosophila (258).  PAX6 regulates a plethora of genes both
directly and indirectly (259, 260), including the crystallin genes (261, 262), and other
transcription factors including MAF (263), the EYA genes (1, 2, & 3) (247), and itself
(256, 264).   PAX6 is expressed in the central nervous system (CNS), eye, nose, and
pancreas in mouse (139, 256, 265, 266), and in man (29, 267).  Mutations in PAX6 are
dominant to semidominant, and homozygous lethal, causing cataract, and
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micropthalmia (small eye) in the mouse (31, 265, 268), and aniridia, foveal
hypoplasia, cataract, and corneal abnormalities in man (29, 30, 269-273).
The transcription factors heat shock factor 4 (HSF4), paired-like homeodomain
transcription factor 3 (PITX3), & sex-determining region Y (SRY) box 1 (SOX1), are
also expressed during embryogenesis, and play critical roles in lens development.
HSF4 is a member of the heat shock factor family of transcription factors which
regulate the transcription of heat shock proteins and molecular chaperones in response
to heat shock or other stresses.  HSF4 binds to the heat shock response element, and
represses transcription of heat shock response genes (274).  In man, HSF4 is expressed
in brain, heart, muscle and pancreas (274).  In mouse, Hsf4 is expressed in the
developing and adult lens anterior epithelium, and fiber cells and regulates the
differentiation of secondary lens fibers (275).   Hsf4 also regulates expression of
gamma crystallins in the developing and adult lens (276), and Hsf4 null mice maintain
lens fiber cell nuclei and organelles, causing lens opacity (275).  Mutations in HSF4
cause cataract in man (277, 278), mouse (279) and in dogs (138).
PITX3 is a transcription factor in the pituitary homeobox (PTX) family.  It is
important in eye, brain, and pituitary development, and is involved in the regulation of
Foxe3 (280).  In the developing lens, Pitx3 is expressed in the lens placode (281, 282),
and throughout the lens vesicle, including the anterior lens epithelium and lens equator
(283). Mutations in PITX3 cause cataract (34, 284-286), and anterior segment
mesenchymal dysgenesis (ASMD) in man (33), and aphakia in mouse (35, 36).
The SOX family of transcription factors, like SRY protein, contains a high
mobility group (HMG) DNA-binding domain.  A member of this family, SOX1, is
expressed in the developing nervous system, as well as the lens fiber cells and the
anterior lens epithelium of the developing lens (184, 287).  SOX1 regulates expression
of crystallin genes (184, 288, 289), and is required for normal lens development and
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elongation of the lens fiber cells (184).  Sox1 null mice have cataracts and
microphthalmia (184).
The musculoaponeurotic fibrosarcoma homologue (MAF) family of genes
encode basic leucine-zipper (b-ZIP) transcription factors which bind as homo, and
heterodimers to DNA targets, and function as regulators of cell differentiation (290).
During embryogenesis, Maf is expressed in the lens placode, lens vesicle, lens fiber
cells, epithelial cells and optic nerve (180, 291). However, in the adult mouse, Maf
expression is restricted to the secondary lens fibers (180).  During lens development,
Maf is required for normal differentiation, and elongation of lens fiber cells, and for
crystallin gene expression (179, 180, 291).  As a result, targeted mutations of the Maf
gene in mice result in abnormal lens development with lens fibers that fail to elongate
normally, and that contain decreased expression of crystallin genes (179, 180, 291).
Mutations in MAF cause cataract in man (292-294) and mouse (295, 296).
The transcription factor homologue of Drosophila Sine oculis homeo box 5
(SIX5) is a member of the sine oculis family of homeobox genes.  SIX5 interacts with
EYA1 to activate gene transcription (297), and also plays a role in maintaining ionic
homeostasis in the lens, which is necessary for lens transparency (298, 299).  SIX5 is
expressed in the lens epithelium, cornea, ciliary body, and retina in man (300), and in
mouse (298, 299).  Mutations in Six5 cause cataracts in mice (298, 301).
Radiation hybrid mapping
Transcription factors, membrane proteins, and structural proteins in the lens
are all critical for normal lens development and function, and the genes which encode
these proteins are candidates for cataract formation in dogs.  In order to study these
genes in dogs their locations in the canine genome should first be identified.
Radiation hybrid mapping is a technique used to locate genes and markers on
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chromosomes.  This technique requires the creation of a radiation hybrid panel of cells
created by fusing cells from two species.  Canine-hamster radiation hybrid cell lines
have been made by irradiating thymidine kinase positive (TK+) canine fibroblast cells
to fragment their chromosomes, and then fusing these cells with TK-negative hamster
cells (55).  To select fused cells containing canine DNA, only those cells which are
TK(+ ) are chosen for inclusion in a radiation hybrid panel.  Each hybrid cell contains
a random complement of canine chromosome fragments, and hamster DNA.  Enough
canine-hamster radiation hybrid cells are then selected for a panel to represent the
entire canine genome.
Canine-specific PCR primers designed for genes or markers of interest, can
then be used to amplify DNA from each radiation hybrid cell line in the panel.  Only
those cell lines containing the chromosomal fragment on which the gene or marker is
located will produce a positive PCR reaction.  The resulting pattern of positive and
negative PCR reactions from each cell line can then be analyzed statistically using
software such as MULTIMAP (302).  Such analysis reveals the predicted location of
genes and markers in relation to one another, or in relation to a set of established
markers when information from previously determined markers is combined with
current data.
A canine-hamster RH3000 panel (containing canine fibroblast cells irradiated
with 3000 rads of radiation) is available commercially (Research Genetics, Inc.,
Huntsville, AL), and consists of 92 cell lines, and an RH5000 panel (created using
5000 rads of radiation) containing 126 cell lines is available to the academic
community (55, 56).   The location of genes on canine chromosomes can be
determined using these radiation hybrid panels.  Establishing the location of cataract
genes in the canine genome in relation to established markers creates a tool for
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association and linkage testing in pedigrees segregating cataract phenotypes, and also
facilitates the development of the dog as a model for molecular studies.
PAX6
Although the Paired box 6 (PAX6) gene is associated with cataracts in both
man (271, 303), and mouse (304), mutations in PAX6 are also the primary cause of
human aniridia (270, 305).  Aniridia is an ocular condition characterized by the
complete, or nearly complete absence of the iris.  Normally, the iris is composed of
three layers.  1) The anterior epithelial layer of the iris, derived from ectoderm, is
visible when looking at the eye and determines the eye color. This layer crosses the
iridocorneal angle and is continuous with the posterior epithelium of the cornea.  2)
The stromal layer, which lies beneath the anterior epithelia, is derived from
mesenchyme, and is composed of connective tissue and muscle.  The sphincter muscle
located at the pupillary circumference of the iris causes pupil constriction, while the
dilator muscle composed of radial fibers spanning from the outer ciliary portion of the
iris to the inner pupillary portion, causes pupil dilation.  3) The posterior pigmented
epithelium, or innermost layer, lies posterior to the stromal layer of the iris.  It is an
extension of the retinal pigment epithelium (RPE) and therefore is derived from
ectoderm.
All three layers of the iris are partially or completely missing in patients with
aniridia.   The mechanism of the pathogenesis of aniridia is not known but there are at
least three theories: 1) aniridia results from abnormal migration and/or proliferation of
mesenchymal cells, 2) aniridia results from abnormalities at the tip of the optic cup
which derives from neuroectoderm, or 3) aniridia is a result of abnormal remodeling,
and regression of iris tissue which involves inappropriate apoptosis (306).  In man,
aniridia is often accompanied by other ocular abnormalities such as cataract, corneal
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opacification, foveal hypoplasia, nystagmus and glaucoma (OMIM#106210).
Aniridia has also been described in the Catalan sheepdog breed in Spain (307).
Affected dogs have classic aniridia phenotype with practically complete absence of the
iris, and, like man, some dogs also have cataract, corneal opacity, and glaucoma.
Because the vast majority of human aniridia cases are caused by mutations in PAX6
(270, 305), this gene is also a prime candidate for canine aniridia.
PAX6 Expression
In the mouse, Pax6 expression is first detected at embryonic day 8 (E-8), in the
surface ectoderm, prosencephalon, rhombencephalon (hindbrain), and spinal cord
(139, 256).  In the developing eye, Pax6 is expressed in the optic sulcus at day 8.5,
optic vesicle at day 9.5, and in the optic cup, surface ectoderm, lens placode, and lens
vesicle, between days 10-12 (139, 256).  Pax6 expression is maintained in the surface
ectoderm as it develops into the anterior corneal epithelium, and conjunctiva, and in
the lens vesicle as it forms the lens (139, 256, 308).  The surface ectoderm thickens to
form the lens placode, which invaginates and pinches off to form the lens vesicle
which will form the lens, while the remaining surface ectoderm gives rise to the
cornea, conjunctiva, and eye lids.  Pax6 expression is crucial for the induction of the
lens placode from the surface ectoderm (256, 309).  As well, Pax6 is expressed in the
optic stalk (day 12.5) as it forms a trough for optic nerve elongation, and in the inner
and outer layers of the optic cup (day 10.5) as they form the developing neural retina,
and pigmented retinal epithelium, respectively (139, 256). In chick embryos, Pax6 is
expressed at the distal tip of the optic cup, and in the developing iris smooth muscle
and epithelium (310)
Similarly, in man PAX6 expression is first detected between day 22-23 in the
neural tube, and later in the forebrain, hindbrain, somites, and spinal cord (267).  In 6
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week-old human embryos, PAX6 is expressed in the surface ectoderm, lens vesicle, the
inner and outer layers of the optic cup and the optic stalk (311).  By 8-22 weeks,
expression is present in the developing cornea, conjunctiva, and lens, as well as the
developing retina, and ciliary epithelia (29, 311).  The inner layer of the optic cup
develops into the neural retina while the outer layer develops into the retinal pigment
epithelium (RPE).  At the distal tip of the optic cup, the outer layer of pigmented
epithelium will form the ciliary body, the posterior layer of the iris, and the sphincter
and dilator muscles within the stromal layer of the iris.  Also, the connective tissue of
the iris stromal layer derives from neural crest cells and mesoderm, while the blood
vessels originate from the hyaloid vasculature which originated from angiogenic
mesenchyme (141).  After 21 weeks, PAX6 expression in the retina is restricted to the
inner nuclear, and ganglion cell layers (311). In the adult human eye, PAX6 continues
to be expressed in the cornea, and lens (312), and in the inner nuclear, and ganglion
cell layers of the retina (313).
To date, no studies have been done to determine PAX6 expression in canine
embryos, or in adult dogs.  However, if the expression of PAX6 in the dog is similar to
that of the mouse and man, then it should occur in the same developing structures,
including the CNS, eye, nose, and pancreas.  Likewise, within the developing canine
eye, PAX6 expression would occur within the same developing ocular structures as
man and mouse, but at their unique time of development in the dog.  Thus, PAX6
expression in the canine optic vesicle and lens placode would occur at days 15-17,
expression in the optic cup, at day 19, in the lens vesicle at days 19-25, and in the
differentiating retina, at days 25-33 (140, 141).  Although this is purely speculative,
the consistency in Pax6 expression patterns across species supports these assumptions
(314).
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PAX6 mutations cause a variety of ocular phenotypes
Mutations in PAX6 cause a wide variety of ocular phenotypes in addition to
cataracts and aniridia.  These include: corneal dystrophy, keratitis, iris coloboma,
ectopic pupil, foveal hypoplasia, and optic nerve dystrophy (OMIM# 607108).  In
addition, mutations in PAX6 have also been associated with Peter’s anomaly (315),
nystagmus (40), and microphthalmia (303).  Furthermore, PAX6 is expressed in
multiple structures of the eye during development including the surface ectoderm, lens
placode, lens vesicle, optic cup, optic stalk, retina, cornea, conjunctiva, and the ciliary
body and iris (29, 267, 311-313).  The wide variety of phenotypes associated with
PAX6 mutations, the number of ocular structures involved, and the pervasive
expression of PAX6 during eye morphogenesis, make this gene a candidate for a wide
variety of ocular diseases.
Siberian huskies with cataract
Naturally occurring hereditary cataracts have been documented in over 20
breeds of dog (102, 103, 138).  Siberian huskies are predisposed to developing
cataracts (103), and have an increased prevalence of primary cataracts when compared
with other dog breeds in North America (102).  Hereditary cataracts in Siberian
huskies are typically posterior cortical, and can be present at birth (congenital), or
develop very early, typically being diagnosed by 1.5 years of age (102).  These
cataracts may be unilateral or bilateral, and may remain static or progress to a total
cataract. The mode of inheritance is unknown.  The association of PAX6 with cataracts
in man (40, 271, 303, 316) and in mouse (31, 304), and its expression in the
embryonic surface ectoderm, lens placode, lens vesicle, and lens (29, 139, 256, 311),
make PAX6 a prime candidate for cataracts in Siberian huskies.
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Basenjis with persistent pupillary membranes
During prenatal development, a vascular structure called the tunica vasculosa
lentis (TVL) provides the anterior and posterior blood supply of the embryonic lens.
This structure is developed in man by 9 weeks of gestation, and is formed from the
hyaloid vasculature derived from embryonic mesoderm (317).  The anterior part of the
TVL lies posterior to the iris and is continuous with the pupillary membrane, which is
supplied by the major arterial circle, and the posterior ciliary arteries (317).  The
pupillary membrane regresses 10-12 days postnatally in the mouse (318), while in man
this membrane begins to regress late in gestation, and may continue to regress after
birth (317).  Similarly, in dogs, the hyaloid blood vessels begin to regress prenatally in
late gestation (day 45), while the pupillary membranes continue to regress postnatally
until around day 14 (103).  The presence of the pupillary membrane, beyond this
period, is considered abnormal.  The precise mechanism responsible for the normal
attenuation and regression of the pupillary membrane vasculature is unclear, but
involves apoptosis and macrophage-mediated phagocytosis of endothelial cells (319).
Strands of PPM originate at the iris collarette; the junction between the inner
pupillary, and outer ciliary zones of the iris.  From the iris collarette, strands may cross
the pupil and connect back to the iris, or connect from iris to cornea, or iris to lens.  If
the strands connect iris to iris there is usually little consequence, and vision is not
affected.  However, iris to cornea and iris to lens strands can result in areas of opacity
at the attachment site, leading to corneal or lens opacities respectively.  In some cases,
PPM may have one connection to the iris and one end floating free within the aqueous
humor of the anterior chamber.  In more severe cases, the pupil is obstructed and
deprivation amblyopia may result. Such cases require surgical intervention to remove
the obstructing membrane over the pupil and allow light to pass through to the retina.
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Inherited, congenital PPM occurs in Basenji dogs (103, 320-324). The mode of
inheritance for this disease is not clear, but Basenjis often have strands which connect
the iris collarette to the cornea and cause corneal opacities which may affect normal
vision.  In man, PPM can occur in association with aniridia (325, 326).  Patients with
PAX6 mutations have also been observed with PPM in conjuction with
circumpupillary aplasia (partial aniridia), and nystagmus (327).  These patients may
also have cataract, corneal dystrophy, foveal hypoplasia, and hypoplastic optic nerve
heads.  Another patient with a PAX6 mutation had PPM with nystagmus, cataract,
optic nerve hypoplasia, and iris ectropion (a condition where the pigmented epithelium
of the posterior iris protrudes into the anterior iris) (328). In addition, some PAX6
mutations are associated with persistent hyperplastic primary vitreous (PHPV) in man
(329). This supports a relationship between PAX6 and phenotypes involving intra-
ocular vascular structures. The association of PPM with aniridia phenotypes, the
association of aniridia with PAX6 mutations, and the identification of patients with
PAX6 mutations which have PPM, as well as those with PHPV, supports the selection
of this gene for evaluation in dogs with PPM.
Soft-coated wheaten terriers with persistent pupillary membrane, sclero-cornea, and
choroidal hypoplasia
Soft-coated wheaten terriers (SCWTs) have been observed with congenital
ocular abnormalities including lens luxation/subluxation, cataract, microphthalmia,
PPM, corneal edema, sclero-cornea, and choroidal hypoplasia (330).  Similarly,
SCWTs with a recessively inherited, ocular syndrome consisting of PPM, sclero-
cornea, and choroidal hypoplasia were observed by a veterinary ophthalmologist in
our laboratory.  Some of these dogs also had cataracts, and/or microcornea; however,
lens luxation/subluxation, microphthalmia, and corneal edema were not observed.
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PAX6 was evaluated in SCWTs with PPM, sclero-cornea, and choroidal hypoplasia
because mutations in PAX6 have been associated with these abnormalities.
Persistent pupillary membranes and their association with PAX6 were
described above.  Sclero-cornea is a condition where the limbic border is obscured by
an invasion of scleral tissue into the cornea.  The sclera is the white, fibrous, outer
covering of the eye, composed of elastin and collagen fibers. The connective tissue of
the sclera develops from neural crest (141).  The cornea is the transparent, avascular
covering over the iris, pupil, and aqueous humor of the anterior eye chamber. The
refraction of light rays as they pass through the cornea is important for normal vision.
An elevated density of sensory nerve fibers in the cornea make it extremely sensitive
to stimuli, while the lack of blood vessels gives the cornea immune privilege.  The line
of demarcation between the transparent cornea and the fibrous sclera is referred to as
the limbus.  When the white sclera invades the clear cornea, obscuring the normal
limbus, sclero-cornea results, and vision is adversely affected.  PAX6 is expressed in
both the developing (29, 311), and adult (312) cornea.  In man, mutations in PAX6 can
cause corneal dystrophy, corneal opacity, pannus and autosomal dominant keratitis
(OMIM#106210).  In addition, a missense mutation in the PAX6 paired domain results
in sclero-cornea with microphthalmia (331) (332).  Because PAX6 mutations cause
corneal diseases as well as sclero-cornea, this gene is a candidate for sclero-cornea in
SCWTs.
The uvea is the pigmented vascular structure of the eye, composed of the iris,
the ciliary body and the choroid.  The choroid is located between the outer sclera, and
the inner retina and is continuous with the ciliary body and iris.  The choroid is
composed of pigmented cells called melanocytes which derive from neural crest cells,
as well as blood vessels which derive from angiogenic mesoderm, and connective
tissue derived from both neural crest and mesoderm (141).  The lack of development
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of the choroid layer of the eye, characterized by areas of depigmentation (paleness), is
referred to as choroidal hypoplasia.  Since the choroid is derived from both neural
crest and mesodermal cells, abnormalities in either could contribute to the
development of choroidal hypoplasia. Mutations in PAX6 are associated with
abnormal development of the uvea including the iris, and ciliary body (305), as well as
the choroid (329).  As a result, PAX6 is a candidate gene for choroidal hypoplasia in
SCWTs.
Conclusion
Cataracts are a major cause of visual impairment throughout the world.
Molecular studies using animal models can help us to identify genes associated with
cataract formation. The objective of my research has been to develop the dog as an
animal model for the study of molecular aspects of cataractogenesis.  To facilitate the
development and use of canine models to study cataracts, 21 cataract candidate genes
were mapped to canine chromosomes in relation to microsatellite, and gene markers
(chapter 2).  This created a resource which could be used to test for association and
linkage of these cataract candidate genes with cataract phenotypes in canine pedigrees.
The cataract candidate gene PAX6 was then chosen as the first gene for further
evaluation.  This gene was cloned, and characterized, and compared with the
homologous human and mouse genes (Chapter 3).  Because of its close association
with human aniridia, the canine PAX6 gene was also evaluated for association with
aniridia in a family of Catalan sheepdogs.  In addition, PAX6 was examined for
mutations associated with cataracts, persistent pupillary membranes, sclero-cornea,
and choroidal hypoplasia in three different canine breeds (Chapter 4).
This research has helped to develop the dog as a viable animal model for molecular
studies of cataract, and other inherited ocular diseases which occur in man
33
REFERENCES
1. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R,
Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull
World Health Organ 2004;82(11):844-51. Epub 2004 Dec 14.
2. NEI/NIH. Mission and Challenges for Vision Research Report. In:
National Eye Institute; 2006.
(http://www.nei.nih.gov/resources/strategicplans/neiplan/frm_mission.asp)
3. NEI/NIH. Vision Problems in the U.S.:Prevalence of adult vision
impairment and age-related eye diseases in America. Report. Bethesda, Maryland:
National Eye Institute; 2002. Report No.: Publication No. EY-47.
(http://catalog.nei.nih.gov/productcart/pc/viewPrd.asp?idcategory=25&idproduct=47)
4. West S. Ocular ultraviolet B exposure and lens opacities: a review. J
Epidemiol 1999;9(6 Suppl):S97-101.
5. Manson JE, Christen WG, Seddon JM, Glynn RJ, Hennekens CH. A
prospective study of alcohol consumption and risk of cataract. Am J Prev Med
1994;10(3):156-61.
6. Klein BE, Klein R, Linton KL, Franke T. Cigarette smoking and lens
opacities: the Beaver Dam Eye Study. Am J Prev Med 1993;9(1):27-30.
7. Mares-Perlman JA, Brady WE, Klein BE, Klein R, Haus GJ, Palta M,
Ritter LL, Shoff SM. Diet and nuclear lens opacities. Am J Epidemiol
1995;141(4):322-34.
8. Mares-Perlman JA, Lyle BJ, Klein R, Fisher AI, Brady WE,
VandenLangenberg GM, Trabulsi JN, Palta M. Vitamin supplement use and incident
cataracts in a population-based study. Arch Ophthalmol 2000;118(11):1556-63.
9. Evans CA. 1995 Presidential Address. Public health: vision and reality.
Am J Public Health 1996;86(4):476-9.
10. Evans J, Rooney C, Ashwood F, Dattani N, Wormald R. Blindness and
Partial Sight in England and Wales: April 1990 - March 1991. Health Trends
1996;28:5-12.
34
11. Weigong H, Shibo L. Congenital cataracts: gene mapping. Human
Genetics 2000;106(1):1-13.
12. Bateman JB, Spence MA, Marazita ML, Sparkes RS. Genetic linkage
analysis of autosomal dominant congenital cataracts. Am J Ophthalmol
1986;101(2):218-225.
13. Litt M, Kramer P, LaMorticella DM, Murphey W, Lovrien EW,
Weleber RG. Autosomal dominant congenital cataract associated with a missense
mutation in the human alpha crystallin gene CRYAA. Hum Mol Genet 1998;7(3):471-
474.
14. Ionides A, Francis P, Berry V, Mackay D, Bhattacharya S, Shiels A,
Moore A. Clinical and genetic heterogeneity in autosomal dominant cataract. Br J
Ophthalmol 1999;83(7):802-808.
15. Pras E, Frydman M, Levy-Nissenbaum E, Bakhan T, Raz J, Assia EI,
Goldman B, Pras E. A nonsense mutation (W9X) in CRYAA causes autosomal
recessive cataract in an inbred Jewish Persian family. Invest Ophthalmol Vis Sci
2000;41(11):3511-3515.
16. Pras E, Levy-Nissenbaum E, Bakhan T, Lahat H, Assia E, Geffen-
Carmi N, Frydman M, Goldman B. A missense mutation in the LIM2 gene is
associated with autosomal recessive presenile cataract in an inbred Iraqi Jewish
family. Am J Hum Genet 2002;70(5):1363-7. Epub 2002 Mar 26.
17. Riazuddin SA, Yasmeen A, Yao W, Sergeev YV, Zhang Q, Zulfiqar F,
Riaz A, Riazuddin S, Hejtmancik JF. Mutations in betaB3-crystallin associated with
autosomal recessive cataract in two Pakistani families. Invest Ophthalmol Vis Sci
2005;46(6):2100-2106.
18. Stambolian D, Lewis RA, Buetow K, Bond A, Nussbaum R. Nance-
Horan syndrome: localization within the region Xp21.1-Xp22.3 by linkage analysis.
Am J Hum Genet 1990;47(1):13-19.
19. Francis PJ, Berry V, Hardcastle AJ, Maher ER, Moore AT,
Bhattacharya SS. A locus for isolated cataract on human Xp. J Med Genet
2002;39(2):105-109.
35
20. Mackay DS, Boskovska OB, Knopf HL, Lampi KJ, Shiels A. A
nonsense mutation in CRYBB1 associated with autosomal dominant cataract linked to
human chromosome 22q. American Journal of Human Genetics 2002;5:1216-1221.
21. Gill D, Klose R, Munier FL, McFadden M, Priston M, Billingsley G,
Ducrey N, Schorderet DF, Heon E. Genetic heterogeneity of the Coppock-like
cataract: a mutation in CRYBB2 on chromosome 22q11.2. Invest Ophthalmol Vis Sci
2000;41(1):159-65.
22. Ren Z, Li A, Shastry BS, Padma T, Ayyagari R, Scott MH, Parks MM,
Kaiser-Kupfer MI, Hejtmancik JF. A 5-base insertion in the gammaC-crystallin gene
is associated with autosomal dominant variable zonular pulverulent cataract. Hum
Genet 2000;106(5):531-7.
23. Mackay D, Ionides A, Kibar Z, Rouleau G, Berry V, Moore A, Shiels
A, Bhattacharya S. Connexin46 mutations in autosomal dominant congenital cataract.
Am J Hum Genet 1999;64(5):1357-64.
24. Berry V, Mackay D, Khaliq S, Francis PJ, Hameed A, Anwar K, Mehdi
SQ, Newbold RJ, Ionides A, Shiels A, Moore T, Bhattacharya SS. Connexin 50
mutation in a family with congenital "zonular nuclear" pulverulent cataract of
Pakistani origin. Hum Genet 1999;105(1-2):168-70.
25. Santhiya ST, Shyam Manohar M, Rawlley D, Vijayalakshmi P,
Namperumalsamy P, Gopinath PM, Loster J, Graw J. Novel mutations in the gamma-
crystallin genes cause autosomal dominant congenital cataracts. J Med Genet
2002;39(5):352-8.
26. Gilbert SF. Chapter 12: The central nervous system and the epidermis.
In: Developmental Biology. 6 ed. Sunderland, MA: Sinauer Associates, Inc; 2000. p.
399-403.
27. Francis PJ, Berry V, Moore AT, Bhattacharya S. Lens biology:
development and human cataractogenesis. Trends Genet 1999;15(5):191-6.
28. MGI. Mouse Genome Informatics & Database (MGD). In: The Jackson
Laboratory, Bar Harbor, Maine; 2007. (http://www.informatics.jax.org/)
36
29. Ton CC, Hirvonen H, Miwa H, Weil MM, Monaghan P, Jordan T, van
Heyningen V, Hastie ND, Meijers-Heijboer H, Drechsler M, et al. Positional cloning
and characterization of a paired box- and homeobox-containing gene from the aniridia
region. Cell 1991;67(6):1059-74.
30. Glaser T, Walton DS, Maas RL. Genomic structure, evolutionary
conservation and aniridia mutations in the human PAX6 gene. Nat Genet.
1992;2(3):232-239.
31. Hill RE, Favor J, Hogan BL, Ton CC, Saunders GF, Hanson IM,
Prosser J, Jordan T, Hastie ND, van Heyningen V. Mouse small eye results from
mutations in a paired-like homeobox-containing gene. Nature 1991;354(6354):522-5.
32. Hogan BL, Hirst EM, Horsburgh G, Hetherington CM. Small eye
(Sey): a mouse model for the genetic analysis of craniofacial abnormalities.
Development 1988;103(Supplement):115-119.
33. Semina EV, Ferrell RE, Mintz-Hittner HA, Bitoun P, Alward WL,
Reiter RS, Funkhauser C, Daack-Hirsch S, Murray JC. A novel homeobox gene
PITX3 is mutated in families with autosomal-dominant cataracts and ASMD. Nat
Genet 1998;19(2):167-70.
34. Berry V, Yang Z, Addison PK, Francis PJ, Ionides A, Karan G, Jiang
L, Lin W, Hu J, Yang R, Moore A, Zhang K, Bhattacharya SS. Recurrent 17 bp
duplication in PITX3 is primarily associated with posterior polar cataract (CPP4). J
Med Genet 2004;41(8):e109.
35. Semina EV, Murray JC, Reiter R, Hrstka RF, Graw J. Deletion in the
promoter region and altered expression of Pitx3 homeobox gene in aphakia mice. Hum
Mol Genet. 2000;9(11):1575-1585.
36. Rieger DK, Reichenberger E, McLean W, Sidow A, Olsen BR. A
double-deletion mutation in the Pitx3 gene causes arrested lens development in
aphakia mice. Genomics 2001;72(1):61-72.
37. Weng J, Mata NL, Azarian SM, Tzekov RT, Birch DG, Travis GH.
Insights into the function of Rim protein in photoreceptors and etiology of Stargardt's
disease from the phenotype in abcr knockout mice. Cell 1999;98(1):13-23.
37
38. Karan G, Lillo C, Yang Z, Cameron DJ, Locke KG, Zhao Y,
Thirumalaichary S, Li C, Birch DG, Vollmer-Snarr HR, Williams DS, Zhang K.
Lipofuscin accumulation, abnormal electrophysiology, and photoreceptor
degeneration in mutant ELOVL4 transgenic mice: a model for macular degeneration.
Proc Natl Acad Sci U S A. 2005;102(11):4164-4169.
39. Azuma N, Nishina S, Yanagisawa H, Okuyama T, Yamada M. PAX6
missense mutation in isolated foveal hypoplasia. Nature Genetics 1996;13(2):141-142.
40. Hanson I, Churchill A, Love J, Axton R, Moore T, Clarke M, Meire F,
van Heyningen V. Missense mutations in the most ancient residues of the PAX6
paired domain underlie a spectrum of human congenital eye malformations. Hum Mol
Genet 1999;8(2):165-72.
41. Ostrander EA, Galibert F, Patterson DF. Canine genetics comes of age.
Trends in Genetics 2000;16:117-124.
42. Parker HG, Kim LV, Sutter NB, Carlson S, Lorentzen TD, Malek TB,
Johnson GS, DeFrance HB, Ostrander EA, Kruglyak L. Genetic Structure of the
Purebred Domestic Dog. Science 2004;304(5674):1160-1164.
43. Sutter NB, Ostrander EA, Guyon R, Lorentzen TD, Hitte C, Kim L,
Cadieu E, Parker HG, Quignon P, Lowe JK, Renier C, Gelfenbeyn B, Vignaux F,
DeFrance HB, Gloux S, Mahairas GG, Andre C, Galibert F, Everts RE, Versteeg SA,
Groot PC, Rothuizen J, van Oost BA, Tiret L, Kessler JL, Bentolila S, Faure S, Bach
JM, Weissenbach J, Panthier JJ, Mellersh CS, Richman M, Priat C, Jouquand S,
Werner P, DeRose S, Patterson DF, Neff MW, Broman KW, Ray K, Acland GM,
Aguirre GD, Ziegle JS, Rine J. Dog star rising: the canine genetic system. Nat Rev
Genet 2004;5(12):900-910.
44. Ostrander EA, Wayne RK. The canine genome. Genome Res
2005;15(12):1706-1716.
45. Peltonen L. Positional cloning of disease genes: advantages of genetic
isolates. Hum Hered 2000;50(1):66-75.
46. Ostrander EA, Giniger E. Semper fidelis: what man's best friend can
teach us about human biology and disease. American Journal of Human Genetics
1997;61(3):475-480.
38
47. Starkey MP, Scase TJ, Mellersh CS, Murphy S. Dogs really are man's
best friend--canine genomics has applications in veterinary and human medicine!
Briefings in functional genomics and proteomics 2005;4(2):112-128.
48. Ostrander EA, Kruglyak L. Unleashing the canine genome. Genome
Res 2000;10(9):1271-4.
49. Langston AA, Mellersh CS, Neal CL, Ray K, Acland GM, Gibbs M,
Aguirre GD, Fournier RE, Ostrander EA. Construction of a panel of canine-rodent
hybrid cell lines for use in partitioning of the canine genome. Genomics
1997;46(3):317-25.
50. Li R, Mignot E, Faraco J, Kadotani H, Cantanese J, Zhao B, Lin X,
Hinton L, Ostrander EA, Patterson DF, de Jong PJ. Construction and characterization
of an eightfold redundant dog genomic bacterial artificial chromosome library.
Genomics. 1999;58(1):9-17.
51. Mellersh CS, Langston AA, Acland GM, Fleming MA, Ray K,
Wiegand NA, Francisco LV, Gibbs M, Aguirre GD, Ostrander EA. A linkage map of
the canine genome. Genomics 1997;46(3):326-36.
52. Neff MW, Broman KW, Mellersh CS, Ray K, Acland GM, Aguirre
GD, Ziegle JS, Ostrander EA, Rine J. A second-generation genetic linkage map of the
domestic dog, Canis familiaris. Genetics 1999;151(2):803-20.
53. Werner P, Mellersh CS, Raducha MG, DeRose S, Acland GM, Prociuk
U, Wiegand N, Aguirre GD, Henthorn PS, Patterson DF, Ostrander EA, Breen M,
Langford CF, Carter NP, Holmes NG, Dickens HF, Thomas R, Suter N, Ryder EJ,
Pope M, Binns MM. Anchoring of canine linkage groups with chromosome-specific
markers. Mamm Genome 1999;10(8):814-23.
54. Breen M, Thomas R, Binns MM, Carter NP, Langford CF. Reciprocal
chromosome painting reveals detailed regions of conserved synteny between the
karyotypes of the domestic dog (Canis familiaris) and human. Genomics
1999;61(2):145-55.
55. Vignaux F, Hitte C, Priat C, Chuat JC, Andre C, Galibert F.
Construction and optimization of a dog whole-genome radiation hybrid panel. Mamm
Genome 1999;10(9):888-94.
39
56. Priat C, Hitte C, Vignaux F, Renier C, Jiang Z, Jouquand S, Cheron A,
Andre C, Galibert F. A whole-genome radiation hybrid map of the dog genome.
Genomics 1998;54(3):361-78.
57. Guyon R, Lorentzen TD, Hitte C, Kim L, Cadieu E, Parker HG,
Quignon P, Lowe JK, Renier C, Gelfenbeyn B, Vignaux F, DeFrance HB, Gloux S,
Mahairas GG, Andre C, Galibert F, Ostrander EA. A 1-Mb resolution radiation hybrid
map of the canine genome. Proc Natl Acad Sci U S A 2003;100(9):5296-301. Epub
2003 Apr 16.
58. Hitte C, Madeoy J, Kirkness EF, Priat C, Lorentzen TD, Senger F,
Thomas D, Derrien T, Ramirez C, Scott C, Evanno G, Pullar B, Cadieu E, Oza V,
Lourgant K, Jaffe DB, Tacher S, Dreano S, Berkova N, Andre C, Deloukas P, Fraser
C, Lindblad-Toh K, Ostrander EA, Galibert F. Facilitating genome navigation: survey
sequencing and dense radiation-hybrid gene mapping. Nat Rev Genet 2005;6(8):643-
8.
59. Mellersh CS, Hitte C, Richman M, Vignaux F, Priat C, Jouquand S,
Werner P, Andre C, DeRose S, Patterson DF, Ostrander EA, Galibert F. An integrated
linkage-radiation hybrid map of the canine genome. Mamm Genome 2000;11(2):120-
30.
60. Breen M, Jouquand S, Renier C, Mellersh CS, Hitte C, Holmes NG,
Cheron A, Suter N, Vignaux F, Bristow AE, Priat C, McCann E, Andre C, Boundy S,
Gitsham P, Thomas R, Bridge WL, Spriggs HF, Ryder EJ, Curson A, Sampson J,
Ostrander EA, Binns MM, Galibert F. Chromosome-specific single-locus FISH probes
allow anchorage of an 1800-marker integrated radiation-hybrid/linkage map of the
domestic dog genome to all chromosomes. Genome Res 2001;11(10):1784-95.
61. Breen M, Hitte C, Lorentzen TD, Thomas R, Cadieu E, Sabacan L,
Scott A, Evanno G, Parker HG, Kirkness EF, Hudson R, Guyon R, Mahairas GG,
Gelfenbeyn B, Fraser CM, Andre C, Galibert F, Ostrander EA. An integrated 4249
marker FISH/RH map of the canine genome. BMC Genomics 2004;5(1):65.
62. Yang F, O'Brien PC, Milne BS, Graphodatsky AS, Solanky N,
Trifonov V, Rens W, Sargan D, Ferguson-Smith MA. A complete comparative
chromosome map for the dog, red fox, and human and its integration with canine
genetic maps. Genomics 1999;62(2):189-202.
40
63. Sargan DR, Yang F, Squire M, Milne BS, O'Brien PC, Ferguson-Smith
MA. Use of flow-sorted canine chromosomes in the assignment of canine linkage,
radiation hybrid, and syntenic groups to chromosomes: refinement and verification of
the comparative chromosome map for dog and human. Genomics 2000;69(2):182-95.
64. Richman M, Mellersh CS, Andre C, Galibert F, Ostrander EA.
Characterization of a minimal screening set of 172 microsatellite markers for genome-
wide screens of the canine genome. Journal of biochemical and biophysical methods
2001;47(1-2):137-149.
65. Cargill EJ, Clark LA, Steiner JM, Murphy K, E. Multiplexing of canine
microsatellite markers for whole-genome screens. Genomics 2002;80(3):250-253.
66. Clark LA, Tsai KL, Steiner JM, Williams DA, Guerra T, Ostrander EA,
Galibert F, Murphy KE. Chromosome-specific microsatellite multiplex sets for
linkage studies in the domestic dog. Genomics 2004;84(3):550-554.
67. Kirkness EF, Bafna V, Halpern AL, Levy S, Remington K, Rusch DB,
Delcher AL, Pop M, Wang W, Fraser CM, Venter JC. The dog genome: survey
sequencing and comparative analysis. Science 2003;301(5641):1898-903.
68. Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB,
Kamal M, Clamp M, Chang JL, Kulbokas EJ, 3rd, Zody MC, Mauceli E, Xie X, Breen
M, Wayne RK, Ostrander EA, Ponting CP, Galibert F, Smith DR, DeJong PJ,
Kirkness E, Alvarez P, Biagi T, Brockman W, Butler J, Chin CW, Cook A, Cuff J,
Daly MJ, DeCaprio D, Gnerre S, Grabherr M, Kellis M, Kleber M, Bardeleben C,
Goodstadt L, Heger A, Hitte C, Kim L, Koepfli KP, Parker HG, Pollinger JP, Searle
SM, Sutter NB, Thomas R, Webber C, Baldwin J, Abebe A, Abouelleil A, Aftuck L,
Ait-Zahra M, Aldredge T, Allen N, An P, Anderson S, Antoine C, Arachchi H, Aslam
A, Ayotte L, Bachantsang P, Barry A, Bayul T, Benamara M, Berlin A, Bessette D,
Blitshteyn B, Bloom T, Blye J, Boguslavskiy L, Bonnet C, Boukhgalter B, Brown A,
Cahill P, Calixte N, Camarata J, Cheshatsang Y, Chu J, Citroen M, Collymore A,
Cooke P, Dawoe T, Daza R, Decktor K, DeGray S, Dhargay N, Dooley K, Dorje P,
Dorjee K, Dorris L, Duffey N, Dupes A, Egbiremolen O, Elong R, Falk J, Farina A,
Faro S, Ferguson D, Ferreira P, Fisher S, FitzGerald M, Foley K, Foley C, Franke A,
Friedrich D, Gage D, Garber M, Gearin G, Giannoukos G, Goode T, Goyette A,
Graham J, Grandbois E, Gyaltsen K, Hafez N, Hagopian D, Hagos B, Hall J, Healy C,
Hegarty R, Honan T, Horn A, Houde N, Hughes L, Hunnicutt L, Husby M, Jester B,
Jones C, Kamat A, Kanga B, Kells C, Khazanovich D, Kieu AC, Kisner P, Kumar M,
Lance K, Landers T, Lara M, Lee W, Leger JP, Lennon N, Leuper L, LeVine S, Liu J,
Liu X, Lokyitsang Y, Lokyitsang T, Lui A, Macdonald J, Major J, Marabella R, Maru
K, Matthews C, McDonough S, Mehta T, Meldrim J, Melnikov A, Meneus L, Mihalev
41
A, Mihova T, Miller K, Mittelman R, Mlenga V, Mulrain L, Munson G, Navidi A,
Naylor J, Nguyen T, Nguyen N, Nguyen C, Nicol R, Norbu N, Norbu C, Novod N,
Nyima T, Olandt P, O'Neill B, O'Neill K, Osman S, Oyono L, Patti C, Perrin D,
Phunkhang P, Pierre F, Priest M, Rachupka A, Raghuraman S, Rameau R, Ray V,
Raymond C, Rege F, Rise C, Rogers J, Rogov P, Sahalie J, Settipalli S, Sharpe T,
Shea T, Sheehan M, Sherpa N, Shi J, Shih D, Sloan J, Smith C, Sparrow T, Stalker J,
Stange-Thomann N, Stavropoulos S, Stone C, Stone S, Sykes S, Tchuinga P, Tenzing
P, Tesfaye S, Thoulutsang D, Thoulutsang Y, Topham K, Topping I, Tsamla T,
Vassiliev H, Venkataraman V, Vo A, Wangchuk T, Wangdi T, Weiand M, Wilkinson
J, Wilson A, Yadav S, Yang S, Yang X, Young G, Yu Q, Zainoun J, Zembek L,
Zimmer A, Lander ES. Genome sequence, comparative analysis and haplotype
structure of the domestic dog. Nature. 2005;438(7069):803-19.
69. Jonasdottir TJ, Mellersh CS, Moe L, Vignaux F, Ostrander EA,
Lingaas F. Chromosomal assignment of canine TSC2, PKD1 and CLN3 genes by
radiation hybrid- and linkage analyses. Anim Genet 2000;31(2):123-6.
70. Acland GM, Ray K, Mellersh CS, Langston AA, Rine J, Ostrander EA,
Aguirre GD. A novel retinal degeneration locus identified by linkage and comparative
mapping of canine early retinal degeneration. Genomics 1999;59(2):134-42.
71. Acland GM, Ray K, Mellersh CS, Gu W, Langston AA, Rine J,
Ostrander EA, Aguirre GD. Linkage analysis and comparative mapping of canine
progressive rod-cone degeneration (prcd) establishes potential locus homology with
retinitis pigmentosa (RP17) in humans. Proc Natl Acad Sci U S A 1998;95(6):3048-
53.
72. Sidjanin DJ, Miller B, Kijas J, McElwee J, Pillardy J, Malek J, Pai G,
Feldblyum T, Fraser C, Acland G, Aguirre G. Radiation hybrid map, physical map,
and low-pass genomic sequence of the canine prcd region on CFA9 and comparative
mapping with the syntenic region on human chromosome 17. Genomics
2003;81(2):138-48.
73. Jonasdottir TJ, Mellersh CS, Moe L, Heggebo R, Gamlem H, Ostrander
EA, Lingaas F. Genetic mapping of a naturally occurring hereditary renal cancer
syndrome in dogs. Proc Natl Acad Sci U S A 2000;97(8):4132-7.
74. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong
PJ, Nishino S, Mignot E. The sleep disorder canine narcolepsy is caused by a mutation
in the Hypocretin (Orexin) receptor 2 gene. Cell 1999;98:365-376.
42
75. Siegel JM. Narcolepsy: a key role for hypocretins (orexins). Cell
1999;98(4):409-412.
76. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin
(orexin) deficiency in human narcolepsy. The Lancet 2000;355(9197):39-40.
77. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y,
Nevsimalova S, M. A, Reynolds D, Albin R, Li R, Hungs M, Pedrazzoli M, Padigaru
M, Kucherlapati M, Fan J, Maki R, Lammers GJ, Bouras C, Kucherlapati R, Nishino
S, Mignot E. A mutation in a case of early onset narcolepsy and a generalized absence
of hypocretin peptides in human narcoleptic brains. Nature Genetics 2000;6(9):991-
997.
78. Milunsky A, Huang XL, Milunsky J, DeStefano A, Baldwin CT. A
locus for autosomal recessive achromatopsia on human chromosome 8q. Clinical
Genetics 1999;56(1):82-85.
79. Winick JD, Blundell ML, Galke BL, Salam AA, Leal SM, Karayiorgou
M. Homozygosity mapping of the Achromatopsia locus in the Pingelapese. American
Journal of Human Genetics 1999;64(6):1679-1685.
80. Kohl S, Baumann B, Broghammer M, Jagle H, Sieving P, Kellner U,
Spegal R, Anastasi M, Zrenner E, Sharpe LT, Wissinger B. Mutations in the CNGB3
gene encoding the beta-subunit of the cone photoreceptor cGMP-gated channel are
responsible for achromatopsia (ACHM3) linked to chromosome 8q21. Human
Molecular Genetics 2000;9(14):2107-2116.
81. Sidjanin DJ, Lowe JK, McElwee JL, Milne BS, Phippen TM, Sargan
DR, Aguirre GD, Acland GM, Ostrander EA. Canine CNGB3 mutations establish
cone degeneration as orthologous to the human achromatopsia locus ACHM3. Hum
Mol Genet 2002;11(16):1823-33.
82. Dryja TP, McGee TL, Reichel E, Hahn LB, Cowley GS, Yandell DW,
Sandberg MA, Berson EL. A point mutation of the rhodopsin gene in one form of
retinitis pigmentosa. Nature 1990;343(6256):364-366.
83. Berson EL, Rosner B, Sandberg MA, Dryja TP. Ocular findings in
patients with autosomal dominant retinitis pigmentosa and a rhodopsin gene defect
(Pro-23-His). Arch Ophthalmol 1991;109(1):92-101.
43
84. Cideciyan AV, Hood DC, Huang Y, Banin E, Li ZY, Stone EM, Milam
AH, Jacobson SG. Disease sequence from mutant rhodopsin allele to rod and cone
photoreceptor degeneration in man. Proc Natl Acad Sci U S A 1998;95(12):7103-
7108.
85. Kijas JW, Cideciyan AV, Aleman TS, Pianta MJ, Pearce-Kelling SE,
Miller BJ, Jacobson SG, Aguirre GD, Acland GM. Naturally occurring rhodopsin
mutation in the dog causes retinal dysfunction and degeneration mimicking human
dominant retinitis pigmentosa. Proc Natl Acad Sci U S A 2002;99(9):6328-33. Epub
2002 Apr 23.
86. Kijas JW, Miller BJ, Pearce-Kelling SE, Aguirre GD, Acland GM.
Canine models of ocular disease: outcross breedings define a dominant disorder
present in the English mastiff and bull mastiff dog breeds. Journal of heredity
2003;94(1):27-30.
87. Cideciyan AV, Jacobson SG, Aleman TS, Gu D, Pearce-Kelling SE,
Sumaroka A, Acland GM, Aguirre GD. In vivo dynamics of retinal injury and repair
in the rhodopsin mutant dog model of human retinitis pigmentosa. Proc Natl Acad Sci
U S A 2005;102(14):5233-5238.
88. Meindl A, Dry K, Herrmann K, Manson F, Ciccodicola A, Edgar A,
Carvalho MR, Achatz H, Hellebrand H, Lennon A, Migliaccio C, Porter K, Zrenner E,
Bird A, Jay M, Lorenz B, Wittwer B, D'Urso M, Meitinger T, Wright A. A gene
(RPGR) with homology to the RCC1 guanine nucleotide exchange factor is mutated in
X-linked retinitis pigmentosa (RP3). Nat Genet 1996;13(1):35-42.
89. Acland GM, Blanton SH, Hershfield B, Aguiree GD. XLPRA: a canine
retinal degeneration inherited as an X-linked trait. American Journal of Medical
Genetics 1994;52(1):27-33.
90. Zeiss CJ, Acland GM, Aguirre GD. Retinal pathology of canine X-
linked progressive retinal atrophy, the locus homologue of RP3. Invest Ophthalmol
Vis Sci 1999;40(13):3292-3304.
91. Zhang Q, Acland GM, Wu WX, Johnson JL, Pearce-Kelling S, Tulloch
B, Vervoort R, Wright AF, Aguirre GD. Different RPGR exon ORF15 mutations in
Canids provide insights into photoreceptor cell degeneration. Hum Mol Genet
2002;11(9):993-1003.
44
92. Narfstrom K, Wrigstad A, Nilsson SE. The Briard dog: a new animal
model of congenital stationary night blindness. British Journal of Ophthalmology
1989;73(9):750-756.
93. Aguirre GD, Baldwin V, Pearce-Kelling S, Narfstrom K, Ray K,
Acland GM. Congenital stationary night blindness in the dog: common mutation in the
RPE65 gene indicates founder effect. Mol Vis 1998;4(23).
94. Veske A, Nilsson SE, Narfstrom K, Gal A. Retinal dystrophy of
Swedish briard/briard-beagle dogs is due to a 4-bp deletion in RPE65. Genomics
1999;57(1):57-61.
95. Marlhens F, Bareil C, Griffoin JM, Zrenner E, Amalric P, Eliaou C, Liu
SY, Harris E, Redmond TM, Arnaud B, Claustres M, Hamel CP. Mutations in RPE65
cause Leber's congenital amaurosis. Nat Genet 1997;17(2):139-141.
96. Gu SM, Thompson DA, Srikumari CR, Lorenz B, Finckh U, Nicoletti
A, Murthy KR, Rathmann M, Kumaramanickavel G, Denton MJ, Gal A. Mutations in
RPE65 cause autosomal recessive childhood-onset severe retinal dystrophy. Nat Genet
1997;17(2):194-197.
97. Morimura H, Fishman GA, Grover SA, Fulton AB, Berson EL, Dryja
TP. Mutations in the RPE65 gene in patients with autosomal recessive retinitis
pigmentosa or leber congenital amaurosis. Proc Natl Acad Sci U S A
1998;95(6):3088-3093.
98. Thompson DA, Gyurus P, Fleischer LL, Bingham EL, McHenry CL,
Apfelstedt-Sylla E, Zrenner E, Lorenz B, Richards JE, Jacobson SG, Sieving PA, Gal
A. Genetics and phenotypes of RPE65 mutations in inherited retinal degeneration.
Invest Ophthalmol Vis Sci 2000;41(13):4293-4299.
99. Acland GM, Aguirre GD, Ray J, Zhang Q, Aleman TS, Cideciyan AV,
Pearce-Kelling SE, Anand V, Zeng Y, Maguire AM, Jacobson SG, Hauswirth WW,
Bennett J. Gene therapy restores vision in a canine model of childhood blindness. Nat
Genet 2001;28(1):92-5.
100. Narfstrom K, Katz ML, Bragadottir R, Seeliger M, Boulanger A,
Redmond TM, Caro L, Lai CM, Rakoczy PE. Functional and structural recovery of the
retina after gene therapy in the RPE65 null mutation dog. Invest Ophthalmol Vis Sci
2003;44(4):1663-1672.
45
101. Acland GM, Aguirre GD, Bennett J, Aleman TS, Cideciyan AV,
Bennicelli J, Dejneka NS, Pearce-Kelling SE, Maguire AM, Palczewski K, Hauswirth
WW, Jacobson SG. Long-term restoration of rod and cone vision by single dose
rAAV-mediated gene transfer to the retina in a canine model of childhood blindness.
Molecular Therapy 2005;12(6):1072-1082.
102. Gelatt KN, Mackay EO. Prevalence of primary breed-related cataracts
in the dog in North America. Vet Ophthalmol 2005;8(2):101-11.
103. Gelatt KN. Chapter 10: Diseases and surgery of the canine lens. In:
Katz S, editor. Essentials of Veterinary Ophthalmology. 1 ed. Baltimore, Maryland:
Lippincott Williams and Wilkins; 2000. p. 227-252.
104. Curtis R, Barnett KC. A survey of cataracts in golden and labrador
retrievers. Journal of Small Animal Practice 1989;30:277-286.
105. Sidjanin DJ, McElwee J, Miller B, Aguirre GD. Cloning of canine
galactokinase (GALK1) and evaluation as a candidate gene for hereditary cataracts in
Labrador retrievers. Anim Genet 2005;36(3):265-266.
106. Rubin LF. Cataract in Golden Retrievers. Journal of the American
Veterinary Medical Association 1974;165(5):457-458.
107. Gelatt KN. Cataracts in the Golden Retriever dog. Veterinary
Medicine/Small Animal Clinician 1972;67(10):1113-1115.
108. Gelatt KN, Whitley RD, Lavach JD, Barrie KP, Williams LW.
Cataracts in Chesapeake Bay Retrievers. Journal of the American Veterinary Medical
Association 1979;175(11):1176-1178.
109. Gelatt KN, Wallace MR, Andrew SE, MacKay EO, Samuelson DA.
Cataracts in the Bichon Frise. Vet Ophthalmol 2003;6(1):3-9.
110. Wallace MR, MacKay EO, Gelatt KN, Andrew SE. Inheritance of
cataract in the Bichon Frise. Vet Ophthalmol 2005;8(3):203-5.
46
111. Rubin LF, Flowers RD. Inherited cataract in a family of standard
poodles. Journal of the American Veterinary Medical Association 1972;161(2):207-
208.
112. Barnett KC, Startup FG. Hereditary cataract in the standard poodle.
Veterinary Research 1985;117(1):15-16.
113. Van Buskirk R. The lens epithelium of American cocker spaniels with
inherited and non-inherited lens cataracts. Research Veterinary Science
1977;22(2):237-242.
114. Yakely W. A study of heritability of cataracts in the American Cocker
Spaniel. Journal of the American Veterinary Medical Association 1978;172:814-817.
115. Barnett K. Hereditary cataract in the German shepherd. Journal of
Small Animal Practice 1986;27:387-395.
116. Leppanen M, Martenson J, Maki K. Results of ophthalmologic
screening examinations of German Pinschers in Finland--a retrospective study. Vet
Ophthalmol 2001;4(3):165-169.
117. Bjerkas E, Bergsjo T. Hereditary cataract in the Rottweiler dog.
Progress in Veterinary and Comparative Ophthalmology 1991;1:7-10.
118. Ketteritzsch K, Hamann H, Brahm R, Grussendor H, Rosenhagen CU,
Distl O. Genetic analysis of presumed inherited eye diseases in Tibetan Terriers. The
Veterinary Journal 2004;168(2):151-159.
119. Roberts SR, Helper LC. Cataracts in Afghan hounds. Journal of the
American Veterinary Medical Association 1972;160(4):427-432.
120. Muller C, Wohlke A, Distl O. Evaluation of three canine gamma-
crystallins (CRYGB, CRYGC, and CRYGS) as candidates for hereditary cataracts in
the dachshund. Mol Vis 2007;13:125-132.
121. Heinrich CL, Lakhani KH, Featherstone HJ, Barnett KC. Cataract in
the UK Leonberger population. Vet Ophthalmol 2006;9(5):350-356.
47
122. Spiess BM. [Inherited eye diseases in the Entlebucher mountain dog].
Schweiz Arch Tierheilkd. 1994;136(3):105-110.
123. Heitmann M, Hamann H, Brahm R, Grussendorf H, Rosenhagen CU,
Distl O. Analysis of prevalence of presumed inherited eye diseases in Entlebucher
Mountain Dogs. Vet Ophthalmol 2005;8(3):145-151.
124. Muller C, Wohlke A, Distl O. Evaluation of canine gamma-crystallin C
(CRYGC) with hereditary cataracts in Entlebucher mountain dogs. Anim Genet
2006;37(4):422-423.
125. Rubin LF, Koch SA, Huber RJ. Hereditary cataracts in miniature
schnauzers. Journal of the American Veterinary Medical Association
1969;154(11):1456-1458.
126. Gelatt KN, Samuelson DA, Bauer JE, Das ND, Wolf ED, Barrie KP,
Andresen TL. Inheritance of congenital cataracts and microphthalmia in the Miniature
Schnauzer. American Journal of Veterinary Research 1983;44(6):1130-1132.
127. Gelatt KN, Samuelson DA, Barrie KP, Das ND, Wol fED, Bauer JE,
Andresen TL. Biometry and clinical characteristics of congenital cataracts and
microphthalmia in the Miniature Schnauzer. Journal of the American Veterinary
Medical Association 1983;183(1):99-102.
128. Zhang RL, Samuelson DA, Zhang ZG, Reddy VN, Shastry BS.
Analysis of eye lens-specific genes in congenital hereditary cataracts and
microphthalmia of the miniature schnauzer dog. Invest Ophthalmol Vis Sci
1991;32(9):2662-2665.
129. Shastry BS, Reddy VN. Studies on congenital hereditary cataract and
microphthalmia of the miniature schnauzer dog. Biochemical and Biophysical
Research Communications 1994;203(3):1663-1667.
130. Barnett KC. Hereditary cataract in the Welsh Springer spaniel. The
Journal of Small Animal Practice 1980;21(11):621-625.
131. Olesen HP, Jensen OA, Norn MS. Congenital hereditary cataract in
Cocker Spaniels. Journal of Small Animal Practice 1974;15(12):741-750.
48
132. Narfstrom K. Cataract in the West Highland white terrier. The Journal
of Small Animal Practice 1981;22(7):467-471.
133. Koch SA. Cataracts in interrelated old English Sheepdogs. Journal of
the American Veterinary Medical Association 1972;160(3):299-301.
134. Collins BK, Collier LL, Johnson GS, Shibuya H, Moore CP, da Silva
Curiel JM. Familial cataracts and concurrent ocular anomalies in chow chows. Journal
of the American Veterinary Medical Association 1992;200(10):1485-1491.
135. Bjerkas E, Haaland MB. Pulverulent nuclear cataract in the Norwegian
buhund. Journal of Small Animal Practice 1995;36(11):471-474.
136. Laratta LJ, Riis RC, Kern TJ, Koch SA. Multiple congenital ocular
defects in the Akita dog. The Cornell Veterinarian 1985;75(3):381-392.
137. Davidson MG. Congenital cataracts in English cocker spaniels.
Veterinary Research 1988;122(23):568.
138. Mellersh CS, Pettitt L, Forman OP, Vaudin M, Barnett KC.
Identification of mutations in HSF4 in dogs of three different breeds with hereditary
cataracts. Vet Ophthalmol 2006;9(5):369-378.
139. Walther C, Gruss P. Pax-6, a murine paired box gene, is expressed in
the developing CNS. Development 1991;113(4):1435-49.
140. Aguirre G, Rubin LF, Bistner SI. Development of the canine eye.
American Journal of Veterinary Research 1972;33(12):2399-2414.
141. Noden DM, de Lahunta A. Chapter 6: Central nervous system and eye.
In: The Embryology of Domestic Animals; Developmental Mechanisms and
Malformations. Baltimore, Maryland: Williams and Wilkins; 1985. p. 92-119.
142. O'Rahilly R, Muller F. Developmental stages in human embryos.
Publication 637 ed. Davis, California: Carnegie Institute of Washington; 1987.
49
143. Quinlan RA, Sandilands A, Procter JE, Prescott AR, Hutcheson AM,
Dahm R, Gribbon C, Wallace P, Carter JM. The eye lens cytoskeleton. Eye
1999;13(Pt 3b):409-416.
144. Bassnett S. Lens organelle degradation. Experimental Eye Research
2002;74(1):1-6.
145. Sandilands A, Prescott AR, Carter JM, Hutcheson AM, Quinlan RA,
Richards J, FitzGerald PG. Vimentin and CP49/filensin form distinct networks in the
lens which are independently modulated during lens fibre cell differentiation. Journal
of Cell Science 1995;108(4):1397-1406.
146. DePianto DJ, Hess JF, Blankenship TN, FitzGerald PG. Isolation and
characterization of the human CP49 gene promoter. Invest Ophthalmol Vis Sci
2003;44(1):235-243.
147. Hess JF, Casselman JT, Kong AP, FitzGerald PG. Primary sequence,
secondary structure, gene structure, and assembly properties suggests that the lens-
specific cytoskeletal protein filensin represents a novel class of intermediate filament
protein. Experimental Eye Research 1998;66(5):625-644.
148. Carter JM, Hutcheson AM, Quinlan RA. In vitro studies on the
assembly properties of the lens proteins CP49, CP115: coassembly with alpha-
crystallin but not with vimentin. Experimental Eye Research 1995;60(2):181-192.
149. Graw J. Congenital hereditary cataracts. Int Journal of Developmental
Biology 2004;48(8-9):1031-1044.
150. Alizadeh A, Clark J, Seeberger T, Hess J, Blankenship T, FitzGerald
PG. Targeted deletion of the lens fiber cell-specific intermediate filament protein
filensin. Invest Ophthalmol Vis Sci 2003;44(12):5252-5258.
151. Alizadeh A, Clark JI, Seeberger T, Hess J, Blankenship T, Spicer A,
FitzGerald PG. Targeted genomic deletion of the lens-specific intermediate filament
protein CP49. Invest Ophthalmol Vis Sci 2002;43(12):3722-3727.
152. Ramachandran RD, Perumalsamy V, Hejtmancik JF. Autosomal
recessive juvenile onset cataract associated with mutation in BFSP1. Hum Genet
2007;121(3-4):475-482.
50
153. Zhang L, Gao L, Li Z, Qin W, Gao W, Cui X, Feng G, Fu S, He L, Liu
P. Progressive sutural cataract associated with a BFSP2 mutation in a Chinese family.
Mol Vis 2006;12:1626-1631.
154. Conley YP, Erturk D, Keverline A, Mah TS, Keravala A, Barnes LR,
Bruchis A, Hess JF, FitzGerald PG, Weeks DE, Ferrell RE, Gorin MB. A juvenile-
onset, progressive cataract locus on chromosome 3q21-q22 is associated with a
missense mutation in the beaded filament structural protein-2. Am J Hum Genet
2000;66(4):1426-31. Epub 2000 Mar 22.
155. Jakobs PM, Hess JF, FitzGerald PG, Kramer P, Weleber RG, Litt M.
Autosomal-dominant congenital cataract associated with a deletion mutation in the
human beaded filament protein gene BFSP2. Am J Hum Genet 2000;66(4):1432-6.
Epub 2000 Mar 16.
156. Sandilands A, Prescott AR, Wegener A, Zoltoski RK, Hutcheson AM,
Masaki S, Kuszak JR, Quinlan RA. Knockout of the intermediate filament protein
CP49 destabilises the lens fibre cell cytoskeleton and decreases lens optical quality,
but does not induce cataract. Experimental Eye Research 2003;76(3):385-391.
157. Simirskii VN, Lee RS, Wawrousek EF, Duncan MK. Inbred FVB/N
mice are mutant at the cp49/Bfsp2 locus and lack beaded filament proteins in the lens.
Invest Ophthalmol Vis Sci 2006;47(11):4931-4934.
158. Sandilands A, Wang X, Hutcheson AM, James J, Prescott AR,
Wegener A, Pekny M, Gong X, Quinlan RA. Bfsp2 mutation found in mouse 129
strains causes the loss of CP49' and induces vimentin-dependent changes in the lens
fibre cell cytoskeleton. Experimental Eye Research 2004;78(4):875-889.
159. Alizadeh A, Clark J, Seeberger T, Hess J, Blankenship T, FitzGerald
PG. Characterization of a mutation in the lens-specific CP49 in the 129 strain of
mouse. Invest Ophthalmol Vis Sci 2004;45(3):884-891.
160. Brekken RA, Sage EH. SPARC, a matricellular protein: at the
crossroads of cell-matrix communication. Matrix Biology 2001;19(8):816-827.
161. Norose K, Lo WK, Clark JI, Sage EH, Howe CC. Lenses of SPARC-
null mice exhibit an abnormal cell surface-basement membrane interface.
Experimental Eye Research 2000;71(3):295-307.
51
162. Lane TF, Sage EH. The biology of SPARC, a protein that modulates
cell-matrix interactions. FASEB Journal 1994;8(2):163-173.
163. Weaver MS, Sage EH, Yan Q. Absence of SPARC in lens epithelial
cells results in altered adhesion and extracellular matrix production in vitro. Journal of
Cell Biochemistry 2006;97(2):423-432.
164. Yan Q, Perdue N, Blake D, Sage EH. Absence of SPARC in murine
lens epithelium leads to increased deposition of laminin-1 in lens capsule. Invest
Ophthalmol Vis Sci 2005;46(12):4652-4660.
165. Yan Q, Clark JI, Wight TN, Sage EH. Alterations in the lens capsule
contribute to cataractogenesis in SPARC-null mice. Journal of Cell Science
2002;115(13):2747-2756.
166. Yan Q, Blake D, Clark JI, Sage EH. Expression of the matricellular
protein SPARC in murine lens: SPARC is necessary for the structural integrity of the
capsular basement membrane. Journal of Histochemistry and Cytochemistry
2003;51(4):503-511.
167. Bassuk JA, Birkebak T, Rothmier JD, Clark JM, Bradshaw A,
Muchowski PJ, Howe CC, Clark JI, Sage EH. Disruption of the Sparc locus in mice
alters the differentiation of lenticular epithelial cells and leads to cataract formation.
Experimental Eye Research 1999;68(3):321-331.
168. Norose K, Clark JI, Syed NA, Basu A, Heber-Katz E, Sage EH, Howe
CC. SPARC deficiency leads to early-onset cataractogenesis. Invest Ophthalmol Vis
Sci 1998;39(13):2674-2680.
169. Sage H, Vernon RB, Decker J, Funk S, Iruela-Arispe ML. Distribution
of the calcium-binding protein SPARC in tissues of embryonic and adult mice. Journal
of Histochemistry and Cytochemistry 1989;37(6):819-829.
170. Yan Q, Clark JI, Sage EH. Expression and characterization of SPARC
in human lens and in the aqueous and vitreous humors. Experimental Eye Research
2000;71(1):81-90.
171. Kantorow M, Huang Q, Yang XJ, Sage EH, Magabo KS, Miller KM,
Horwitz J. Increased expression of osteonectin/SPARC mRNA and protein in age-
52
related human cataracts and spatial expression in the normal human lens. Mol Vis
2000;6:24-29.
172. Gilbert RE, Cox AJ, Kelly DJ, Wilkinson-Berka JL, Sage EH, Jerums
G, Cooper ME. Localization of secreted protein acidic and rich in cysteine (SPARC)
expression in the rat eye. Connective Tissue Research 1999;40(4):295-303.
173. Kantorow M, Horwitz J, Carper D. Up-regulation of
osteonectin/SPARC in age-related cataractous human lens epithelia. Mol Vis
1998;4:17.
174. Gilmour DT, Lyon GJ, Carlton MB, Sanes JR, Cunningham JM,
Anderson JR, Hogan BL, Evans MJ, Colledge WH. Mice deficient for the secreted
glycoprotein SPARC/osteonectin/BM40 develop normally but show severe age-onset
cataract formation and disruption of the lens. Embo J 1998;17(7):1860-70.
175. Cartier M, Tsui L-C, Ball SP, Lubsen NH. Crystallin Genes and
Cataract. In: Wright AF, Jay B, editors. Molecular Genetics of Inherited Eye
Disorders. Chur, Switzerland: Harwood Academic Publishers; 1994. p. 413-443.
176. Bateman OA, Sarra R, van Genesen ST, Kappe G, Lubsen NH,
Slingsby C. The stability of human acidic beta-crystallin oligomers and hetero-
oligomers. Experimental Eye Research 2003;77(4):409-422.
177. Sergeev YV, Wingfield PT, Hejtmancik JF. Monomer-dimer
equilibrium of normal and modified beta A3-crystallins: experimental determination
and molecular modeling. Biochemistry 2000;39(51):15799-15806.
178. Yang Y, Cvekl A. Tissue-specific regulation of the mouse alphaA-
crystallin gene in lens via recruitment of Pax6 and c-Maf to its promoter. Journal of
Molecular Biology 2005;351(3):453-469.
179. Kim JI, Li T, Ho IC, Grusby MJ, Glimcher LH. Requirement for the c-
Maf transcription factor in crystallin gene regulation and lens development. Proc Natl
Acad Sci U S A 1999;96(7):3781-5.
180. Kawauchi S, Takahashi S, Nakajima O, Ogino H, Morita M, Nishizawa
M, Yasuda K, Yamamoto M. Regulation of lens fiber cell differentiation by
53
transcription factor c-Maf. Journal of Biological Chemistry 1999;274(27):19254-
19260.
181. Lengler J, Krausz E, Tomarev S, Prescott A, Quinlan RA, Graw J.
Antagonistic action of Six3 and Prox1 at the gamma-crystallin promoter. Nucleic
Acids Research 2001;29(2):515-526.
182. Cvekl A, Sax CM, Bresnick EH, Piatigorsky J. A complex array of
positive and negative elements regulates the chicken alpha A-crystallin gene:
involvement of Pax-6, USF, CREB and/or CREM, and AP-1 proteins. Molecular And
Cellular Biology 1994;14(11):7363-7376.
183. Yang Y, Chauhan BK, Cveklova K, Cvekl A. Transcriptional
regulation of mouse alphaB- and gammaF-crystallin genes in lens: opposite promoter-
specific interactions between Pax6 and large Maf transcription factors. Journal of
Molecular Biology 2004;344(2):351-368.
184. Nishiguchi S, Wood H, Kondoh H, Lovell-Badge R, Episkopou V.
Sox1 directly regulates the gamma-crystallin genes and is essential for lens
development in mice. Genes Dev 1998;12(6):776-81.
185. Horwitz J. The function of alpha-crystallin in vision. Semin Cell Dev
Biol 2000;11(1):53-60.
186. He W, Li S. Congenital cataracts: gene mapping. Hum Genet
2000;106(1):1-13.
187. Beby F, Commeaux C, Bozon M, Denis P, Edery P, Morle L. New
phenotype associated with an Arg116Cys mutation in the CRYAA gene: nuclear
cataract, iris coloboma, and microphthalmia. Arch Ophthalmol 2007;125(2):213-216.
188. Santhiya ST, Soker T, Klopp N, Illig T, Prakash MV, Selvaraj B,
Gopinath PM, Graw J. Identification of a novel, putative cataract-causing allele in
CRYAA (G98R) in an Indian family. Mol Vis 2006;12:768-773.
189. Vanita V, Singh JR, Hejtmancik JF, Nuernberg P, Hennies HC, Singh
D, Sperling K. A novel fan-shaped cataract-microcornea syndrome caused by a
mutation of CRYAA in an Indian family. Mol Vis 2006;12:518-522.
54
190. Liu M, Ke T, Wang Z, Yang Q, Chang W, Jiang F, Tang Z, Li H, Ren
X, Wang X, Wang T, Li Q, Yang J, Liu J, Wang QK. Identification of a CRYAB
mutation associated with autosomal dominant posterior polar cataract in a Chinese
family. Invest Ophthalmol Vis Sci 2006;47(8):3461-3466.
191. Berry V, Francis P, Reddy MA, Collyer D, Vithana E, MacKay I,
Dawson G, Carey AH, Moore A, Bhattacharya SS, Quinlan RA. Alpha-B crystallin
gene (CRYAB) mutation causes dominant congenital posterior polar cataract in
humans. American Journal of Human Genetics 2001;69(5):1141-1145.
192. Graw J, Loster J, Soewarto D, Fuchs H, Meyer B, Reis A, Wolf E,
Balling R, Hrabe de Angelis M. Characterization of a new, dominant V124E mutation
in the mouse alphaA-crystallin-encoding gene. Invest Ophthalmol Vis Sci
2001;42(12):2909-2915.
193. Chang B, Hawes NL, Roderick TH, Smith RS, Heckenlively JR,
Horwitz J, Davisson MT. Identification of a missense mutation in the alphaA-
crystallin gene of the lop18 mouse. Mol Vis 1999;5:21.
194. Salim A, Zaidi ZH. Homology models of human gamma-crystallins:
structural study of the extensive charge network in gamma-crystallins. Biochemical
and Biophysical Research Communications 2003;300(3):624-630.
195. Rajini B, Shridas P, Sundari CS, Muralidhar D, Chandani S, Thomas F,
Sharma Y. Calcium binding properties of gamma-crystallin: calcium ion binds at the
Greek key beta gamma-crystallin fold. J Biol Chem 2001;276(42):38464-38471.
196. Billingsley G, Santhiya ST, Paterson A, D,, Ogata K, Wodak S,
Hosseini S, M,, Manisastry S, M,, Vijayalakshmi P, Gopinath PM, Graw J, Heon E.
CRYBA4, a novel human cataract gene, is also involved in microphthalmia. American
Journal of Human Genetics 2006;79(4):702-709.
197. Yao K, Tang X, Shentu X, Wang K, Rao H, Xia K. Progressive
polymorphic congenital cataract caused by a CRYBB2 mutation in a Chinese family.
Mol Vis 2005;11:758-63.
198. Litt M, Carrero-Valenzuela R, LaMorticella DM, Schultz DW, Mitchell
TN, Kramer P, Maumenee IH. Autosomal dominant cerulean cataract is associated
with a chain termination mutation in the human beta-crystallin gene CRYBB2. Hum
Mol Genet 1997;6(5):665-8.
55
199. Graw J, Jung M, Loster J, Klopp N, Soewarto D, Fella C, Fuchs H,
Reis A, Wolf E, Balling R, Hrabe de Angelis M. Mutation in the betaA3/A1-crystallin
encoding gene Cryba1 causes a dominant cataract in the mouse. Genomics
1999;62(1):67-73.
200. Kannabiran C, Rogan PK, Olmos L, Basti S, Rao GN, Kaiser-Kupfer
M, Hejtmancik JF. Autosomal dominant zonular cataract with sutural opacities is
associated with a splice mutation in the betaA3/A1-crystallin gene. Mol Vis
1998;4:21.
201. Graw J, Loster J, Soewarto D, Fuchs H, Reis A, Wolf E, Balling R,
Hrabe de Angelis M. Aey2, a new mutation in the betaB2-crystallin-encoding gene of
the mouse. Invest Ophthalmol Vis Sci 2001;42(7):1574-80.
202. Brakenhoff RH, Henskens HA, van Rossum MW, Lubsen NH,
Schoenmakers JG. Activation of the gamma E-crystallin pseudogene in the human
hereditary Coppock-like cataract. Human Molecular Genetics 1994;3(2):279-283.
203. Heon E, Priston M, Schorderet DF, Billingsley GD, Girard PO, Lubsen
N, Munier FL. The gamma-crystallins and human cataracts: a puzzle made clearer.
Am J Hum Genet 1999;65(5):1261-7.
204. Mackay DS, Andley UP, Shiels A. A missense mutation in the
gammaD crystallin gene (CRYGD) associated with autosomal dominant "coral-like"
cataract linked to chromosome 2q. Mol Vis 2004;10:155-62.
205. Sun H, Ma Z, Li Y, Liu B, Li Z, Ding X, Gao Y, Ma W, Tang X, Li X,
Shen Y. Gamma-S crystallin gene (CRYGS) mutation causes dominant progressive
cortical cataract in humans. J Med Genet 2005;42(9):706-10.
206. Graw J, Neuhauser-Klaus A, Klopp N, Selby PB, Loster J, Favor J.
Genetic and allelic heterogeneity of Cryg mutations in eight distinct forms of
dominant cataract in the mouse. Invest Ophthalmol Vis Sci 2004;45(4):1202-13.
207. Graw J, Loster J, Soewarto D, Fuchs H, Reis A, Wolf E, Balling R,
Hrabe de Angelis M. V76D mutation in a conserved gD-crystallin region leads to
dominant cataracts in mice. Mamm Genome 2002;13(8):452-5.
56
208. Bu L, Yan S, Jin M, Jin Y, Yu C, Xiao S, Xie Q, Hu L, Xie Y, Solitang
Y, Liu J, Zhao G, Kong X. The gamma S-crystallin gene is mutated in autosomal
recessive cataract in mouse. Genomics 2002a;80(1):38-44.
209. Klopp N, Loster J, Graw J. Characterization of a 1-bp deletion in the
gammaE-crystallin gene leading to a nuclear and zonular cataract in the mouse. Invest
Ophthalmol Vis Sci 2001;42(1):183-187.
210. Klopp N, Favor J, Loster J, Lutz RB, Neuhauser-Klaus A, Prescott A,
Pretsch W, Quinlan RA, Sandilands A, Vrensen GF, Graw J. Three murine cataract
mutants (Cat2) are defective in different gamma-crystallin genes. Genomics
1998;52(2):152-8.
211. Gilbert SF. Chapter 6: Cell-cell communication in development. In:
Developmental Biology. 6 ed. Sunderland, MA: Sinauer Associates, Inc; 2000. p. 143-
181.
212. Gerido DA, White TW. Connexin disorders of the ear, skin, and lens.
Biochimica et Biophysica Acta 2004;1662(1-2):159-170.
213. Xia CH, Liu H, Cheung D, Cheng C, Wang E, Du X, Beutler B, Lo
WK, Gong X. Diverse gap junctions modulate distinct mechanisms for fiber cell
formation during lens development and cataractogenesis. Development
2006;133(10):2033-2040.
214. Graw J, Loster J. Developmental genetics in ophthalmology.
Ophthalmic Genetics 2003;24(1):1-33.
215. Gong X, Li E, Klier G, Huang Q, Wu Y, Lei H, Kumar NM, Horwitz J,
Gilula NB. Disruption of alpha3 connexin gene leads to proteolysis and
cataractogenesis in mice. Cell 1997;91(6):833-43.
216. White TW, Goodenough DA, Paul DL. Targeted ablation of
connexin50 in mice results in microphthalmia and zonular pulverulent cataracts. J Cell
Biol 1998;143(3):815-25.
217. Vanita V, Hennies HC, Singh D, Nurnberg P, Sperling K, Singh JR. A
novel mutation in GJA8 associated with autosomal dominant congenital cataract in a
family of Indian origin. Mol Vis 2006;12:1217-1222.
57
218. Devi RR, Vijayalakshmi P. Novel mutations in GJA8 associated with
autosomal dominant congenital cataract and microcornea. Mol Vis 2006;12:190-195.
219. Arora A, Minogue PJ, Liu X, Reddy MA, Ainsworth JR, Bhattacharya
SS, Webster AR, Hunt DM, Ebihara L, Moore AT, Beyer EC, Berthoud VM. A novel
GJA8 mutation is associated with autosomal dominant lamellar pulverulent cataract:
further evidence for gap junction dysfunction in human cataract. Journal of Medical
Genetics 2006;43(1):e2.
220. Willoughby CE, Arab S, Gandhi R, Zeinali S, Luk D, Billingsley G,
Munier FL, Heon E. A novel GJA8 mutation in an Iranian family with progressive
autosomal dominant congenital nuclear cataract. J Med Genet 2003;40(11):e124.
221. Shiels A, Mackay D, Ionides A, Berry V, Moore A, Bhattacharya S. A
missense mutation in the human connexin50 gene (GJA8) underlies autosomal
dominant "zonular pulverulent" cataract, on chromosome 1q. Am J Hum Genet
1998;62(3):526-32.
222. Chang B, Wang X, Hawes NL, Ojakian R, Davisson MT, Lo WK,
Gong X. A Gja8 (Cx50) point mutation causes an alteration of alpha 3 connexin
(Cx46) in semi-dominant cataracts of Lop10 mice. Hum Mol Genet 2002;11(5):507-
13.
223. Graw J, Loster J, Soewarto D, Fuchs H, Meyer B, Reis A, Wolf E,
Balling R, Hrabe de Angelis M. Characterization of a mutation in the lens-specific
MP70 encoding gene of the mouse leading to a dominant cataract. Experimental Eye
Research 2001;73(6):867-876.
224. Rong P, Wang X, Niesman I, Wu Y, Benedetti LE, Dunia I, Levy E,
Gong X. Disruption of Gja8 (alpha8 connexin) in mice leads to microphthalmia
associated with retardation of lens growth and lens fiber maturation. Development
2002;129(1):167-174.
225. Steele ECJ, Lyon MF, Favor J, Guillot PV, Boyd Y, Church RL. A
mutation in the connexin 50 (Cx50) gene is a candidate for the No2 mouse cataract.
Curr Eye Res 1998;17(9):883-889.
226. Rees MI, Watts P, Fenton I, Clarke A, Snell RG, Owen MJ, Gray J.
Further evidence of autosomal dominant congenital zonular pulverulent cataracts
58
linked to 13q11 (CZP3) and a novel mutation in connexin 46 (GJA3). Hum Genet
2000;106(2):206-9.
227. Jiang H, Jin Y, Bu L, Zhang W, Liu J, Cui B, Kong X, Hu L. A novel
mutation in GJA3 (connexin46) for autosomal dominant congenital nuclear
pulverulent cataract. Mol Vis 2003;9:579-583.
228. Li Y, Wang J, Dong B, Man H. A novel connexin46 (GJA3) mutation
in autosomal dominant congenital nuclear pulverulent cataract. Mol Vis 2004;10:668-
671.
229. Bennett TM, Mackay DS, Knopf HL, Shiels A. A novel missense
mutation in the gene for gap-junction protein alpha3 (GJA3) associated with
autosomal dominant "nuclear punctate" cataracts linked to chromosome 13q. Mol Vis
2004;10:376-382.
230. Hansen L, Yao W, Eiberg H, Funding M, Riise R, Kjaer KW,
Hejtmancik JF, Rosenberg T. The congenital "ant-egg" cataract phenotype is caused
by a missense mutation in connexin46. Mol Vis 2006;12:1033-1039.
231. Addison PK, Berry V, Holden KR, Espinal D, Rivera B, Su H,
Srivastava AK, Bhattacharya SS. A novel mutation in the connexin 46 gene (GJA3)
causes autosomal dominant zonular pulverulent cataract in a Hispanic family. Mol Vis
2006;12:791-795.
232. Verkman AS. Role of aquaporin water channels in eye function.
Experimental Eye Research 2003;76(2):137-143.
233. Gonen T, Sliz P, Kistler J, Cheng Y, Walz T. Aquaporin-0 membrane
junctions reveal the structure of a closed water pore. Nature 2004;429(6988):193-197.
234. Varadaraj K, Kumari S, Shiels A, Mathias RT. Regulation of aquaporin
water permeability in the lens. Invest Ophthalmol Vis Sci 2005;46(4):1393-1402.
235. Varadaraj K, Kumari SS, Mathias RT. Functional expression of
aquaporins in embryonic, postnatal, and adult mouse lenses. Developmental Dynamics
2007;236(5):1319-1328.
59
236. Francis P, Chung JJ, Yasui M, Berry V, Moore A, Wyatt MK, Wistow
G, Bhattacharya SS, Agre P. Functional impairment of lens aquaporin in two families
with dominantly inherited cataracts. Human Molecular Genetics 2000;9(15):2329-
2334.
237. Berry V, Francis P, Kaushal S, Moore A, Bhattacharya S. Missense
mutations in MIP underlie autosomal dominant 'polymorphic' and lamellar cataracts
linked to 12q. Nat Genet 2000;25(1):15-7.
238. Sidjanin DJ, Parker-Wilson DM, Neuhauser-Klaus A, Pretsch W, Favor
J, Deen PM, Ohtaka-Maruyama C, Lu Y, Bragin A, Skach WR, Chepelinsky AB,
Grimes PA, Stambolian DE. A 76-bp deletion in the Mip gene causes autosomal
dominant cataract in Hfi mice. Genomics 2001;74(3):313-319.
239. Shiels A, Bassnett S. Mutations in the founder of the MIP gene family
underlie cataract development in the mouse. Nat Genet 1996;12(2):212-5.
240. Okamura T, Miyoshi I, Takahashi K, Mototani Y, Ishigaki S, Kon Y,
Kasai N. Bilateral congenital cataracts result from a gain-of-function mutation in the
gene for aquaporin-0 in mice. Genomics 2003;81(4):361-368.
241. Zhou L, Chen T, Church RL. Temporal expression of three mouse lens
fiber cell membrane protein genes during early development. Mol Vis 2002;8:143-
148.
242. Chen T, Li X, Yang Y, Church RL. Localization of lens intrinsic
membrane protein MP19 and mutant protein MP19(To3) using fluorescent expression
vectors. Mol Vis 2002;8:372-388.
243. Steele EC, Jr., Kerscher S, Lyon MF, Glenister PH, Favor J, Wang J,
Church RL. Identification of a mutation in the MP19 gene, Lim2, in the cataractous
mouse mutant To3. Mol Vis 1997;3:5.
244. Steele ECJ, Wang JH, Lo WK, Saperstein DA, Li X, Church RL.
Lim2(To3) transgenic mice establish a causative relationship between the mutation
identified in the lim2 gene and cataractogenesis in the To3 mouse mutant. Mol Vis
2000;6:85-94.
60
245. Shiels A, King JM, Mackay DS, Bassnett S. Refractive defects and
cataracts in mice lacking lens intrinsic membrane protein-2. Invest Ophthalmol Vis
Sci 2007;48(2):500-508.
246. Percin E, Ploder L, Yu J, Arici K, Horsford D, Rutherford A, Bapat,
Cox D, Duncan A, Kalnins V, Kocak-Altintas A, ., Sowden J, Trabousli E, Sarfarazi
M, McInnes R. Human microphthalmia associated with mutations in the retinal
homeobox gene CHX10. Nat Genet 2000;25:397-401.
247. Xu PX, Woo I, Her H, Beier DR, Maas RL. Mouse Eya homologues of
the Drosophila eyes absent gene require Pax6 for expression in lens and nasal placode.
Development 1997;124(1):219-231.
248. Xu PX, Cheng J, Epstein JA, Maas RL. Mouse Eya genes are expressed
during limb tendon development and encode a transcriptional activation function. Proc
Natl Acad Sci U S A 1997;94(22):11974-11979.
249. Rayapureddi JP, Kattamuri C, Steinmetz BD, Frankfort BJ, Ostrin EJ,
Mardon G, Hegde RS. Eyes absent represents a class of protein tyrosine phosphatases.
Nature 2003;426(6964):295-298.
250. Buller C, Xu X, Marquis V, Schwanke R, Xu PX. Molecular effects of
Eya1 domain mutations causing organ defects in BOR syndrome. Human Molecular
Genetics 2001;10(24):2775-2781.
251. Azuma N, Hirakiyama A, Inoue T, Asaka A, Yamada M. Mutations of
a human homologue of the Drosophila eyes absent gene (EYA1) detected in patients
with congenital cataracts and ocular anterior segment anomalies. Hum Mol Genet
2000;9(3):363-6.
252. Blixt A, Mahlapuu M, Aitola M, Pelto-Huikko M, Enerback S,
Carlsson P. A forkhead gene, FoxE3, is essential for lens epithelial proliferation and
closure of the lens vesicle. Genes Dev 2000;14(2):245-54.
253. Semina EV, Brownell I, Mintz-Hittner HA, Murray JC, Jamrich M.
Mutations in the human forkhead transcription factor FOXE3 associated with anterior
segment ocular dysgenesis and cataracts. Hum Mol Genet 2001;10(3):231-6.
61
254. Valleix S, Niel F, Nedelec B, Algros MP, Schwartz C, Delbosc B,
Delpech M, Kantelip B. Homozygous nonsense mutation in the FOXE3 gene as a
cause of congenital primary aphakia in humans. American Journal of Human Genetics
2006;79(2):358-364.
255. Chi N, Epstein JA. Getting your Pax straight: Pax proteins in
development and disease. Trends in Genetics 2002;18(1):41-47.
256. Grindley JC, Davidson DR, Hill RE. The role of Pax-6 in eye and nasal
development. Development 1995;121(5):1433-42.
257. Chow RL, Altmann CR, Lang RA, Hemmati-Brivanlou A. Pax6
induces ectopic eyes in a vertebrate. Development 1999;126(19):4213-22.
258. Halder G, Callaerts P, Gehring WJ. Induction of ectopic eyes by
targeted expression of the eyeless gene in Drosophila. Science 1995;267(5205):1788-
92.
259. Chauhan BK, Reed NA, Yang Y, Cermak L, Reneker L, Duncan MK,
Cvekl A. A comparative cDNA microarray analysis reveals a spectrum of genes
regulated by Pax6 in mouse lens. Genes To Cells 2002;7(12):1267-83.
260. Chauhan BK, Zhang W, Cveklova K, Kantorow M, Cvekl A.
Identification of differentially expressed genes in mouse Pax6 heterozygous lenses.
Invest Ophthalmol Vis Sci 2002;43(6):1884-1890.
261. Cvekl A, Yang Y, Chauhan BK, Cveklova K. Regulation of gene
expression by Pax6 in ocular cells: a case of tissue-preferred expression of crystallins
in lens. The International Journal of Developmental Biology 2004;48(8-9):829-844.
262. Chauhan BK, Yang Y, Cveklova K, Cvekl A. Functional interactions
between alternatively spliced forms of Pax6 in crystallin gene regulation and in
haploinsufficiency. Nucleic Acids Research 2004;32(5):1696-1709.
263. Duncan MK, Xie L, David LL, Robinson ML, Taube JR, Cui W,
Reneker L. Ectopic Pax6 expression disturbs lens fiber cell differentiation. Invest
Ophthalmol Vis Sci 2004;45(10):3589-3598.
62
264. Plaza S, Dozier C, Saule S. Quail Pax-6 (Pax-QNR) encodes a
transcription factor able to bind and trans-activate its own promoter. Cell Growth and
Differentiation 1993;4(12):1041-1050.
265. Ton CC, Miwa H, Saunders GF. Small eye (Sey): cloning and
characterization of the murine homolog of the human aniridia gene. Genomics
1992;13(2):251-6.
266. St-Onge L, Sosa-Pineda B, Chowdhury K, Mansouri A, Gruss P. Pax6
is required for differentiation of glucagon-producing alpha-cells in mouse pancreas.
Nature 1997;387(6631):406-409.
267. Gerard M, Abitbol M, Delezoide AL, Dufier JL, Mallet J, Vekemans
M. PAX-genes expression during human embryonic development, a preliminary
report. Comptes rendus de l'Académie des sciences. Série III, Sciences de la vie
1995;318(1):57-66.
268. Quiring R, Walldorf U, Kloter U, Gehring WJ. Homology of the
eyeless gene of Drosophila to the Small eye gene in mice and Aniridia in humans.
Science 1994;265(5173):785-9.
269. Davis A, Cowell JK. Mutations in the PAX6 gene in patients with
hereditary aniridia. Hum Mol Genet. 1993;2(12):2093-2097.
270. Hanson IM, Seawright A, Hardman K, Hodgson S, Zaletayev D, Fekete
G, van Heyningen V. PAX6 mutations in aniridia. Hum Mol Genet 1993;2(7):915-20.
271. Glaser T, Jepeal L, Edwards JG, Young SR, Favor J, Maas RL. PAX6
gene dosage effect in a family with congenital cataracts, aniridia, anophthalmia and
central nervous system defects. Nature Genetics 1994;7(4):463-71.
272. Martha A, Strong LC, Ferrell RE, Saunders GF. Three novel aniridia
mutations in the human PAX6 gene. Human Mutation 1995;6(1):44-49.
273. Azuma N, Hotta Y, Tanaka H, Yamada M. Missense mutations in the
PAX6 gene in aniridia. Investigative Ophthalmology and Visual Science
1998;39(13):2524-2528.
63
274. Nakai A, Tanabe M, Kawazoe Y, Inazawa J, Morimoto RI, Nagata K.
HSF4, a new member of the human heat shock factor family which lacks properties of
a transcriptional activator. Molecular And Cellular Biology 1997;17(1):469-481.
275. Min JN, Zhang Y, Moskophidis D, Mivechi NF. Unique contribution of
heat shock transcription factor 4 in ocular lens development and fiber cell
differentiation. Genesis 2004;40(4):205-217.
276. Fujimoto M, Izu H, Seki K, Fukuda K, Nishida T, Yamada S, Kato K,
Yonemura S, Inouye S, Nakai A. HSF4 is required for normal cell growth and
differentiation during mouse lens development. The EMBO Journal
2004;23(21):4297-306. Epub 2004 Oct 14.
277. Bu L, Jin Y, Shi Y, Chu R, Ban A, Eiberg H, Andres L, Jiang H, Zheng
G, Qian M, Cui B, Xia Y, Liu J, Hu L, Zhao G, Hayden MR, Kong X. Mutant DNA-
binding domain of HSF4 is associated with autosomal dominant lamellar and Marner
cataract. Nat Genet 2002b;31(3):276-8. Epub 2002 Jun 24.
278. Smaoui N, Beltaief O, BenHamed S, M'Rad R, Maazoul F, Ouertani A,
Chaabouni H, Hejtmancik JF. A homozygous splice mutation in the HSF4 gene is
associated with an autosomal recessive congenital cataract. Invest Ophthalmol Vis Sci
2004;45(8):2716-21.
279. Talamas E, Jackson L, Koeberl M, Jackson T, McElwee JL, Hawes NL,
Chang B, Jablonski MM, Sidjanin DJ. Early transposable element insertion in intron 9
of the Hsf4 gene results in autosomal recessive cataracts in lop11 and ldis1 mice.
Genomics 2006;88(1):44-51.
280. Shi X, Luo Y, Howley S, Dzialo A, Foley S, Hyde DR, Vihtelic TS.
Zebrafish foxe3: roles in ocular lens morphogenesis through interaction with pitx3.
Mechanisms of Development 2006;123(10):761-782.
281. Khosrowshahian F, Wolanski M, Chang WY, Fujiki K, Jacobs L,
Crawford MJ. Lens and retina formation require expression of Pitx3 in Xenopus pre-
lens ectoderm. Developmental Dynamics 2005;234(3):577-589.
282. Pommereit D, Pieler T, Hollemann T. Xpitx3: a member of the
Rieg/Pitx gene family expressed during pituitary and lens formation in Xenopus
laevis. Mechanisms of Development 2001;102(1-2):255-257.
64
283. Semina EV, Reiter RS, Murray JC. Isolation of a new homeobox gene
belonging to the Pitx/Rieg family: expression during lens development and mapping
to the aphakia region on mouse chromosome 19. Human Molecular Genetics
1997;6(12):2109-2116.
284. Burdon KP, McKay JD, Wirth MG, Russell-Eggit IM, Bhatti S, Ruddle
JB, Dimasi D, Mackey DA, Craig JE. The PITX3 gene in posterior polar congenital
cataract in Australia. Molecular Vision 2006;12:367-371.
285. Bidinost C, Matsumoto M, Chung D, Salem N, Zhang K, Stockton
DW, Khoury A, Megarbane A, Bejjani BA, Traboulsi EI. Heterozygous and
homozygous mutations in PITX3 in a large Lebanese family with posterior polar
cataracts and neurodevelopmental abnormalities. Invest Ophthalmol Vis Sci
2006;47(4):1274-1280.
286. Finzi S, Li Y, Mitchell TN, Farr A, Maumenee IH, Sallum JM, Sundin
O. Posterior polar cataract: genetic analysis of a large family. Ophthalmic Genetics
2005;26(3):125-130.
287. Donner AL, Ko F, Episkopou V, Maas RL. Pax6 is misexpressed in
Sox1 null lens fiber cells. Gene Expression Patterns 2007;7(5):606-613.
288. Ijichi N, Tsujimoto N, Iwaki T, Fukumaki Y, Iwaki A. Distal Sox
binding elements of the alpha B-crystallin gene show lens enhancer activity in
transgenic mouse embryos. Journal of Biochemistry 2004;135(3):413-420.
289. Muta M, Kamachi Y, Yoshimoto A, Higashi Y, Kondoh H. Distinct
roles of SOX2, Pax6 and Maf transcription factors in the regulation of lens-specific
delta1-crystallin enhancer. Genes Cells 2002;7(8):791-805.
290. Blank V, Andrews NC. The Maf transcription factors: regulators of
differentiation. Trends in Biochem Sci 1997;22(11):437-441.
291. Ring BZ, Cordes SP, Overbeek PA, Barsh GS. Regulation of mouse
lens fiber cell development and differentiation by the Maf gene. Development
2000;127(2):307-317.
292. Vanita V, Singh D, Robinson PN, Sperling K, Singh JR. A novel
mutation in the DNA-binding domain of MAF at 16q23.1 associated with autosomal
65
dominant "cerulean cataract" in an Indian family. American Journal of Medical
Genetics 2006;140(6):558-566.
293. Jamieson RV, Munier F, Balmer A, Farrar N, Perveen R, Black GC.
Pulverulent cataract with variably associated microcornea and iris coloboma in a MAF
mutation family. Br J Ophthalmol 2003;87(4):411-412.
294. Jamieson RV, Perveen R, Kerr B, Carette M, Yardley J, Heon E, Wirth
MG, van Heyningen V, Donnai D, Munier F, Black GC. Domain disruption and
mutation of the bZIP transcription factor, MAF, associated with cataract, ocular
anterior segment dysgenesis and coloboma. Hum Mol Genet 2002;11(1):33-42.
295. Perveen R, Favor J, Jamieson RV, Ray DW, Black GC. A heterozygous
c-Maf transactivation domain mutation causes congenital cataract and enhances target
gene activation. Hum Mol Genet 2007;16(9):1030-1038.
296. Lyon MF, Jamieson RV, Perveen R, Glenister PH, Griffiths R, Boyd Y,
Glimcher LH, Favor J, Munier FL, Black GC. A dominant mutation within the DNA-
binding domain of the bZIP transcription factor Maf causes murine cataract and results
in selective alteration in DNA binding. Human Molecular Genetics 2003;12(6):585-
594.
297. Hoskins BE, Cramer CH, Silvius D, Zou D, Raymond RM, Orten DJ,
Kimberling WJ, Smith RJ, Weil D, Petit C, Otto EA, Xu PX, Hildebrandt F.
Transcription factor SIX5 is mutated in patients with branchio-oto-renal syndrome.
American Journal of Human Genetics 2007;80(4):800-804.
298. Sarkar PS, Appukuttan B, Han J, Ito Y, Ai C, Tsai W, Chai Y, Stout
JT, Reddy S. Heterozygous loss of Six5 in mice is sufficient to cause ocular cataracts.
Nat Genet 2000;25(1):110-4.
299. Kawakami K, Ohto H, Takizawa T, Saito T. Identification and
expression of six family genes in mouse retina. Federation of European Biochemical
Societies, Letters 1996;393(2-3):259-263.
300. Winchester CL, Ferrier RK, Sermoni A, Clark BJ, Johnson KJ.
Characterization of the expression of DMPK and SIX5 in the human eye and
implications for pathogenesis in myotonic dystrophy. Human Molecular Genetics
1999;8(3):481-492.
66
301. Klesert TR, Cho DH, Clark JI, Maylie J, Adelman J, Snider L, Yuen
EC, Soriano P, Tapscott SJ. Mice deficient in Six5 develop cataracts: implications for
myotonic dystrophy. Nat Genet 2000;25(1):105-109.
302. Matise TC, Perlin M, Chakravarti A. Automated construction of
genetic linkage maps using an expert system (MultiMap): a human genome linkage
map. Nat Genet 1994;6(4):384-90.
303. Azuma N, Yamaguchi Y, Handa H, Hayakawa M, Kanai A, Yamada
M. Missense mutation in the alternative splice region of the PAX6 gene in eye
anomalies. Am J Hum Genet 1999;65(3):656-63.
304. Favor J, Peters H, Hermann T, Schmahl W, Chatterjee B, Neuhauser-
Klaus A, Sandulache R. Molecular characterization of Pax6(2Neu) through
Pax6(10Neu): an extension of the Pax6 allelic series and the identification of two
possible hypomorph alleles in the mouse Mus musculus. Genetics 2001;159(4):1689-
700.
305. Prosser J, van Heyningen V. PAX6 mutations reviewed. Human
Mutation 1998;11(2):93-108.
306. Beauchamp GR, Meisler DM. An alternative hypothesis for iris
maldevelopment (aniridia). Journal of Pediatric Ophthalmology and Strasbismus
1986;23(6):281-283.
307. Villagrasa M. Aplasia-hipoplasia de iris con carácter hereditario en el
gos d'atura. Clinica Veterinaria de Pequeños Animales 1996;16(4):201-205.
308. Koroma BM, Yang JM, Sundin OH. The Pax-6 homeobox gene is
expressed throughout the corneal and conjunctival epithelia. Investigative
Ophthalmology and Visual Science 1997;38(1):108-120.
309. Ashery-Padan R, Gruss P. Pax6 lights-up the way for eye development.
Current opinion in cell biology 2001;13(6):706-714.
310. Jensen AM. Potential roles for BMP and Pax genes in the development
of iris smooth muscle. Developmental Dynamics 2005;232(2):385-392.
67
311. Nishina S, Kohsaka S, Yamaguchi Y, Handa H, Kawakami A,
Fujisawa H, Azuma N. PAX6 expression in the developing human eye. British Journal
of Ophthalmology 1999;83(6):723-727.
312. Zhang W, Cveklova K, Oppermann B, Kantorow M, Cvekl A.
Quantitation of PAX6 and PAX6(5a) transcript levels in adult human lens, cornea, and
monkey retina. Molecular Vision 2001;7:1-5.
313. Stanescu D, Iseli HP, Schwerdtfeger K, Ittner LM, Reme CE, Hafezi F.
Continuous expression of the homeobox gene Pax6 in the ageing human retina. Eye
2007;21(1):90-93.
314. Callaerts P, Halder G, Gehring WJ. PAX-6 in development and
evolution. Annual Reviews in Neuroscience 1997;20:483-532.
315. Hanson IM, Fletcher JM, Jordan T, Brown A, Taylor D, Adams RJ,
Punnett HH, van Heyningen V. Mutations at the PAX6 locus are found in
heterogeneous anterior segment malformations including Peters' anomaly. Nat Genet
1994;6(2):168-73.
316. Epstein JA, Glaser T, Cai J, Jepeal L, Walton DS, Maas RL. Two
independent and interactive DNA-binding subdomains of the Pax6 paired domain are
regulated by alternative splicing. Genes and Development 1994;8(17):2022-34.
317. Cook CS, Ozanics V, Jakobiec FA. Prenatal Development of the Eye
and its Adnexa. In: Tasman W, Jaeger EA, editors. Duane's Foundations of Clinical
Ophthalmology. Philadelphia: Lippincott, Williams & Wilkins; 2004. p. 1-48.
318. Ito M, Yoshioka M. Regression of the hyaloid vessels and pupillary
membrane of the mouse. Anatomy and Embryology 1999;200(4):403-411.
319. Mitchell CA, Risau W, Drexler HC. Regression of vessels in the tunica
vasculosa lentis is initiated by coordinated endothelial apoptosis: a role for vascular
endothelial growth factor as a survival factor for endothelium. Developmental
Dynamics 1998;213(3):322-333.
320. Roberts SR, Bistner SI. Persistent pupillary membrane in Basenji dogs.
Journal of the American Veterinary Medical Association 1968;153(5):533-542.
68
321. Barnett KC, Knight GC. Persistent pupillary membrane and associated
defects in the Basenji. Veterinary Research 1969;85(9):242-248.
322. Bistner SI, Rubin LF, Roberts SR. A review of persistent pupillary
membranes in the Basenji dog. Journal of the American Animal Hospital Association
1971;7:143-157.
323. Mason TA. Persistent pupillary membrane in the Basenji. Australian
Veterinary Journal 1976;52(8):343-344.
324. James RW. Persistent pupillary membrane in basenji dogs. Veterinary
Research 1991;128(12):287-288.
325. Hamming N, Wilensky J. Persistent pupillary membrane associated
with aniridia. American Journal of Ophthalmology 1978;86(1):118-120.
326. Hamming NA, Miller MT, Rabb M. Unusual variant of familial
aniridia. Journal of Pediatric Ophthalmology and Strasbismus 1986;23(4):195-200.
327. Gronskov K, Rosenberg T, Sand A, Brondum-Nielsen K. Mutational
analysis of PAX6: 16 novel mutations including 5 missense mutations with a mild
aniridia phenotype. European Journal of Human Genetics 1999;7(3):274-286.
328. Willcock C, Grigg J, Wilson M, Tam P, Billson F, Jamieson R.
Congenital iris ectropion as an indicator of variant aniridia. Br J Ophthalmol
2006;90(5):658-659.
329. Azuma N, Yamaguchi Y, Handa H, Tadokoro K, Asaka A, Kawase E,
Yamada M. Mutations of the PAX6 gene detected in patients with a variety of optic-
nerve malformations. am J Hum Genet. 2003;72(6):1565-1570.
330. van der Woerdt A, Stades FC, van der Linde-Sipman JS, Boeve MH.
Multiple ocular anomalies in two related litters of soft coated wheaten terriers.
Veterinary and Comparative Ophthalmololgy 1995;5(2):78-82.
69
331. Vincent MC, Pujo AL, Olivier D, Calvas P. Screening for PAX6 gene
mutations is consistent with haploinsufficiency as the main mechanism leading to
various ocular defects. European Journal of Human Genetics 2003;11(2):163-169.
332. Neethirajan G, Krishnadas SR, Vijayalakshmi P, Shashikant S, Sundaresan P.
PAX6 gene variations associated with aniridia in south India. BMC Medical Genetics
2004;5(9).
70
CHAPTER 2
RADIATION HYBRID MAPPING OF CATARACT GENES IN THE DOG∗
Abstract
Purpose: To facilitate the molecular characterization of naturally occurring cataracts in
dogs by providing the radiation hybrid location of 21 cataract-associated genes along
with their closely associated polymorphic markers. These can be used for segregation
testing of the candidate genes in canine cataract pedigrees.  Methods: Twenty-one
genes with known mutations causing hereditary cataracts in man and/or mouse were
selected and mapped to canine chromosomes using a canine:hamster radiation hybrid
RH5000 panel. Each cataract gene ortholog was mapped in relation to over 3000
markers including microsatellites, expressed sequence tags (ESTs), genes, and
bacterial artificial chromosome (BAC) clones. The resulting independently determined
RH-map locations were compared with the corresponding gene locations from the
draft sequence of the canine genome.  Results: Twenty-one cataract orthologs were
mapped to canine chromosomes. The genetic locations and nearest polymorphic
markers were determined for 20 of these orthologs. In addition, the resulting cataract
gene locations, as determined experimentally by this study, were compared with those
determined by the canine genome project. All genes mapped within or near
chromosomal locations with previously established homology to the corresponding
human gene locations based on canine:human chromosomal synteny.
Conclusion: The location of selected cataract gene orthologs in the dog, along with
their nearest polymorphic markers, serves as a resource for association and linkage
testing in canine pedigrees segregating inherited cataracts. The recent development of
canine genomic resources make canine models a practical and valuable resource for
                                                 
∗ Hunter et. al., 2006. Molecular Vision Volume 12, pages 588-596.
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the study of human hereditary cataracts. Canine models can serve as large animal
models intermediate between mouse and man for both gene discovery and the
development of novel cataract therapies.
Introduction
As the leading cause of worldwide blindness and low vision, cataracts affect
millions of individuals, and billions of dollars are spent annually on cataract medical
and surgical expenses [1]. The etiology of cataracts varies; they can be hereditary,
traumatic or secondary to ocular inflammatory or systemic diseases, or as a sequelae
to taking certain pharmaceuticals/medications. The onset of cataract also varies.
Congenital cataracts occur in over 2 out of 10,000 live births [2] and are the leading
cause of treatable visual impairment in children worldwide [3, 4]. Approximately 1/3
of all congenital cataracts are inherited [5]. Age-related cataracts, however, are the
most common type of cataract; approximately 26.6 million Americans older than 40
years have cataract or have had cataract surgery, and this number is projected to
increase to 39.6 million by the year 2020 [6]. The risk factors associated with the
development of age-related cataract include ultraviolet light exposure [7], cigarette
smoking [8], alcohol consumption [9], and nutrition [10]. In addition, the role of
genetics in age-related cataract has been reviewed suggesting an interaction between
genetic background and environmental risk factors [11].
Most of our knowledge of cataractogenesis comes from genetic studies of
hereditary cataracts in man and mice. Mutations causing non-syndromic inherited
cataract have been identified in at least 15 genes in man [12], and at least 18 genes in
the mouse (Mouse Genome Informatics [MGI]: http://www.informatics.jax.org/).
Here, we propose the development of the dog as a complementary large animal model
for molecular studies of cataracts to facilitate gene discovery and the development of
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novel and alternative cataract therapies. There are over 300 breeds of dog, and of
these, 20 breeds are known to have hereditary cataracts while another 125 breeds are
suspected of having hereditary cataract [13]. It is likely that some hereditary cataracts
in dogs will be caused by mutations in cataract genes already identified in humans or
mice. However, to date no mutations causing cataract have been identified in any
canine pedigrees. Because of the recent progress in canine genomics [14-19], and the
success in identifying canine models for retinal diseases [20-22] it is likely that similar
progress will be possible with molecular studies of canine cataracts.
To begin the molecular identification of cataract phenotypes in the dog we
have selected 21 genes known to cause cataracts in man and/or mouse. These include
genes encoding; structural proteins (6), crystallin proteins (6) and transcription factors
(9). We have determined the canine chromosomal locations of each gene using a
radiation hybrid (RH) 5000 rad panel [23] and compared our experimentally derived
chromosomal locations for each gene with that of the draft sequence of the canine
genome. RH-mapping and genome sequencing are complementary procedures which
identify gene locations, order and distance, along with regions of conserved synteny
across species. Combining data from RH-maps with that from genomic sequences,
maximizes the information obtained from both methodologies [24] and helps to
resolve discrepancies that might arise with the draft sequence information currently
available. The identification of cataract gene locations along with their nearest
polymorphic markers provides an integrated resource essential for segregation analysis
of cataract phenotypes in canine cataract pedigrees. This resource will aid in the
development of the dog as a complementary large animal model for the molecular
study of cataracts and will help to advance our knowledge of naturally occurring
cataracts in mammalian species. This may one day contribute to the development of
new therapies to prevent, delay or even reverse cataracts.
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Methods
Selection Of Cataract Gene Orthologs
Twenty-one gene orthologs were selected as cataract candidate genes in dogs
based on their ability to cause cataracts in man and/or mouse. These candidate genes
include STRUCTURAL PROTEIN GENES: Beaded filament structural protein 2
(BFSP2), Connexin 46 (CX46), Connexin 50 (CX50), Lens intrinsic membrane protein
2 (LIM2), Major intrinsic protein of lens fiber (MIP), and Secreted protein acidic
cysteine-rich (SPARC); CRYSTALLIN GENES: Beta crystallin B2 (CRYBB2),
Gamma crystallin A (CRYGA), Gamma crystallin B (CRYGB), Gamma crystallin C
(CRYGC), Gamma crystallin D (CRYGD) and Gamma crystallin S (CRYGS);
TRANSCRIPTION FACTOR GENES: CEH10 homeodomain-containing homolog
(CHX10), Homolog of Drosophila eyes absent 1 (EYA1), Forkhead Box E3 (FOXE3),
Heat shock transcription factor 4 (HSF4), Avian musculoaponeurotic fibrosarcoma
oncogene homologue (MAF), Paired-box 6 transcription factor (PAX6), Paired-like
homeodomain transcription factor 3 (PITX3), Homologue of Drosophila sine oculis
homeobox (SIX5), and Sex determining region-Y (SRY)-box 1 (SOX1).
Canine Orthologous Sequences
Human gene cDNAs obtained from the National Center for Biotechnology
Information (NCBI) database were analyzed against drafts of the canine genome to
obtain orthologous sequences. The corresponding accession numbers for the human
cDNA sequences are listed in Table 2.1.
74
Table 2.1. PCR primer sequences used to place cataract orthologs on canine
chromosomes using an RH5000 panel. Primer melting temperature (Tm), PCR
product size, and corresponding NCBI reference accession numbers are represented.
(NCBI-National Center for Biotechnology Information).
GENE REFERENCE
ACCESSION
NO.
CANINE PRIMER SEQUENCES Tm
°C
PRO-
DUCT
SIZE
(bp)
Structural Protein  Genes
1. BFSP2 NM003571 F: CCT CTT CAT AGT TCC TTG AC 50.7
R: CCC TAC AGT TCT ATG CTT CCA G 55.8
419
2. CX46 NM021954 F: CCA GAG AAT GCT AAT TTG TCC C 54.9
R: CAG CAC ATG CAC TTA CAC AGG 57.6
365
3. CX50 NM005267 F: GGG ATA ACC AGA GGG TAG CAC 57.8
R: GGA TCT CGA AGT TCT CCT ACC 54.9
386
4. LIM2 NM030657 F: GGC AAC AAG TGC TAC CTG C 56.9
R: CCC AGT TTC CAA CCT AGT TC 53.0
353
5. MIP NM012064 F: GGG CAC GAG TAC GAG CAC TG 61.0
R: GCC TGC ACG CTT CGC AAG C 63.5
308
6. SPARC NM003118 F: CTG ATC ATG TGG CCT TGA GC 56.2
R: GGC CTA ATC TGA TCT GCT AAG 52.5
343
Crystallin  Genes
7.  CRYBB2 NM000496 F: GGA GAG CAG TTT GTG TTC GAG 55.9
R: GTG CAA TGT GGC AAC CCT TAG 56.9
356
8. CRYGA NM014617 F: CCT ACG AAG GAA TCC CTT TTG 53.2
R: GAG TGG AGC TCA TTG AGC CG 58.1
349
9. CRYGB NM005210 F: GCT CCT GGC ATC CAG TGG G 61.0
R: CTG CTC CTG CTG CTC TAC TC 57.3
404
10. CRYGC NM020989 F: CTC TAA CCC AGA CTC TGA ACC 54.3
R: GGA CCC AGC AGC CCT CCA G 63.3
373
11. CRYGD NM006891 F: GAC AGC GGC TGC TGG ATG C 62.1
R: CCA GGA CAG GAC CTA TTG CTG 57.4
381
12. CRYGS NM017541 F: CAG CTC ATC CCA AGA CTG AAT G 55.7
R: GAC ACC ATC CAG CAC CTT ACT G 57.7
390
Transcription Factors
13. CHX10 NM182894 F: CGT AAG TTA AGT ACC AGA GGG 52.1
R: CTA AAC CTG TGA TTT CTG TGC C 54.0
390
14. EYA1 NM172060 F: CTA CTG CCC AAA CTC ATC AC 53.2
R: CCC ACA GAA AGA ATG TAG ATG 50.7
386
15. FOXE3 NM012186 F: GCA AGT CAC TGC AGG GAC TG 58.6
R: GTT CTT TAG TGG TGC TGG AGG 55.5
342
16. HSF4 NM001538 F: GAT TCC TGA GCT CTA CCA TAG 51.7
R: GCC AGG GTC TGG TTG AAG C 58.9
463
17. MAF NM005360 F: GTT AAC AGC ACG GAG GTT ACA C 55.9
R: CCC TTC CAC TGC ATC TGA GTC 57.6
340
18. PAX6 NM001604 F: GCC ACA TCT TCA GTA CAA AG 49.6
R: TAG TTC AGG CAT TGA CTG ATG 50.3
300
19. PITX3 NM005029 F: CCT CCC TGA ACA GGG TGA TAG 57.5
R: CCG CAC CAT TGC ACA CCA CG 63.0
304
20. SIX5 NM175875 F: GAC CCG CAG CTT CTC AAG C 59.0
R: CCT TCC TAC TGC AAA GTG AGC 55.8
371
21. SOX1 NM005986 F: CTC AAG AAT GAT ATC CAC TGC TTC 53.5
R: GTA CAT TTC AGA GTC AAT GTG GC 54.1
299
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Human gene cDNAs for BFSP2, CX46, CX50, MIP, PAX6, and PITX3 were analyzed
against the original 1.5X (poodle) canine genome sequence through collaboration with
The Institute for Genomic Research (TIGR). Human gene cDNAs for CHX10,
CRYBB2, CRYGA, CRYGB, EYA1, FOXE3, HSF4, MAF, SIX5, SOX1, and SPARC
were analyzed against the publicly available 1.5X (poodle) canine genome using the
Blast function (http://www.ncbi.nlm.nih.gov/genome/seq/CfaBlast.html), and cDNAs
for CRYGC, CRYGD, CRYGS and LIM2 were analyzed against the 7.5X (boxer)
canine whole genome shotgun sequence using the Blat function
(http://genome.ucsc.edu/cgibin/hgBlat?command=start&org=Dog&db=canFam1&hgs
id=60802051). Primers were designed from putative intronic or untranslated regions
of canine orthologs of each cataract candidate gene using Amplify® software (Bill
Engels, University of Wisconsin, Madison, WI). Primers were designed to amplify
canine-specific sequences suitable for RH mapping and are summarized in Table 2.1.
The average melting temperature of the primers was 56.2°C, and the average PCR
product size was 363bp. All PCRs were performed on the MJ Research Tetrad 2
thermocycler (Global Medical Instrumentation Inc., Ramsey, MN) using Taq DNA
polymerase (Invitrogen Corporation, Carlsbad, CA). To ensure canine specificity,
initial PCRs were carried out at 25µl volume on control canine, hamster and
canine:hamster (1:5 ratio) DNA. PCR conditions were as follows: 2 min 94°C,
followed by 30 cycles of (30 sec 94°C, 30 sec 56°C, 30 sec 72°C), and a final
extension of 5 min 72°C. The PCR product sizes ranged from 144-463bp. PCRs were
optimized by adjusting the annealing temperature where needed.
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RH5000 Panel
Canine cataract candidate genes were positioned on a canine radiation hybrid
map using an RH5000 panel consisting of 118 cell lines made by fusing 5000 rad-
irradiated canine fibroblast cells with TK-HTK3 hamster cells [23]. Information on the
RH5000 panel may be obtained from the following web site: http://www-
recomgen.univ-rennes1.fr/doggy.html. The RH5000 panel has a retention frequency of
22% and a resolution limit of 600kb [17].  The PCR reactions on the RH5000 panel
were performed at 15µl volume using the same PCR conditions described above, and
run in duplicate or triplicate.  PCR products were analyzed on 2% agarose gels
containing 0.05% ethidium bromide at 50-65 volts. Gel bands were visualized using a
UV transilluminator, and images were taken of each gel. Gels were then scored for
presence, absence, or ambiguity of the band of interest in each of the 118 cell lines.
Radiation Hybrid Map Construction
Radiation hybrid data collected from the 21 cataract gene orthologs was
merged with previous data from 3270 markers [17], and  analyzed using Multimap®
software [25]. Two-point linkage analysis was performed for each canine ortholog to
determine its nearest markers and chromosomal location. A subset of the linked
markers was selected and used as a framework map based on their map locations as
previously provided [17].  Multimap’s® multipoint mapping algorithm was then used
to place the cataract gene orthologs on canine chromosomes in relation to the markers
within the framework map.  The May 2005, 7.5X canine draft sequence predicted
locations of each cataract ortholog were compared with the corresponding locations of
each PCR amplicon used for RH-mapping. The resulting genome locations for each
ortholog and corresponding sequence-tagged site (STS) are listed in Table 2.2
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Table 2.2. Twenty-one cataract genes mapped to the canine genome.
PCR primers (Table 2.1) from 21 cataract genes were used for RH-mapping using an
RH5000 panel. Multimap® two-point linkage analysis was used to identify the
chromosome location and 2 nearest markers [17] along with the corresponding
logarithm of odds (LOD) score and theta value (distance). To confirm these locations,
PCR amplicons were analyzed against the 7.5X canine draft sequence to obtain
sequence tagged site (STS) locations which were compared with the corresponding
ortholog locations within the draft sequence.
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Gene Chromosome Closest
Markers
LOD Theta STS
Location
Canine
Ortholog
Location
BFSP2 CFA23 REN156G20 22.448 0.086 33427673 -
33428089
33388029 -
33450927
REN210D03 17.827 0.169
CX46 CFA 25 EST18C6 9.688 0.276 20988791 -
20989147
20986634 -
20987933
BAC_372_A23 9.617 0.261
CX50 CFA 17 CFOR12C10 20.47 0.056 61506499 -
61506884
61498923 -
61505209
PEZ8 19.834 0.058
LIM2 CFA 1 KLK2 18.201 0.035 108473188 -
108473537
108472780 -
08479290
REN06N11 17.642 0.066
MIP CFA 10 FH2537 25.039 0.09 3684287 -
3684594
3684852 -
3689232
ATP5B 21.428 0.132
SPARC CFA 4 FH4018 14.097 0.048 60879945 -
60880285
60873070 -
60887224
BAC_374_E21 12.897 0.093
CRYBB2 CFA 26 CRYBB1 25.249 0.043 22335395 -
22335748
22331283 -
22338858
REN131L06 24.11 0.064
CRYGA CFA 37 AHT133 20.482 0.092 19453604 -
19453950
19453388 -
19455353
REN105M20 20.482 0.092
CRYGB CFA 37 BAC_381_J22 15.426 0.123 20124535 -
20124930
19440507 -
19442393
FH2708 13.738 0.157
CRYGC CFA 37 BAC_381_J22 24.954 0 19431676 -
19432046
19431504 -
19433284
EST22D1 23.468 0.026
CRYGD CFA37 CRYGB 15.027 0.045 19425779 -
19426157
19424588 -
19426264
BAC_374_E1 8.03 0.354
CRYGS CFA 34 BAC_374_K23 27.708 0.021 22165843 -
22166230
22165569 -
22166681
REN266K05 27.283 0.022
CHX10 CFA 8 EST10D4 23.799 0.025 50510969 -
50511356
50492693 -
50511026
EST27E3 21.735 0.051
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EYA1 CFA 29 STS246A16 19.01 0.119 23177126 -
23177509
23176722 -
23342854
C29_188 18.473 0.138
FOXE3 CFA 15 FH3888 23.211 0.046 16294587 -
16294926
16295972 -
16298254
FH3886 22.806 0.047
HSF4 CFA 5 AHTH201REN 13.127 0.052 85205320 -
85205780
85204186 -
85208678
REN122J03 11.927 0.1
MAF CFA 5 FH3450 9.517 0.244 74976764 -
74977099
74970434 -
74976948
FH3113 9.427 0.224
PAX6 CFA 18 WT1 17.245 0.148 38687699 -
38688008
38671041 -
38693640
FH3824 17.15 0.148
PITX3 CFA 28 EST3H1 19.137 0.083 17763487 -
17763792
17761261 -
17772191
COL17A1 18.606 0.085
SIX5 CFA 1 BAC_375_N13 21.594 0 112730879 -
112731247
112726865 -
12731063
FH2598 21.594 0
SOX1 CFA 22 EST3G2 26.711 0.022 62864830 -
62865127
62861615 -
62864949
BAC_376_O1 24.774 0.045
Table 2.2. (Continued)
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Results and Discussion
Two-Point Linkage Analysis
Twenty-one cataract gene orthologs were positioned on canine chromosomes
using an RH5000 panel of 118 cell lines.  Orthologs were located on 16 of the 39
canine chromosomes with more than one ortholog represented on 3 chromosomes
(CFA1, 5, and 37) (Table 2.2). The nearest chromosomal markers were determined for
each cataract gene ortholog using Multimap® two-point linkage analysis [25].
Logarithm of odds (LOD) scores for the 2 closest linked markers ranged from 8.0
(CRYGD:BAC_374_E1) to 27.7 (CRYGS:BAC_374_K23), with an average LOD
score of 18.9 (Table 2.2). Theta (θ), a measure of the frequency of breakage between
two markers, varies from 0 (no breakage between markers) to 1 (complete breakage
between markers), and represents the distance between markers. Theta ranged from 0
(CRYGC:BAC_381_J22,  SIX5:BAC_375_N13 and SIX5:FH2598) to 0.354
(CRYGD:BAC_374_E1) with an average theta of 0.095 for the 2 closest linked
markers (Table 2.2).
Two-point linkage analysis placed the gamma crystallin genes (CRYGA,
CRYGB, CRYGC and CRYGD) on CFA 37. There are estimated to be 7 gamma
crystallin genes in man; these include gamma A-D, and S, and two pseudogenes,
CRYGE and CRYGF.  There is sequence homology between gamma crystallins A-F,
and these genes form a cluster at HSA 2q33-35, and in mouse they form a cluster on
chromosome 1 (MMU1). In man, CRYGS maps to 3q25-qter, and in mouse to MMU
16. Similarly, canine CRYGS was not part of the gamma crystallin cluster on CFA37,
but mapped to CFA 34 near  BAC_374_K23 and marker REN266K05. Mutations
causing cataracts have previously been identified in murine Cryga [26, 27], Crygb
[26], Crygc [27], Crygd [27, 28], and Crygs [29, 30] as well as human CRYGC [31],
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CRYGD [31], and CRYGS [32]. As a result, there is a high likelihood that the gamma
crystallins will also be involved in canine cataracts.
LOD scores for the two closest linked markers to gamma crystallin genes A, B,
C, and D ranged from 8.0 (CRYGD:BAC_374_E1) to 24.95 (CRYGC:BAC_381_J22)
and theta ranged from 0 (CRYGC:BAC_381_J22) to 0.354 (CRYGD:BAC_374_E1)
(Table 2.2). The two closest linked markers to CRYGD were CRYGB from a previous
study [17]  (LOD=15.027, theta=0.045) and BAC_374_E1 (LOD=8.03, theta=0.354).
Although in the previous study, the CRYGB marker was “unlinked” to any other
marker, the corresponding 171 bp amplicon was located on CFA37 (19,425,908-
19,426,078). Also, in the previous study, markers were incorporated into a 1500
marker map using Multimap pairwise calculation at a threshold of LOD > 8 [33].
The CRYGB marker in that study may have linked to other markers in the data set at a
lower threshold.  Decreased marker density in the vicinity of a gene’s map location
can also result in unlinked gene markers.  However, marker density in the vicinity of
CRYGB should have been sufficient in the previous study since they mapped the same
markers which linked to the gamma crystallins in this study.
The next closest linked marker to CRYGD (BAC_374_E1: LOD=8.03, theta=
0.354) was also on CFA37. The decrease in LOD score from 15.027
(CRYGD:CRYGB) to 8.03 supports linkage but the increase in theta from 0.045
(CRYGD:CRYGB) to 0.354  indicates an increase in the distance between these two
markers. All of the markers which linked to CRYGD with LOD> 4 were located on
CFA37 (data not shown).  In addition, the CRYGD PCR amplicon was located on
CFA37 (19,425,779-19,426,157) within the predicted location for CRYGD  based on
reference sequence NM006891 (19,424,588-19,426,264). Thus, based on two-point
linkage analysis results, and the location of the CRYGD PCR amplicon we place
CRYGD on CFA37.
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Alpha crystallins A and B were previously mapped to CFA31 (CRYAA) and
CFA5 (CRYAB) [34], and beta crystallins A1 and B1 to CFA9 (CRYBA1) [17] and
CFA26 (CRYBB1) [17, 34]. Here we placed CRYBB2 on CFA26 near CRYBB1 and
REN131L06. Similarly, CRYBB1 and CRYBB2 both map to 22q11.2-12.2 in man, and
chromosome 5 in mouse (MMU5). MIP was mapped to CFA10 near FH2537 and
ATP5B, in agreement with previously reported data [34].  Both LIM2 and SIX5
mapped to CFA1, and HSF4 and MAF to CFA 5. All other orthologs (excluding the
gamma crystallins) mapped to individual chromosomes as summarized in Table 2.2
Sequenced Tagged Sites
Sequence-tagged sites (STS) for each cataract ortholog were obtained by
analyzing the corresponding PCR amplicons against the May 2005, 7.5X canine draft
sequence. With the exception of CRYGB, all of the resulting STSs were located inside,
or within 1,300 bp of the predicted gene location based on human reference sequences
(Table 2.2). The CRYGB STS (20,124,535-20,124,930) was not within the predicted
location for canine CRYGB (19,440,507-19,442,393) based on the human reference
sequence (NM005210).  Primers used to amplify CRYGB were designed from the
1.5X (poodle) whole genome shotgun reference sequence AACN010184836. This
sequence was selected from 1.5X canine sequences having homology to human
CRYGB mRNA (NM005210). When analyzed against the 7.5X (boxer) canine
genomic sequence, AACN010184836 had sequence homology to 4 unique sites on
CFA37 (19,417,160-19,418,711; 19,426,006-19,426,485; 19,432,821-19,455,395;
20,124,527-20,126,527). These included the human reference sequence (NM005210)
CRYGB predicted site (19,440,507-19,442,393). However, the actual
AACN010184836 sequence was located on CFA37 from 20,124,527-20,126,527, and
the 396bp portion of this sequence which corresponded to the CRYGB amplicon only
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had homology to CFA37 at 20,124,535-20,124,930 (which is the CRYGB amplicon
location). Therefore, even though the CRYGB primers were designed from the
AACN010184836 sequence which had homology to human CRYGB, this sequence
and the PCR amplicon derived from it were >682kb downstream from the expected
CRYGB site.
Furthermore, there are four CRYGB predicted sites on CFA37 based on human
protein homology (19,415,025-19,433,068; 19,424,652-19,455,135; 19,440,575-
19,442,393 and 20,126,034-20,128,506).  Human protein sequence homology is
determined by analyzing human protein sequences against the human genome to find
exonic sequences corresponding to amino acid sequences. The amino acid sequences
are then analyzed against the canine genomic sequence using tBLASTn to find
predicted canine exons (http://genome.ucsc.edu/cgi-
bin/hgTrackUi?hgsid=67540273&g=blastHg17KG). Three of the four CRYGB
predicted sites based on protein homology overlap and cover a 40kb region
(19,415,026-19,455,135). This region is 670kb upstream of the fourth predicted
CRYGB site (20,126,033-20,128,569). The CRYGB STS amplified here was located
1,104bp upstream to this fourth site. Because there are multiple predicted sites for
CRYGB on CFA37 in the dog genome, and these sites share sequence homology, it is
difficult to design primers specific for any single CRYGB predicted site.  The multiple
sites of CRYGB sequence homology make the actual location of the canine CRYGB
gene unclear. As a result, our CRYGB STS should not be used to predict the exact
location of canine CRYGB.
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Radiation Hybrid Mapping
Markers linked to cataract orthologs, as determined by two-point linkage
analysis, were used to create a framework map with previously established marker
positions [17]. This framework map was then used to determine the map locations of
the cataract orthologs (Figure 2.1). The orthologs were positioned between the 2
closest markers using the multipoint mapping algorithm of Multimap software. In
two cases, the cataract orthologs mapped to the same exact position as a BAC end
marker in the framework map (theta = 0). For example, SIX5 mapped to CFA1 at the
same location as BAC_375_N13, and CRYGC mapped to CFA37 at the same location
as BAC_381_J22.  Since BACs represent large ( 155kb) DNA fragments [35], the
mapping of these 2 genes to the same location as the 2 BACs suggests that these genes
may be located within the BACS.
The RH maps generated by Multimap’s multipoint mapping algorithm were
generally consistent with the results of two-point linkage analysis, and the orthologs
mapped on top of, between, or very near the closest linked markers as determined by
two-point linkage. An exception was CRYGD which was placed on CFA37 based on
two-point linkage results and the location of the CRYGD STS (Table 2.2) but could
not be accurately localized within the framework map. The framework map used to
localize the gamma crystallin genes on CFA37 included the gamma crystallin gene
vectors (CRYGA, B, C, D) along with framework markers whose locations were
previously determined [17]. As a result, the framework map did not include the
unlinked CRYGB marker from the previous study [17], which was the closest linked
marker to CRYGD based on two-point linkage analysis. Instead, the closest linked
marker to CRYGD in the framework map was BAC_374_E1 which linked to CRYGD
with LOD=8.03, and theta=0.354. All of the other markers in the framework map
which linked to CRYGD had a LOD score <8.03 and theta value > 0.354. These theta
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Figure 2.1. Radiation hybrid maps locating 20 cataract genes to canine chromosomes.
In each Canis Familiaris (CFA) chromosome representation, unboxed markers on left
represent framework markers [17]. Markers with an asterisk are polymorphic. Boxed
markers indicate locations of canine orthologs of cataract associated genes. Numbers
on right are distances in centiRays from the top framework marker.
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Figure 2.1. (Continued)
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Figure 2.1. (Continued)
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values indicated an increased frequency of breakage (increased distance) between
CRYGD and the markers on the framework map and decreased the likelihood of
accurately localizing CRYGD on the map. As a result, although we placed CRYGD on
CFA37 based on two-point linkage analysis and the location of the CRYGD amplicon,
we were unable to accurately localize this gene on the framework map using
Multimap’s multipoint mapping algorithm due to the decreasing LOD scores and
increasing theta values of the markers linked to CRYGD. The lack of markers linked to
CRYGD with high LOD scores and low theta values may indicate low marker density
in the vicinity of CRYGD. Even though all of the gamma crystallins orthologs
(CRYGA, B, C, D) were located on CFA37 and were mapped against each other, this
did not resolve the problem of marker density in the vicinity of CRYGD. To resolve
this problem CRYGD should be mapped on the new RH9000 panel [24].
Gamma crystallins A, B, and C mapped to CFA37 as expected based on results
of two-point-linkage analysis. The 5’ 3’ RH-map order on CFA37 (CRYGC,
CRYGB, CRYGA) (Figure 2.1) matched the order of the predicted gene locations
within the 7.5X draft sequence (Table 2.2). However, this RH-map order did not
correspond with the order of the STS locations within the 7.5X draft sequence
(CRYGC, CRYGA, CRYGB) (Table 2.2). Two-point linkage analysis linked the
CRYGB ortholog to multiple markers on CFA37. The two closest linked markers were:
BAC_381_J22 (LOD=15.426, theta=0.123), and FH2708 (LOD=13.738, theta=0.157).
Multimap’s multipoint mapping algorithm placed the CRYGB ortholog on CFA37
between EST22D1 and BAC_374_E1, which are also between BAC_381_J22 and
FH2708.  Thus, two-point linkage analysis and radiation hybrid mapping results are
consistent and place CRYGB on CFA37 in the same region, however this location does
not correspond with the CRYGB STS location.
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Radiation hybrid maps are physical maps based on the statistical analysis of
the pattern of marker retention in a panel of RH-cell lines.  As a result, the order and
location of markers within RH-maps do not always correspond exactly with the order
and location of markers within genomic sequences. Marker order and position on the
canine RH5000 map [17] for example, are not equivalent with their order and position
in the 7.5X canine genomic sequence in all instances. Thus, it is not surprising that the
CRYGB marker in this study mapped to a location on the RH-map that does not
exactly correspond to the physical location of this marker within the canine genome.
Nevertheless, RH-maps are valuable in localizing markers and genes to specific
regions and providing statistically close markers for association and linkage testing.
Furthermore, the discrepancy between the order of CRYGA, B, and C on the
RH-map and their STSs in the draft sequence may also reflect the limited power for
fine resolution of the RH5000 panel which has a resolution limit of 600kb. The
distance between CRYGA and CRYGB STSs is about 670kb, and the distance between
CRYGB and CRYGC STSs is about 692kb. These distances are close to the resolution
limit for the RH5000 panel. Further, the distance between CRYGA and CRYGC STSs
is only 21,558bp and is outside the resolution limit for the panel. Therefore, the
inconsistency between the RH-map order and the STS order for CRYGA, B and C may
be due to the resolution limit of the RH5000 panel. The new RH9000 panel has a
resolution of 200kb [24] and can be used to resolve mapping issues for the gamma
crystallin genes in the dog.
The canine chromosomal locations of the 21 cataract orthologs were consistent
with human and canine established chromosomal synteny [36-38].  All of the cataract
orthologs mapped to canine chromosomal locations which are syntenic with the
corresponding human gene locations, except for 4 orthologs (SPARC, HSF4, CX46,
and PITX3) which mapped to locations which are directly adjacent to the
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corresponding syntenic region of the human gene location. Although CRYGD was not
localized on the RH-map, the results of the two-point linkage analysis did place this
gene on CFA37 in a region with homology to HSA2q33-35 where the gene is located
in man.
To facilitate the molecular characterization of naturally occurring cataracts in
the dog we have provided the radiation hybrid location of 20 cataract-associated genes
along with their associated polymorphic markers (Figure 2.1).  Primers for selected
polymorphic markers near cataract-associated genes can be obtained from the RH5000
website (http://idefix.univ-rennes1.fr:8080/Dogs/RH3270-page.html) and serve as a
resource for association and linkage testing in canine pedigrees segregating inherited
cataracts. Although CRYGD is not represented in Figure 2.1, two-point linkage
analysis did link CRYGD to BAC_374_E1 which localizes it on CFA37 to some
degree. Also, the CRYGD STS location (19,425,779-19,426,157) can be used to
identify proximal markers in the canine genome sequence. Though the RH5000 panel
was used to map cataract-associated genes in this study, these results have not been
incorporated into the RH5000 map. Nevertheless, the RH5000 map can be used to
locate the markers referred to in this study (Table 2.2 and Figure 2.1). In addition,
while the RH5000 and RH9000 maps will not be merged,  a subset of 545 BACs has
been mapped on both RH-panels and is part of both maps allowing navigation between
the RH5000 and RH9000 maps (http://idefix.univ-rennes1.fr:8080/Dogs/RH10K-
SOM-web.html).
Animal models provide a tremendous tool in the study of cataract, and
molecular studies in mice have been instrumental in advancing our knowledge of the
mechanisms of cataract formation. The dog has recently emerged as a promising
model organism for gene discovery and genomic studies, and is a complementary
species to the mouse for molecular genetic studies. There are over 300 known breeds
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of dogs, and most function as genetic isolates due to restricted mating.  As a result,
there is a decrease in genetic diversity within breeds and an increase in diversity
between breeds such that genetic diseases within one breed tend to be caused by the
same mutations (founder effect). This facilitates the mapping of disease loci. In
addition, developments in canine genomic resources which include integrated RH
maps [14-17, 24], the availability of the canine genomic sequence [18, 19] , and
comparative chromosome maps of the human and dog genomes which identify
homologous segments and conserved synteny between canine and human karyotypes
[36-38] make it practical to develop and use canine models.
Although mutations causing human cataracts have been identified in 15 genes
there are many other genes with mutations yet to be identified. The study of naturally
occurring cataracts in the dog could reveal novel genes and/or mutations not yet
identified in either man or the mouse. The dog represents a valuable yet largely
untapped resource to study the molecular genetics of cataracts. This study takes some
initial steps towards developing the tools needed to begin studies on the canine
cataract model. We have identified the chromosomal locations of 20 canine orthologs
of cataract-associated genes and  their nearest polymorphic markers (Figure 2.1)
which can be used for association and linkage testing in cataract pedigrees. This
resource, along with the recent advances in canine genomics, will help facilitate the
development of such models for the study of naturally occurring inherited cataracts.
Once developed, canine cataract models should help to identify new cataract genes
and disease causing mutations, assist in the development of new therapies, and provide
an intermediate large animal model between mouse and man for pre-clinical trials of
new therapies.
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APPENDIX
Figure A2.2. Representative 2% agarose gel showing PCR products
generated from different cell lines in the RH5000 panel to identify those
containing canine gamma crystallin A (CRYGA). There are 8 rows
containing 17 columns (wells) each. The first column of each row contains a
positive canine control (350bp band) and the last column of each row
contains a phiX174 DNA marker.  CRYGA was amplified in 29 cell lines
and was localized to canine chromosome 37.
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CHAPTER 3
CLONING AND CHARACTERIZATION OF CANINE PAX6 AND
EVALUATION AS A CANDIDATE GENE IN A CANINE MODEL OF
ANIRIDIA∗
Abstract
Purpose: Mutations in PAX6 cause human aniridia.  The small eye (sey) mouse
represents an animal model for aniridia; however, no large animal model currently
exists.  We cloned and characterized canine PAX6, and evaluated PAX6 for causal
associations with inherited aniridia in dogs.  Methods: Canine PAX6 was cloned from
a retinal cDNA library using primers designed from human and mouse PAX6
consensus sequences.  An RH3000 radiation hybrid panel was used to localize PAX6
within the canine genome.  Genomic DNA was extracted from whole blood from dogs
with inherited aniridia, and association testing was performed using markers on
CFA18.  Fourteen PAX6 exons were sequenced and scanned for mutations, and a
Southern blot was used to test for large deletions.  Results: Like the human gene,
canine PAX6 has 13 exons and 12 introns, plus an alternatively spliced exon (5a).
PAX6 nucleotide and amino acid sequences were highly conserved between dog,
human, and mouse.  The canine PAX6 cDNA sequence determined in this study spans
2 large gaps present in the current canine genomic sequence.  Radiation hybrid
mapping placed canine PAX6 on CFA18 in a region with synteny to HSA11p13.
Exon-scanning revealed single nucleotide polymorphisms, but no pathological
mutations, and Southern blot analysis revealed no differences between normal and
affected animals.  Conclusion: Canine PAX6 was cloned and characterized, and results
                                                 
∗ Hunter et. al., 2007. Molecular Vision, volume 13, pages 431-442
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provide sequence information for gaps in the current canine genome sequence.  Canine
PAX6 nucleotide and amino acid sequences, as well as gene organization and map
location, were highly homologous with that of the human gene.  PAX6 was evaluated
in dogs with an inherited form of aniridia, and sequence analysis indicated no
pathological mutations in the coding regions or splice sites of aniridia- affected dogs,
and Southern blot analysis showed no large deletions within the regions analyzed.
Introduction
Mutations in the paired-box 6 (PAX6) gene cause aniridia in man, a panocular
disorder primarily characterized by complete or partial absence of iris tissue.  Aniridia
is often associated with other ocular abnormalities including corneal dystrophy,
cataract, and glaucoma.  The disease has a high penetrance, but variable expressivity,
and, within pedigrees, phenotypes can vary in patients having the same mutation [1].
The incidence of aniridia is 1:65,000-1:100,000 in man, and approximately 2/3 of
aniridia cases are inherited.  In addition to aniridia, PAX6 mutations can also cause
Peter’s anomaly, cataract, corneal dystrophy, keratitis, coloboma, ectopic pupillae,
foveal hypoplasia, and optic nerve hypoplasia
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM).  Over 300 PAX6
mutations have been described in man, and can be viewed at the Human PAX6 Allelic
Variant Database (http://PAX6.hgu.mrc.ac.uk/).  PAX6 mutations are dominant to
semidominant and homozygous lethal; homozygous or compound heterozygous
patients have anophthalmia and multiple, severe CNS malformations [2, 3].
PAX6 is expressed during embryogenesis in the developing CNS, eye, nose,
pituitary and pancreas [4-8].  It functions as a master control gene in ocular
development across species, both vertebrate and invertebrate, and is able to induce
ectopic eye development in Drosophila melanogaster [9] and Xenopus laevis [10].
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Mutations in the Drosophila PAX6 homologue eyeless cause partial to complete loss
of the compound eye, and surrounding sensory bristles [11].  Pax6 mutations in mouse
are dominant, and result in the small eye (sey) phenotype characterized by
microphthalmia and small body size [12].  Experimentally induced mutations in
mouse Pax6 exhibit a range of phenotypes including partial to complete aniridia, iris
abnormalities, cataract, and corneal adhesions [13].  Homozygous Pax6 mutations are
lethal in the mouse, and, as in man, result in small embryos with anopthalmia and
severe CNS malformations [3, 12].
PAX6 is a highly conserved member of the PAX family of DNA-binding
transcription factors.  It contains a paired domain (PD), a linker region, a
homeodomain (HD), and a proline-serine-threonine rich (PST) region which functions
as a transcription activator [3].  Both the paired and homeo domains of the PAX6
protein recognize and bind to DNA target sequences.  The paired domain is further
divided into an N-terminal subdomain (NTS) and a C-terminal subdomain (CTS).  An
alternatively spliced form of PAX6 inserts an additional 14 amino acids, encoded by
exon 5a, into the NTS of the paired domain, thereby altering its binding ability [14,
15].  In the shorter PAX6, the NTS binds to DNA targets while in the longer
PAX6(5a) the CTS preferentially binds.  Thus, the alternatively spliced exon 5a acts as
a molecular switch which can determine DNA-binding targets [14, 16].
In an effort to identify the causal gene, and mutation responsible for canine
aniridia, a family of Spanish Catalan sheepdogs with an inherited form of aniridia was
analyzed.  Affected dogs presented with partial to nearly complete absence of the iris
with or without keratitis, cataract, and glaucoma.  Because limited pedigree
information and samples precluded a genome wide scan, a candidate gene approach
was used.  PAX6 was selected for evaluation because it is the primary aniridia gene in
man.  The canine PAX6 has not been cloned, and the current draft of the canine
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genomic sequence [17] (http://genome.ucsc.edu/cgi-bin/hgGateway) does not contain
an annotated PAX6.  Moreover, the canine draft genomic sequence does not contain
the entire sequence for this gene.  As a result, PAX6 was cloned from a canine retinal
cDNA library, characterized and evaluated for mutations that could be causally
associated with the disease.
Methods
Animals and DNA
Catalan sheepdogs (Gos d'Atura) with an inherited form of aniridia were
ascertained by Dr. Manuel Villagrasa at the Veterinary Ophthalmology Center in
Madrid, Spain [18].  The dogs were privately owned pets or working sheepedogs, and
were not part of a research colony. Dogs were examined using direct and indirect
ophthalmoscopy and slit lamp biomicroscopy.  Clinical signs included partial to nearly
complete absence of the iris with ciliary processes visible at the circumferential border
(Figure 3.1).  Some canine patients also exhibited persistent remnants from the
pupillary membrane, corneal edema, keratitis, cataract, and glaucoma.  A total of 10
dogs were examined, including 7 which were part of one pedigree (GD2, GD3, GD5,
GD6, GD8, GD9, GD10) (Figure 3.2), and 3 which were unrelated (GD12, GD13,
GD14).  Six dogs were affected with aniridia (GD5, GD6, GD9, GD10, GD12,
GD14), and 4 were normal (GD2, GD3, GD8, GD13).  Although the pedigree
information available was very limited, the disease appeared to segregate as an
autosomal recessive trait in that aniridia-affected dogs were produced from
phenotypically normal parents (Figure 3.2) [18].  Whole blood was collected in
EDTA-anticoagulant tubes, and total genomic
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Figure 3.1. The canine aniridia phenotype.  Note absence of the iris, visible
ciliary processes located near the lens equator (white arrowheads) and
pupillary membrane remnants (black arrows).
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Figure 3.2.  Spanish Catalan sheepdog pedigree showing aniridia-affected dogs.
Note that the parents of affected dogs in 3 litters were clinically normal.
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DNA (gDNA) was extracted from blood lymphocytes using standard
phenol:chloroform extraction protocols with ethanol precipitation [19].
Cloning and characterization of canine PAX6
Oligonucleotide primers were designed based on human (XM_012065) and
mouse (X63963) PAX6 consensus sequences using Amplify© software (Bill Engels,
University of Wisconsin, Madison, WI).  PAX6 was amplified from a canine retinal
cDNA library made with the pBK-CMV phagemid vector (Stratagene, LaJolla, CA),
using primers listed in Table 3.1.  Vector primers PBKIII and PBKVI from the cDNA
library were used to extend the resulting PAX6 sequence in the 5’ and 3’ directions,
respectively.  Additional sequence information was obtained from The Institute For
Genomic Research (TIGR) 1.5X (Poodle) canine genomic sequence [20].  Additional
primers were designed to cross introns in gDNA in order to obtain the intron/exon
boundary sequences which were then used to design primers for exon scanning.
Intron/exon boundaries were analyzed, and intronic sizes were determined for 9 of the
13 introns.  For the larger introns (2, 4, 7, and 11), which could not be amplified
directly, genomic sequence at the intron/exon boundaries was obtained from TIGR
(Poodle) canine genomic sequence [20], and used to design primers for exon scanning.
PCRs for the cloning of PAX6 were run in a 25µl reaction volume using Taq
DNA polymerase (Invitrogen Corporation, Carlsbad, CA), with the following
conditions: 2 min 94°C followed by 30 cycles of (60 sec 94°C, 60 sec 58°C, 60 sec
72°C), and a final extension of 7 min 72°C.  PCRs were run on Amplitron II
Thermolyne thermocyclers (Barnstead Thermolyne Co., Dubuque, IA), and amplified
products were electrophoresed on 2% agarose gels (Invitrogen, Carlsbad, CA) with 1X
TAE buffer (0.04 M Tris-acetate buffer, pH 8, 100 mM EDTA) at 60V.  Gels were
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Table 3.1.  Primer Sequences Used To Clone PAX6 From A Canine Retinal cDNA
Library
PRIMER (location) SEQUENCE Tm
(°C)
PRODUCT
SIZE (bp)
PAX6-1F (exons 4-
5)
GCAGAACAGTCACAGCGGAG
TG
60.4
PAX6-3R (exon 7) CCGTCTGCGCCCATCTGTTG 61.4
464
PAX6-4F (exon 7) GTCATCAATAAACAGAGTTCT
TCGC
54.3
PAX6-5R (exon 10) GTGTTGCTGGCCTGTCTTCTCT
G
60.1
485
PAX6-6F (exon 9) GATCTACCTGAAGCAAGAAT
ACAGG
54.9
PAX6-7R (exon 12) GGTGTAGGTATCATAACTCCG 51.9
380
Primers used to clone 5’ end of PAX6
PBKIII F(vector) GGTCGACACTAGTGGATCCAA
AG
57.1
PAX6-3R (exon 7) CCGTCTGCGCCCATCTGTTG 61.4
550
Primers used to clone 3’ end of PAX6
PAX6-6F (exon 9) GATCTACCTGAAGCAAGAAT
ACAGG
54.9
PBKVI R (vector) GCTCTCATGAAGATCTCGCCG 57.7
600
PAX6-27F (exon 12) AACAGTCAGCCAATGGGCAC 53.7
PBKVI R (vector) GCTCTCATGAAGATCTCGCCG 57.7
200
Primers used to amplify alternatively transcribed EXON 5a
PAX6-14F (exon 5) CTCGGTGGTGTCTTTGTCAAC 54.2
PAX6-15R (exon 6) CTACTCTCGGTTTACTACCAC
C
54.7
250
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stained with ethidium bromide, visualized using an ultraviolet transilluminator
(Spectronics Corporation, Westbury, NY), and digitally photographed.
PCR products were purified using the Concert™ PCR purification kit (Gibco, BRL,
Gaithersburg, MD), or gel bands were excised and purified using the Qiaex II® Gel
Extraction kit (QIAGEN Inc., Valencia, CA).  Purified PCR products were then
sequenced on the Applied Biosystems Automated 3730 DNA Analyzer using Big Dye
Terminator chemistry and Ampli Taq-FS DNA Polymerase.  Sequence assembly and
analysis were performed using Sequencher™ software (Gene Codes Corporation, Ann
Arbor, MI).
Exon scanning
PAX6 exons, along with their intron/exon junctions, were scanned using PCR
amplification of genomic DNA from 4 aniridia-affected dogs (GD5, GD6, GD9,
GD10), and 3 non-affected dogs (GD2, GD3, GD8) from the same pedigree.  In
addition, one non-affected, unrelated Beagle (B15) was scanned as a control.  Primers
were designed in introns near the intron/exon boundaries (Table 3.2) using Amplify©
software.  PCR and electrophoresis conditions were the same as those described
earlier.  Gel bands corresponding to exon sizes were excised and gel purified using the
QIAquick Gel Extraction kit (QIAGEN Inc., Valencia, CA).  Gel-purified PCR
products were sequenced and analyzed as previously described.
Radiation Hybrid Mapping
Canine PAX6 was positioned on a radiation hybrid map using a canine/hamster
radiation hybrid (RH3000) panel consisting of 92 cell lines made by fusing 3000 rad-
irradiated canine fibroblast cells with TK-HTK3 hamster cells (Research Genetics,
Inc., Huntsville, AL).  Canine PAX6 was linked to CFA18 in relation to 7 gene
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Table 3.2. PAX6 Primer Sequences Used For Exon Scanning
EXON PRIMER (location) PRIMER SEQUENCE Tm
(°C)
PRODUCT
SIZE (bp)
PX6-40F (5'UTR) TCAGGCGCAGGAGGAAGTG 59.91
PX6-41R (intron 1) TCAGCGGCTGGAGAGTGAG 59.3
194
PX6-42F (intron 1) CTCACTCTCCAGCCGCTGAC 60.12
PX6-43R (intron 2) CTCTCCCGGCGTGGCAGTG 63.6
400
PX6-44F (intron 2) GAGAGTCCATGGGCCTGTGC 60.63
PX6-45R (intron 3) CTTCTCCCATGTGAACAATGAAG 53.9
200
PX6-84F (intron 3) GCGACTGAGTGGATCCCTTC 58.24
PX6-83R (intron 4) CCCTCCAGCCGGACTGC 61.0
302
PX6-86F (intron 4) CCGCATGGACGTGTGGTCC 61.75
PX6-79R (intron 5) GGAGTTATCTTATGTGACTGAC 51.4
558
PX6-50F (intron 5) CTCTCTACAGTAAGTTCTCATAC 49.65A
PX6-39R (exon 6) CCAGTCTCGTAATACCTGCC 53.7
210
PAX6-34F (exon 5A) GTCCAAGTGCTGGACAATC 51.06
PAX6-29R (intron 6) AACAAGCTCCCAGCCATCCT 53.7
917
PX6-51F (intron 6) GTTGTTCTTTAAGAGAGTGGGTG 53.57
PX6-52R (intron 7) CCAGTGGCTGCCTATATGGAG 57.3
310
PX6-53F (intron 7) GCCTCTTTGGGAGGCTCCAAG 60.48
PX6-54R (intron 8) CTGGCTAAATATAGCTCTTTGTAC 51.2
300
PAX6-30F (intron 8) GCCACATCTTCAGTACAAAG 49.69
PX6-21R (exon 10) GCCTGTCTTCTCTGGTTCC 53.1
800
PAX6-6F (exon 9) GATCTACCTGAAGCAAGAATACAGG 54.910
PX6-23R (exon  11) GTGTTTGTGAGGGCTGTGTC 53.7
590
PX6-22F (exon 10) CCCAGTCACATCCCCATCAG 55.811
PX6-55R (intron 11) CCCACTCCTCGCTTCTCCG 60.1
350
PX6-61F (intron 11) CGATCATCAGGCTATCATAC 49.912
PX6-62R (intron 12) CCAGGAGGTTTCTCTTAAGG 52.2
415
PX6-63F (intron 12) CATAGTCCATGCTTGTCTCTC 52.713
PX6-88R (3'UTR) CACAGGACACAACTGCAGAAC 57.4
318
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markers (WT1, CD44, COLF1, COLF2, DLA79, ROM1, TPCR63) and 7 microsatellite
markers (Wilms-TF, REN47J11, REN248C19, C18.156, C18.460, AHT130, FH2356).
All of these markers were previously mapped and positioned on CFA18 [21, 22].
Primers for RH mapping are listed in Table 3.3.  PAX6 primers 30F and 21R, which
amplify intron 8, were used to amplify PAX6 in the RH3000 panel.
PCR reactions were run on the 92 cell lines of the RH3000 panel, in duplicate
or triplicate, at 25 µl volume using Taq DNA polymerase (Invitrogen Corporation,
Carlsbad, CA).  PCR conditions were as follows: 2 min 94°C, followed by 30 cycles
of (30 sec 94°C, 30 sec 56°C, 30 sec 72°C), and a final extension of 5 min 72°C.
PCRs were optimized by adjusting the annealing temperature as needed.  PCR
products were electrophoresed and analyzed as described earlier.  Gel images were
recorded for each gel, and scored for presence or absence of the band of interest in
each of the 92 cell lines.  Radiation hybrid data was analyzed using Multimap®
software [23].
Association Testing
Ten dogs, 6 affected and 4 non-affected, were used to test for association of
aniridia with the PAX6 locus.  Seven of the ten animals were part of one small
pedigree, and 3 were unrelated (Figure 3.3).  Autosomal recessive inheritance was
assumed based on a previous report [18], and limited pedigree information, but
phenotypic variability prevented the exclusion of dominant inheritance with
incomplete penetrance.  In addition, a founder effect mutation was hypothesized based
on the small breed size.  This mutation appears to have occurred recently in that the
previous clinical [18] report is the first and only description of aniridia in the breed,
and, as this is a working dog breed, the visual impairment caused by aniridia would be
readily recognized in these dogs once it occurred.
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Table 3.3. Primers Used For Radiation Hybrid Mapping
PRIMER (location) PRIMER SEQUENCE Tm
(°C)
PRODUCT
SIZE (bp)
PAX6-30F (intron 8) GCCACATCTTCAGTACAAAG 49.6
PAX6-31R (intron 8) TAGTTCAGGCATTGACTGATG 50.3
300
WT1 (Wilms tumor 1)-F GGTGCCTGGAAACGTCCG 59.2
WT1 (Wilms tumor 1)-R ACCGGGAGAACTTTCGCTGAC 59.5
155
CD44 (Cell differentiation
antigen 44 variant)-F
TGGAAGAGAAGGTGGACATCTTCC 58.2
CD44 (Cell differentiation
antigen 44 variant)-R
GGTCACCGGGATGAGGGTC 60.1
106
COLF1 (Canine olfactory
receptor gene 1) -F
GTCTCGGGGCATCTGTGTAT 57.4
COLF1 (Canine olfactory
receptor gene 1) -R
GATGGCCACAGAAGTCAGGT 57.4
357
COLF2 (Canine olfactory
receptor gene 2)-F
AGAGTGTGCTCCCTGCTGAT 57.4
COLF2 (Canine olfactory
receptor gene 2)-R
TGCAACAGCAGTTAAGTGGG 55.4
357
DLA79 (MHC class IB) -F TCTATTCTGGCATTGGGGAC 55.4
DLA79 (MHC class IB) -R TGAGTAGCTCCCTCCTTTTCTG 58.1
270
ROM1 –F CTCTTTGATCCTCGTCAGCC 57.4
ROM1 –R TGAGGGTCAGTAGGTCCCTG 59.5
230
TPCR63 (Putative
olfactory receptor)-F
AGGATACGTTCCTCAGAGGGCC 61.9
TPCR63 (Putative
olfactory receptor)-R
ATCTAATGAGTGGTTGGTCCCTGGT 60.6
129
Wilms-TF (tetra repeat)-F CCCAATCTCCAGAGATTTTCC 52.3
Wilms-TF (tetra repeat)-R CCAGTCTCAGCTGTGTCCAA 53.7
300
REN47J11-F  (CA)11 TCTCCTCGCGTGTTTCTG 50.2
REN47J11-R (CA)11 GGGGACACTCAGAAGGACG 55.3
163
REN248C19-F (CA)10 TGACTGTGGCAAGCAAGAAC 51.7
REN248C19-R (CA)10 GGCAAAGAAAGATGGACTGG 51.7
319
 C18.156-F (AC)15 ACAACCAACACACACAAAAACC 54.7
 C18.156-R (AC)15 TGTTATCCCAGTGGCATTAGG 54.5
136
C18.460-F (TG)17 CTTCCCATTATAGCCCTGTCC 54.8
C18.460-R (TG)17 GGTGTCAGGAAAATGAGACCA 54.8
147
AHT130-F (GT)19 CCTCTCCTGGTAAGTGCTGC 57.6
AHT130-R (GT)19 TGGAACACTGGTCCCCAG 57.0
113
FH2356-F (tetra repeat) CTTGCATTCCCGCTCTCACT 57.6
FH2356-R (tetra repeat) TCCTGAAATAGCTCCAGCGC 57.4
235
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Figure 3.3. Test for association of aniridia phenotypes with CFA18 markers.
Four microsatellites and 2 single nucleotide polymorphisms were analyzed
in 10 dogs (6 affected, and 4 non-affected).  Two of the 6 affected dogs
were heterozygous; one of these was heterozygous for the PAX6 exon 7
SNP.
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Four microsatellite markers (C18.156, COS18, Wilms-TF, REN47J11) which
were previously mapped to CFA18 using an RH5000 panel [21, 22] were used for
association testing along with 2 SNPs identified within canine PAX6: one in exon 7
and one in intron 8.  In exon 7 there is a TC change (ACT>ACC) at nucleotide 501
of the 1311bp coding sequence (PAX6(5a)) that does not alter the translated amino
acid (threonine).  In intron 8 (which is 484bp), there is a G A change at intronic
nucleotide position 351.
Primers used for association testing, along with PCR product sizes, genomic
locations, and inter-marker distances are listed in Table 3.4.  The previous RH5000
map placement of the 4 microsatellite markers gives 22.0 cRays between C18.156 and
COS18, 57.5 cRays between COS18 and Wilms-TF, and 64.7 cRays between Wilms-
TF and REN47J11 [22].  According to the current genomic sequence, PAX6 lies
between Wilms-TF and REN47J11 (Table 3.4).  PCRs were run as previously
described, and products for microsatellite markers were electrophoresed on 6%
polyacrylamide gels, and microsatellite sizes were scored for each dog.  PCR products
for the exon 7 SNP were electrophoresed on 2% agarose gels (Invitrogen, Carlsbad,
California), gel purified, sequenced and analysed as previously described.  Intron 8
PCR products were digested with BstNI (New England Biolabs, Ipswich, MA) and
electrophoresed on 6% polyacrylamide gels.  Dogs homozygous (G/G) for the intron 8
SNP had 230bp and 220bp bands, while heterozygous dogs (G/A) had 230bp, 220bp,
and 450bp bands after enzyme digestion. Homozygous (A/A) dogs would have a
450bp band, but there were none in this pedigree.   
Southern blot
Southern (DNA) analysis was performed using ten micrograms (10µg) of
gDNA from 2 non-affected dogs (GD2 and GD8), 2 affected progeny (GD6 and
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Table 3.4. Primer sequences used for association testing and genomic location of
amplicons.  The exact location of COS18* and PAX6 exon 7** could not be
determined in the current canine genome draft sequence. The site given for COS18
represents the region between its flanking markers BAC_375-H17 and BAC_373-
K16 (24,25). The site given for exon 7 represents the boundaries of the gap in the
canine genome which begins in PAX6 intron 4 and ends in intron 8.
PRIMER
NAME
PRIMER SEQUENCE Tm
(°C)
PRODUCT
SIZE (bp)
CANINE
GENOMIC
SEQ.
LOCATION
DIST.
BTWN
MARKERS
C18.156-F
(AC)15
ACAACCAACACACAC
AAAAACC
54.7
C18.156-
R (AC)15
TGTTATCCCAGTGGC
ATTAGG
54.5
136 Chr18:25401870+
25402003
COS-18-F
(TC)19
CGTGGTGCCGGCCCT
TTGAT
63.4
2.2MB
COS-18-R
(TC)19
TTTAGCGCCTGCCTTT
GGAC
58.4
360 Chr18:27577535-
30076377*
Wilms-
TF-F
(tetra
repeat)
CCCAATCTCCAGAGA
TTTTCC
52.3
8.1MB
Wilms-
TF-R
(tetra
repeat)
CCAGTCTCAGCTGTG
TCCAA
53.7
300 Chr18:38163822+
38164112
PAX6-
51F (exon
7 SNP)
GTTGTTCTTTAAGAG
AGTGGGTG
53.5
510KB
PAX6-
52R (exon
7 SNP)
CCAGTGGCTGCCTATA
TGGAG
57.3
310 Chr18:38675041-
38687664**
PAX6-
30F
(intron 8
SNP)
GCCACATCTTCAGTA
CAAAG
49.6
2.8KB
PAX6-
21R
(intron 8
SNP)
GCCTGTCTTCTCTGGTT
CC
53.1
824 Chr18:38687699+
38688522
REN47J1
1-F
(CA)11
TCTCCTCGCGTGTTTC
TG
50.2
6.6MB
REN47J1
1-R
(CA)11
GGGGACACTCAGAAG
GACG
55.3
163 Chr18:45329434-
45329603
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agarose gel, and transferred to a nylon hybridization transfer membrane (GeneScreen
Plus Perkin Elmer, Boston, MA).  The nylon membrane was prehybridized and
hybridized with ExpressHyb (Clontech, Palo Alto, California).  Probes were labeled
with αP32 dCTP (3000Ci/mmol, 10mCi/ml) using the RadPrime DNA Labeling
System (Life Technologies™, Inc Palo Alto, California).
Two probes were designed from the canine PAX6.  A 580bp fragment
including all of exon 1, intron 1, exon 2 and part of intron 2 was used as a 5’UTR
probe.  This probe was amplified using primers PAX6-40F and 43R (Table 3.2).  A
373bp fragment in the PST domain, including part of intron 11, all of exon 12 and part
of intron 12, was used as a 3’ end probe.  This probe was amplified using PAX6-61F
and 62R (Table 3.2).  Each probe was amplified in gDNA, gel purified using the
QIAquick Gel Extraction kit (QIAGEN Inc., Valencia, CA), and verified by
sequencing.
Results
Characterization of canine PAX6
A 1072bp fragment of canine PAX6 cDNA, representing the 3’ end of exon 4
through the 5’ end of exon 12, was amplified from a canine retinal cDNA library using
primers designed from human/mouse PAX6 consensus sequence (Table 3.1).  cDNA
library vector primers, PBKIII and PBKVI, were used to extend the sequence to
1472bp which included the 3’ end of exon 2 through the 5’ end of exon 13.  This
fragment contained the complete PAX6 coding sequence for isoform a, which does not
contain the alternatively transcribed exon 5a.  This 1269bp coding sequence began at
the ATG start codon in exon 4, and ended at the TAA stop codon in exon 13.  A poly-
A sequence of at least 20 residues followed the stop codon, and it was unclear where
non-coding exon 13 ended.  Similarly, in man the ATG start codon occurs in exon 4,
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and the TAA stop codon in exon 13 is followed by a poly-A sequence of 21 residues.
Exon 13 in man is estimated to be 1110bp (NM_001604).  Unlike the human and
canine genes, mouse Pax6 contains 12 exons instead of 13, and mouse exons 2-12
correspond with human and canine exons 3-13 (Figure 3.4).  As a result, the mouse
ATG start codon is in exon 3 (instead of exon 4), and the TAA stop codon is in exon
12 (instead of exon 13), and it is not followed by a poly-A sequence (NM_013627).
A 42bp alternatively transcribed exon 5a was amplified from the canine retinal
cDNA library, and was located between exons 5 and 6, as in man; this alternatively
transcribed exon is located between exons 4 and 5 in the mouse.  The coding sequence
for canine PAX6 isoform b, which includes this alternatively transcribed exon, was
1311bp, and was the same length as the human and mouse PAX6(5a) coding
sequences.
Sequences for exon 1 and the 5’ end of exon 2 could not be amplified from the
cDNA library, and were obtained from TIGR 1.5X (Poodle) canine genomic sequence
[20].  Within the 5’UTR, the predicted sizes for canine exons 1 and 2, and introns 1
and 2, were similar in size to the corresponding human exons and introns (Table 3.5).
Exon 1 was predicted to be 103bp based on the TIGR canine genomic sequence, and
sequences amplified from genomic DNA in canine patients.  In man, PAX6 exon 1 is
119bp (NM_001604) or 196bp (NM_000280).  PAX6 exon 2 is 188bp in man
(NM_001604 and NM_000280), and predicted to be 224bp in the dog.  The additional
36bp in canine exon 2 included a 23bp poly-A sequence near the center of the exon
followed by highly repetitive sequence.  In the mouse, the comparable exon 1 is 386pb
(NM_013627), while exon 2 is 80bp and corresponds with human and canine exon 3
(77bp) (Figure 3.4 & Table 3.5).
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Figure 3.4. Comparison of canine, human, and mouse PAX6 organization.  Open
boxes represent non-coding exons, and filled boxes represent coding exons.  Exon
sizes are given above exon boxes.  Lines represent introns with sizes written above.
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Table 3.5. Comparison Of Human, Canine And Mouse PAX6 Exon And Intron
Sizes. *Human sizes were determined using reference sequence NM_001604 and the
UCSC human genome sequence. **Mouse sizes were determined using reference
sequence NM_013627 and the UCSC mouse genome sequence. † Canine intron 2
and 7 estimates are based on the TIGR 1X (poodle) sequence. ∆Canine intron 4 and
11 estimates are based on UCSC 7.5X (boxer) sequence.  The complete size of
canine exon 13 is unknown. The ATG start codon is located in human and canine
exon 4, and mouse exon 3. The TAA stop codon is located in human and canine
exon 13, and mouse exon 12.
PAX6 EXONS &
INTRONS
HUMAN*
SIZES (bp)
CANINE
SIZES
(bp)
MOUSE
EXONS/
INTRONS
MOUSE**
SIZES
(bp)
EXON 1 119 103
INTRON 1 197 99
EXON 2 188 224 EXON 1 386
INTRON 2 3902 > 1704† INTRON 1 2971
EXON 3 77 77 EXON 2 80
INTRON 3 386 366 INTRON 2 357
EXON 4 (ATG) 61 61 EXON 3 (ATG) 61
INTRON 4 3567 >3492 ∆ INTRON 3 3520
EXON 5 131 131 EXON 4 131
INTRON 5 791 792 INTRON 4 792
EXON 5A 42 42 EXON 4a 42
INTRON 5A 94 94 INTRON 4a 94
EXON 6 216 216 EXON 5 216
INTRON 6 704 737 INTRON 5 675
EXON 7 166 166 EXON 6 166
INTRON 7 5902 > 2417 † INTRON 6 5621
EXON 8 159 159 EXON 7 159
INTRON 8 515 484 INTRON 7 470
EXON 9 83 83 EXON 8 83
INTRON 9 229 234 INTRON 8 193
EXON 10 151 151 EXON 9 151
INTRON 10 98 99 INTRON 9 116
EXON 11 116 116 EXON 10 116
INTRON 11 2577 >2816 ∆ INTRON 10 2453
EXON 12 151 151 EXON 11 151
INTRON  12 690 716 INTRON 11 813
EXON 13 (TAA) 1110 >99 EXON 12 (TAA) 799
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The canine PAX6 cDNA sequence (1786bp) representing exons 1-13,
including exon 5a, and a 20bp poly-A 3’end, was analyzed against the 2005 canine
7.6X genomic sequence (Boxer) using the blat function:
(http://genome.ucsc.edu/cgibin/hgBlat?command=start&org=Dog&db=canFam2&hgs
id=73037822).  As of November, 2006, there was 99.9% identity spanning >21kb in
the genomic sequence (38,671,042-38,692,610) on chromosome 18.  Matching
sequences were identified for exons 3-4, and 9-13.  However, PAX6 exons 1-2 and 5-8
(including exon 5a) were missing from the current canine draft sequence.  A 714bp
gap in the canine sequence, from 38,666,389-38,667,102, included predicted exons 1
and 2, while a second, larger 12,622bp gap from 38,675,042-38,687,663, included
exons 5-8.  As a result, our cloned sequence provides the complete PAX6 coding
sequence (accession numbers EF141016, and EF141017) which was unavailable from
the latest canine genomic sequence.
Primers designed to cross introns were used to determine intronic sizes for 9 of
the 13 canine introns.  The estimated sizes of the remaining 4 introns (2, 4, 7, and 11)
were determined using genomic sequence information from TIGR 1.5X (Poodle) [20]
and the 7.6X (Boxer) [17] public canine genome sequence
(http://genome.ucsc.edu/cgi-bin/hgGateway) (Figure 3.4).  Canine exons 3-12, and
intron 5a are identical in size to the human counterparts, while exons 1, and 2, and
introns 1-12 are similar in size (Table 3.5).  Both canine and human isoform b
(PAX6(5a)) nucleotide coding sequences were 1311bp and shared 97.3% identity,
while the corresponding amino acid sequences shared 99.8% identity (Figure 3.5).
Interestingly, the canine and mouse coding sequences were only 93.2% identical, and
had 89 nucleotide differences: 15-PD, 13-Linker, 11-HD, 50-PST.  Eighty-four of the
89 nucleotide differences between dog and mouse, occurred in the 3rd codon position
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Figure 3.5. Comparison of the canine and human PAX6 coding (CDS), and amino acid
sequences.  First row is the human (NM_001604) CDS, second row is the canine
CDS, and the third row is the corresponding amino acid sequence (436 aa). The first
underlined region is the Paired domain (426bp), followed by the Linker region
(234bp). The second underlined region is the homeodomain (183bp), followed by the
PST domain (459bp). Asterisks (*) mark the 36 nucleotide differences between dog
and man: 2 - PD, 3 - linker, 5 - HD, and 26 - PST domain.  Thirty-five of the 36
nucleotide differences occurred in the third position of the triplet codon, and did not
alter the translated amino acid.  Only one nucleotide difference occurred at the first
position of a codon (base pair 1213) resulting in an ACC (threonine) in man, and a
GCC (alanine) in the dog. This change occurred in exon 12 which was part of the PST
domain.  As a result, the human and canine PAX6 nucleotide coding sequences were
97.3% identical, and the corresponding amino acid sequences were 99.8% identical.
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H:ATGCAGAACA GTCACAGCGG AGTGAATCAG CTCGGTGGTG TCTTTGTCAA 50
C:ATGCAGAACA GTCACAGCGG AGTGAATCAG CTCGGTGGTG TCTTTGTCAA
  METGlnAsnS erHisSerGl yValAsnGln LeuGlyGlyV alPheValAs
                                         *
H:CGGGCGGCCA CTGCCGGACT CCACCCGGCA GAAGATTGTA GAGCTAGCTC 100
C:CGGGCGGCCA CTGCCGGACT CCACCCGGCA GAAGATCGTA GAGCTAGCTC
  nGlyArgPro LeuProAspS erThrArgGl nLysIleVal GluLeuAlaH
H:ACAGCGGGGC CCGGCCGTGC GACATTTCCC GAATTCTGCA GACCCATGCA 150
C:ACAGCGGGGC CCGGCCGTGC GACATTTCCC GAATTCTGCA GACCCATGCA
  isSerGlyAl aArgProCys AspIleSerA rgIleLeuGl nThrHisAla
H:GATGCAAAAG TCCAAGTGCT GGACAATCAA AACGTGTCCA ACGGATGTGT 200
C:GATGCAAAAG TCCAAGTGCT GGACAATCAA AACGTGTCCA ACGGATGTGT
  AspAlaLysV alGlnValLe uAspAsnGln AsnValSerA snGlyCysVa
H:GAGTAAAATT CTGGGCAGGT ATTACGAGAC TGGCTCCATC AGACCCAGGG 250
C:GAGTAAAATT CTGGGCAGGT ATTACGAGAC TGGCTCCATC AGACCCAGGG
  lSerLysIle LeuGlyArgT yrTyrGluTh rGlySerIle ArgProArgA
H:CAATCGGTGG TAGTAAACCG AGAGTAGCGA CTCCAGAAGT TGTAAGCAAA 300
C:CAATCGGTGG TAGTAAACCG AGAGTAGCGA CTCCAGAAGT TGTAAGCAAA
  laIleGlyGl ySerLysPro ArgValAlaT hrProGluVa lValSerLys
H:ATAGCCCAGT ATAAGCGGGA GTGCCCGTCC ATCTTTGCTT GGGAAATCCG 350
C:ATAGCCCAGT ATAAGCGGGA GTGCCCGTCC ATCTTTGCTT GGGAAATCCG
  IleAlaGlnT yrLysArgGl uCysProSer IlePheAlaT rpGluIleAr
                                                      *
H:AGACAGATTA CTGTCCGAGG GGGTCTGTAC CAACGATAAC ATACCAAGCG 400
C:AGACAGATTA CTGTCCGAGG GGGTCTGTAC CAACGATAAC ATACCAAGTG
  gAspArgLeu LeuSerGluG lyValCysTh rAsnAspAsn IleProSerV
H:TGTCATCAAT AAACAGAGTT CTTCGCAACC TGGCTAGCGA AAAGCAACAG 450
C:TGTCATCAAT AAACAGAGTT CTTCGCAACC TGGCTAGCGA AAAGCAACAG
  alSerSerIl eAsnArgVal LeuArgAsnL euAlaSerGl uLysGlnGln
H:ATGGGCGCAG ACGGCATGTA TGATAAACTA AGGATGTTGA ACGGGCAGAC 500
C:ATGGGCGCAG ACGGCATGTA TGATAAACTA AGGATGTTGA ACGGGCAGAC
  MetGlyAlaA spGlyMetTy rAspLysLeu ArgMetLeuA snGlyGlnTh
                         *                      *
H:CGGAAGCTGG GGCACCCGCC CTGGTTGGTA TCCGGGGACT TCGGTGCCAG 550
C:CGGAAGCTGG GGCACCCGCC CCGGTTGGTA TCCGGGGACT TCTGTGCCAG
  rGlySerTrp GlyThrArgP roGlyTrpTy rProGlyThr SerValProG
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Figure 3.5 (Continued)
H:GGCAACCTAC GCAAGATGGC TGCCAGCAAC AGGAAGGAGG GGGAGAGAAT 600
C:GGCAACCTAC GCAAGATGGC TGCCAGCAAC AGGAAGGAGG GGGAGAGAAT
  lyGlnProTh rGlnAspGly CysGlnGlnG lnGluGlyGl yGlyGluAsn
                                               *
H:ACCAACTCCA TCAGTTCCAA CGGAGAAGAT TCAGATGAGG CTCAAATGCG 650
C:ACCAACTCCA TCAGTTCCAA CGGAGAAGAT TCAGATGAGG CCCAAATGCG
  ThrAsnSerI leSerSerAs nGlyGluAsp SerAspGluA laGlnMetAr
                            *
H:ACTTCAGCTG AAGCGGAAGC TGCAAAGAAA TAGAACATCC TTTACCCAAG 700
C:ACTTCAGCTG AAGCGGAAGC TGCAGAGAAA TAGAACATCC TTTACCCAAG
  gLeuGlnLeu LysArgLysL euGlnArgAs nArgThrSer PheThrGlnG
             *
H:AGCAAATTGA GGCCCTGGAG AAAGAGTTTG AGAGAACCCA TTATCCAGAT 750
C:AGCAAATTGA AGCCCTGGAG AAAGAGTTTG AGAGAACCCA TTATCCAGAT
  luGlnIleGl uAlaLeuGlu LysGluPheG luArgThrHi sTyrProAsp
                           *         *
H:GTGTTTGCCC GAGAAAGACT AGCAGCCAAA ATAGATCTAC CTGAAGCAAG 800
C:GTGTTTGCCC GAGAAAGACT AGCGGCCAAA ATCGATCTAC CTGAAGCAAG
  ValPheAlaA rgGluArgLe uAlaAlaLys IleAspLeuP roGluAlaAr
                            *
H:AATACAGGTA TGGTTTTCTA ATCGAAGGGC CAAATGGAGA AGAGAAGAAA 850
C:AATACAGGTA TGGTTTTCTA ATCGGAGGGC CAAATGGAGA AGAGAAGAAA
  gIleGlnVal TrpPheSerA snArgArgAl aLysTrpArg ArgGluGluL
             *               *            *      *  *  *
H:AACTGAGGAA TCAGAGAAGA CAGGCCAGCA ACACACCTAG TCATATTCCT 900
C:AACTGAGGAA CCAGAGAAGA CAGGCTAGCA ACACACCCAG TCACATCCCC
  ysLeuArgAs nGlnArgArg GlnAlaSerA snThrProSe rHisIlePro
                                        *  *
H:ATCAGCAGTA GTTTCAGCAC CAGTGTCTAC CAACCAATTC CACAACCCAC 950
C:ATCAGCAGTA GTTTCAGCAC CAGTGTCTAC CAACCTATCC CACAACCCAC
  IleSerSerS erPheSerTh rSerValTyr GlnProIleP roGlnProTh
     *  *                *                      *
H:CACACCGGTT TCCTCCTTCA CATCTGGCTC CATGTTGGGC CGAACAGACA 1000
C:CACGCCTGTT TCCTCCTTCA CCTCTGGCTC CATGTTGGGC CGGACAGACA
  rThrProVal SerSerPheT hrSerGlySe rMetLeuGly ArgThrAspT
                   *                   *
H:CAGCCCTCAC AAACACCTAC AGCGCTCTGC CGCCTATGCC CAGCTTCACC 1050
C:CAGCCCTCAC AAACACGTAC AGCGCTCTGC CGCCCATGCC CAGCTTCACC
  hrAlaLeuTh rAsnThrTyr SerAlaLeuP roProMetPr oSerPheThr
       *
H:ATGGCAAATA ACCTGCCTAT GCAACCCCCA GTCCCCAGCC AGACCTCCTC 1100
C:ATGGCGAATA ACCTGCCTAT GCAACCCCCA GTCCCCAGCC AGACCTCCTC
  MetAlaAsnA snLeuProMe tGlnProPro ValProSerG lnThrSerSe
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  *                                      *            *
H:ATACTCCTGC ATGCTGCCCA CCAGCCCTTC GGTGAATGGG CGGAGTTATG 1150
C:GTACTCCTGC ATGCTGCCCA CCAGCCCTTC GGTGAACGGG CGGAGTTACG
  rTyrSerCys MetLeuProT hrSerProSe rValAsnGly ArgSerTyrA
             *     *            *
H:ATACCTACAC CCCCCCACAT ATGCAGACAC ACATGAACAG TCAGCCAATG 1200
C:ATACCTACAC GCCCCCCCAT ATGCAGACCC ACATGAACAG TCAGCCAATG
  spThrTyrTh rProProHis MetGlnThrH isMetAsnSe rGlnProMet
               *        *
H:GGCACCTCGG GCACCACTTC AACAGGACTC ATTTCCCCTG GTGTGTCAGT 1250
C:GGCACCTCGG GCGCCACTTC CACAGGACTC ATTTCCCCTG GTGTGTCAGT
  GlyThrSerG ly   ThrSe rThrGlyLeu IleSerProG lyValSerVa
                  *                         *   *
H:TCCAGTTCAA GTTCCCGGAA GTGAACCTGA TATGTCTCAA TACTGGCCAA 1300
C:TCCAGTTCAA GTTCCTGGAA GTGAACCTGA TATGTCTCAG TATTGGCCAA
  lProValGln ValProGlyS erGluProAs pMetSerGln TyrTrpProA
H:GATTACAGTA A 1311
C:GATTACAGTA A
  rgLeuGlnST P
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and represented silent changes.  Of the 5 nucleotide differences which occurred in the
first codon position, only two resulted in an amino acid change: PAX6(5a) coding
sequence nucleotide position 178 in exon 5a (PD) coded for glutamine (CAA) in the
dog and man, but glutamic acid (GAA) in mouse; nucleotide position 1213 in exon 12
(PST) coded for alanine (GCC) in the dog and threonine (ACC) in mouse and man.
Exon Scanning
The 14 exons of canine PAX6 were scanned for mutations, including predicted
exons 1 and 2, cloned exons 3-13, and the alternatively transcribed exon 5a.  Splice
sites at the intron/exon boundaries were also examined; at least 27 intronic nucleotides
before each exon, and at least 30 intronic nucleotides after each exon were included in
the analysis.  PAX6 exon scans were performed in 7 dogs that were part of one
pedigree; this included 4 aniridia-affected dogs and 3 non-affected related dogs
(Figure 3.2).  Non-coding exon 2 (224 bp) contained a 23bp poly-A region followed
by 6 AACC repeats.  The first 133bp of exon 2 was scanned in all 7 dogs, and the
complete exon 2 sequence was scanned in 2 affected dogs (GD 5, 6) and 2 normal
dogs (GD 3, 8).  These 4 dogs had an extra AACC repeat in non-coding exon 2.
PAX6 exon scanning also revealed 2 single nucleotide polymorphisms (SNPs).
The first was located in exon 7 at nucleotide position 501/1311, and involved a C to T
change at the third position of the codon which did not alter the amino acid coded
(ACC to ACT; threonine).  The second SNP occurred in intron 8 (484bp) at intronic
nucleotide position 351, and was an A to G transition.  Both of these SNPs were silent
changes which did not alter the translated amino acids.  No pathological mutations
were identified in all 14 exons scanned or in their exon/intron junctions.
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Radiation Hybrid Mapping
A canine/hamster radiation hybrid (RH3000) panel was used to link canine
PAX6 to CFA 18 in relation to 7 gene markers and 7 microsatellite markers (Table
3.3) which were mapped in previous studies [21, 22].  Multimap analysis could only
place 8 of the 15 markers at unique map positions.  PAX6 and 6 other markers were
placed on CFA18, but could not be localized to a unique position in relation to the
other markers. However, two-point linkage analysis linked canine PAX6 to Wilms-TF
and WT1 on CFA18, with LOD scores of 8.0 and 7.1, respectively. Wilms-TF and
WT1 are both located on CFA18 in a region with homology to HSA11p13, [22, 24,
25] which is where human PAX6 is located.  Similar map locations between the canine
and human PAX6 genes further supports their homology.
Association Testing
Having excluded disease-associated changes in the coding sequence, we
examined whether there was an association of PAX6 with the disease locus.  Ten
Catalan sheepdogs (6 affected and 4 non-affected) were tested for association of PAX6
with the aniridia phenotype.  Seven of these dogs were related and part of the same
pedigree, while 3 dogs were unrelated (Figure 3.3).  Because of the limited genetic
studies to date, it was not definitive whether this disease was recessive or dominant.
Based on a prior report [18], and the production of affected dogs from non-affected
parents, recessive inheritance was assumed.  Furthermore, based on the small breed
size, we hypothesized also that all aniridia-affected dogs resulted from a founder-
effect mutation.  Thus, if the disease is autosomal recessive, all affected dogs would be
homozygous for a common haplotype segment of CFA18.  Alternatively, if the disease
is autosomal dominant with incomplete penetrance, all affected dogs would have at
least one common haplotype segment of CFA18.
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Six polymorphic markers on CFA18 were analyzed that included 4
microsatellite markers (C18.156, COS18, Wilms-TF, and REN47J11), and 2 PAX6
SNPs (exon 7 and intron 8).  All 10 dogs examined shared at least one common
haplotype for all 6 markers (Figure 3.3: "111TG1").  Four of the 6 affected dogs
(GD6, GD9, GD10, GD14) were homozygous for this common haplotype, while 2
affected dogs (GD5, GD12) were heterozygous. All affected dogs, regardless of
homozygosity or heterozygosity for this haplotype, showed a broadly similar aniridia
phenotype.  Haplotypes for GD5 and GD12 were repeated to confirm their
heterozygosity.  All 4 unaffected dogs (GD2, GD3, GD8, GD13) were heterozygous
for the common haplotype.  At 4 of the 6 individual marker loci (C18.156, COS18,
WILMS-TF, and exon 7 SNP) both normal and affected dogs shared common
genotypes.  For 2 marker loci (intron 8 SNP, and REN47J11) non-affected dogs had
both homozygous and heterozygous genotypes while all affected dogs were
homozygous.  Furthermore, at each marker locus there were both affected and non-
affected animals with identical genotypes.  Such degree of haplotype sharing is not
unexpected given the small breed size and degree of inbreeding.
Assuming recessive inheritance, our observations suggested no association of
the PAX6 locus with the aniridia phenotype.  However, if aniridia segregates as a
dominant disease in these dogs, our observations would suggest an association in that
all affected dogs shared at least one common haplotype ("111TG1").  Incomplete
penetrance could explain the presence of this commom haplotype in “non-affected”
dogs (GD2, GD3, GD8, GD13) that did not manifest the aniridia phenotype.
Southern Blot Analysis
A Southern blot analysis was performed using probes designed from both the
5’UTR (exon 1, intron 1, exon 2 and the 5’ end of intron 2) and the 3’ PST domain (3’
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end of intron 11, all of exon 12 and the 5’ end of intron 12) of PAX6.  Identical bands
were found in affected and unaffected dogs from the aniridia pedigree, and a normal
Beagle control using both probes.  The 5’UTR probe hybridized at about 8500bp,
while the 3’ PST probe hybridized at about 7400bp (data not shown).  The absence of
any distinction between the PAX6 bands of affected and non-affected dogs using both
5’ and 3’ end probes suggested that there were no large deletions present in these two
regions of the gene.
Discussion
Human aniridia patients show varying degrees of iris loss including complete
to partial absence of the iris, iris coloboma and thinning of the iris.  They may also
exhibit other related ocular abnormalities including cataract, keratitis, or glaucoma
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM).  In this study, the
clinical manifestation of aniridia in a canine model strongly resembled that seen in
human patients.  Canine subjects showed total to nearly complete absence of the iris
with ciliary processes visible at the circumferential border; in some cases, cataracts,
corneal edema and glaucoma also were present.  The anatomical similarities between
the dog and human eye, along with the clinical similarities in canine and human
aniridia phenotypes, make the dog an important model for this disease.
Because the vast majority of aniridia cases in man are caused by mutations in
the PAX6 gene [26] we used the candidate gene approach to evaluate PAX6 in the
study population.  PAX6 was cloned from a canine retinal cDNA library, and linked to
WT1 and Wilms-TF on CFA18 using an RH3000 panel.  A previous study placed
PAX6 on CFA18 in the same region between markers FH3824 and CFOR04B04 using
an RH5000 panel [27].  WT1 is just 4 cRays away from marker FH3824, and 14
cRays from CFOR04B04 on the RH5000, 4249-marker map [25].  Integrated canine
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maps demonstrate homology between CFA18 and human chromosomes 7 and 11 [28-
30].  PAX6 is located in a region of CFA18 which has homology with human
chromosome 11p13 where PAX6 is located in man.
The canine PAX6 cDNA sequence was 1786bp, and included predicted exons 1
and 2, and cloned exons 3-13, plus alternatively transcribed exon 5a (EF141016,
EF141017).  This cDNA has sequence identity with the current canine genomic
sequence over a span >21kb in length (38,671,042-38,692,610)
[17](http://genome.ucsc.edu/cgi-bin/hgGateway).  This presumably represents the
genomic length of the canine PAX6 gene.  The human PAX6 genomic sequence is
22.4kb (NM001604), while the mouse genomic sequence is 20.6kb (NM013627).
Canine PAX6 exons 3-4 and 9-13 matched sequences in the current genomic sequence.
However, exons 1-2 fell within a 714bp gap, and exons 5-8 fell within a second
12,622bp gap in the sequence.  The exons that are missing in the current draft canine
genomic sequence are provided by our cloning studies.  Thus, this study fills in the
gaps left by the draft canine genome sequence, and provides a complete canine PAX6
sequence.
At the nucleotide level, the canine PAX6(5a) coding sequence (1311bp) had a
higher degree of homology to the human (NM_001604) (97.3% identical) than to the
mouse (NM_013627) (93.2% identical) sequence.  Most of the nucleotide variations
occurred within the PST domain: 26 of the 36 nucleotide differences between dog and
human, and 50 of 89 differences between dog and mouse.  Nevertheless, most of the
nucleotide differences occurred in the third codon position and were synonymous
changes that did not result in corresponding amino acid changes (Figure 3.5).
At the amino acid level, canine PAX6 is 99.8% and 99.5% identical,
respectively, to the human and murine sequences.  The one amino acid difference
between canine and human sequences occurred in the PST region at codon 405
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(nucleotide position 1213/1311) which codes for alanine in the dog, and threonine in
man.  The mouse also has threonine at codon 405, and, in addition, the mouse has
glutamic acid in the PD at codon 60 (nucleotide position 178/1311) while the dog and
human have glutamine.  The extremely high PAX6 nucleotide and amino acid
sequence identities between dog, man and mouse suggest a consistency in protein
structure and function.
Both canine (EF141016, EF141017) and human (NM_001604) PAX6
contained 13 exons plus an alternatively transcribed exon 5a.  Exons 3-12 and intron
5a were the same sizes in both species while intronic sizes were similar.  The mouse
(NM_013627) gene, however, only has 12 exons (plus exon 4a) with mouse exons 2-
12 corresponding to canine and human exons 3-13.  The mouse coding sequence
(exons 3-12) was the same size as the corresponding coding sequences in dog and
human (exons 4-13).  Mouse exon 2, and introns 1-12 were also similar in size to
canine and human, but mouse exon 1 was 386bp compared with 103bp (dog) and
119bp (human).  Mouse exon 1 is more similar in size to canine and human exons 1
and 2 combined, 327 (canine) and 307 (human), and may explain why the mouse has
one less exon than the canine and human genes.
No pathological mutations were detected in the canine PAX6 coding sequence,
non-coding exons, or in the intron/exon junctions of aniridia-affected dogs.  This
included coding exons 4-13, the alternatively transcribed exon 5a, and the non-coding
exons 1-3 in the 5’UTR.  Because the dogs used in this study were privately owned
pets or working dogs, we were unable to obtain tissue samples to examine PAX6 RNA
products to detect splicing defects or other transcript variants.  We also were unable to
examine PAX6 expression in normal and affected animals to rule out mutations in a
promoter or enhancer.
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Southern blot analysis showed no difference in normal from affected dogs
using either 5’ or 3’ end probes.  In the case of a recessively inherited deletion, normal
and affected dogs would be distinguishable on Southern analysis because all affected
dogs would be homozygous for the deletion, and have either no PAX6 band (if the
probe is in the deletion), or a smaller PAX6 band (if the probe is not in the deletion,
and the deletion is > 50bp).  Thus, if canine aniridia is a recessive trait, we have
excluded a large deletion in PAX6 at both the 5’ and 3’ ends of the gene.  However, in
the case of dominant inheritance, if the Southern blot probe lies within a deletion, the
blot would not distinguish between heterozygous-affected, and normal dogs, making
the results of the Southern analysis inconclusive.  Regardless of the mode of
inheritance, however, deletions in the region of exon 7 and intron 8 can be ruled out in
dogs which were heterozygous for SNPs detected in these regions [exon 7 (GD3,
GD8, GD12, GD13)  and intron 8 (GD3, GD8)].
Limitations in access to a larger sample size of dogs, or the ability to carry out
prospective matings, prevented confirmation of the mode of inheritance of canine
aniridia, and created difficulties in interpreting the association test.  If canine aniridia
is inherited as a recessive trait, the association test suggests no association of the PAX6
locus with the aniridia phenotype. However, if canine aniridia is a dominant disease,
there appears to be association of PAX6 with aniridia in that all affected dogs share at
least one common haplotype ("111TG1").  Dominance with incomplete penetrance
could account for the presence of this common haplotype in the “non-affected” dogs
(GD2, GD3, GD8, GD13).  Nonetheless, the broadly similar aniridia phenotype
present in dogs homozygous or heterozygous for the "111TG1" haplotype argues
against dominant inheritance.  Furthermore, the frequent occurrence of the “111TG1
haplotype may not be associated with the aniridia phenotype, but may instead result
from the degree of relatedness among dogs.
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This emphasizes the need for further analysis of animals to establish the mode of
inheritance, and to conduct a more complete association test and segregation analysis.
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APPENDIX
1353bp
1078bp
872bp
603bp
310bp
271, 281bp
234bp
194bp
318bp
Figure A3.6. Representative 2% agarose gel showing PCR products
amplified from genomic DNA from Spanish Catalan sheepdogs using
primers specific for PAX6 exon 13. The first column contains a
PhiX174 DNA marker, and columns 2-8 show a 318bp band
representing exon 13 in dogs featured in pedigrees (Figures 3.2 and
3.3.).
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CHAPTER 4
EVALUATION OF PAX6 AS A CANDIDATE GENE IN CANINE MODELS OF
CATARACT, PERSISTENT PUPILLARY MEMBRANES AND MULTIPLE
CONGENITAL DEFECTS
Abstract
Purpose:  Mutations that result in premature termination of the PAX6 protein cause
aniridia, while missense mutations are associated with non-aniridia ocular phenotypes
in man.  Because aniridia phenotypes are most commonly selected for PAX6
evaluation, there is an over-representation of premature termination mutations, and a
relative paucity of missense mutations.  To try to identify missense mutations
associated with non-aniridia phenotypes, we evaluated PAX6 in dog breeds with
inherited ocular diseases including cataract, persistent pupillary membrane, sclero-
cornea, and choroidal hypoplasia.
Methods:  PAX6 coding regions and splice sites were analyzed for mutations by direct
sequencing in affected dogs from three breeds with inherited ocular diseases.
Genomic DNA was extracted from whole blood from Siberian huskies with inherited
cataract, Basenjis with persistent pupillary membranes and Soft-coated wheaten
terriers with persistent pupillary membranes, sclero-cornea and choroidal hypoplasia.
Results:  Evaluation of canine PAX6 in three breeds identified four single nucleotide
polymorphisms (SNPs), and two microsatellite expansions.  Two SNPs, and both
microsatellite expansions occurred within the 5’ untranslated region, while the
remaining two SNPs occurred within coding exons 7 and 12.
Conclusion: Although the sequence changes identified in this study were either present
in non-coding regions, or represented synonymous changes in coding exons,
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additional pedigree information is needed to rule out the association of PAX6 with the
disease phenotypes studied.
Introduction
The transcription factor PAX6 is a member of the PAX family of DNA-
binding transcription factors, and is highly conserved across species (1).  PAX6
contains both paired (PD), and homeo (HD) domains which function as binding sites
for DNA targets, as well as a proline-serine-threonine rich (PST) domain which
functions as a transactivator (2).  PAX6 is expressed in the developing CNS, eye, and
nose during embryogenesis (3-7).  Within the eye, it is expressed in the developing
cornea, conjunctiva, lens, ciliary body, and retina (8-11).  PAX6 is a master control
gene for the development of ocular structures in both vertebrates and invertebrates,
and is essential for normal eye morphology. Misexpression of Pax6 in Xenopus laevis,
or the PAX6 homologue eyeless in Drosophila, is sufficient for the formation of
ectopic eyes (12, 13).
PAX6 mutations are inherited as autosomal dominant or semidominant, and are
homozygous lethal.  In mouse, Pax6 mutations cause microphthalmia (small eye),
cataract, abnormal iris, and anophthalmia (14, 15). In man, PAX6 mutations cause
aniridia (OMIM#106210), a panocular disease characterized by partial to complete
absence of the iris, which often occurs with: corneal opacity, cataract, nystagmus,
foveal hypoplasia, optic nerve hypoplasia, or glaucoma.  Because aniridia phenotypes
have been most commonly associated with PAX6 mutations, these phenotypes have
been preferentially selected for PAX6 mutation screening (16, 17). Analysis of the
PAX6 Allelic Variant Database (http://pax6.hgu.mrc.ac.uk/) reveals that mutations
which cause a premature termination in the PAX6 protein are predominantly
associated with aniridia, while missense mutations are associated with non-aniridia
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phenotypes (16, 18). The over-selection of aniridia phenotypes for PAX6 mutation
analysis has, therefore, resulted in the over-representation of mutations which cause
premature termination of the PAX6 protein (17). Conversely, there is an under-
representation of missense mutations which may be associated with non-aniridia
phenotypes (19). Thus, there is a need to select non-aniridia phenotypes for PAX6
mutation screening to try to identify other missense mutations.
Non-aniridia PAX6 phenotypes have been described including Peter’s anomaly
(20), autosomal dominant keratitis (21), ectopic pupil with optic nerve and macular
hypoplasia (19), and ectopic pupil with iris atrophy (22).  Isolated foveal hypoplasia
(23), as well as foveal hypoplasia with nystagmus and cataracts (19), and foveal
hypoplasia with nystagmus, iridocorneal adhesion, corneal opacity, microphthalmos,
sclero-cornea, exotropia and embryotoxon (24), have also been described.  PAX6
mutations affecting the optic nerve have been identified which cause optic nerve
hypoplasia/aplasia, optic nerve coloboma, and morning glory disc anomaly (25).
Although cataracts often occur with aniridia, PAX6 mutations resulting in cataracts
without iris abnormalities have also been described (2, 19, 22, 24, 26).  The spectrum
of ocular phenotypes observed in non-aniridia PAX6 mutations, as well as those
observed in conjunction with aniridia, provide a clue as to which phenotypes may be
worth considering as candidates for PAX6 mutation screening.  These include
phenotypes affecting the cornea, iris, pupil, lens, retina, and optic nerve.
In an attempt to identify PAX6 mutations associated with non-aniridia
phenotypes, we have evaluated PAX6 sequences in canine models with inherited non-
aniridia ocular phenotypes. Canine PAX6 (accession #s EF141016, and EF141017)
was cloned and characterized in a previous study (27).  Both the human and canine
PAX6 genes contain 13 exons plus an alternatively transcribed exon 5a located
between exons 5 and 6 (24, 26, 27).  Human and canine coding sequences are 97.3%
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identical, and the corresponding amino acid sequences are 99.8% identical; only one
amino acid difference occurs in the PST region at codon 405 which codes for
threonine (ACC) in man, and alanine (GCC) in the dog (27).  PAX6 is located on
Canis familiaris autosome 18 (CFA18) in an area homologous to the location of
PAX6 on HSA 11p13 (27-29). Thus, the homology between human and canine PAX6,
with regard to nucleotide and amino acid sequences, as well as gene organization, and
gene location, make the dog a reasonable animal model for molecular analysis of this
gene.  In addition, naturally occurring diseases in dogs are clinically, physiologically,
and histologically similar to their corresponding human diseases, and this has
contributed to the successful use of dogs as models of many human genetic diseases
(30, 31).
In an effort to identify non-aniridia phenotypes with possible PAX6 missense
mutations, we have selected three dog breeds with phenotypes consistent with those
observed in patients with PAX6 mutations. These include: (a) Siberian huskies with
inherited cataracts (32, 33),  (b) Basenjis with inherited, congenital, persistent
pupillary membrane (PPM) (34-38), and (c) Soft-coated wheaten terriers (SCWT) with
an inherited ocular syndrome characterized by PPM, sclero-cornea, and choroidal
hypoplasia.  In man, PAX6 mutations are associated with cataract (2, 19, 22, 24, 26),
and  PPM (39, 40).  In addition, PAX6 is expressed in the developing (9), and adult
(10) cornea, and mutations are associated with corneal dystrophy (2, 19), keratitis
(21), microcornea (41), and sclero-cornea (42, 43).  As well, PAX6 mutations have
been associated with ocular coloboma affecting the choroid, retina, and optic nerve
(25).
Lack of pedigree information and samples prevented association and linkage
studies, and necessitated using an exon scanning approach for molecular evaluation of
these phenotypes. PAX6 was chosen as a candidate gene for analysis because all three
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breeds had ocular phenotypes involving anatomical structures which have been
associated with PAX6 mutations.  Fourteen PAX6 exons (including exon 5a) were
evaluated by direct sequencing of genomic DNA from each breed.  Four single
nucleotide polymorphisms (SNPs) were identified; two in the 5’ untranslated region
(5’UTR), and two within the translated region.  Two microsatellite expansions were
identified in the 5’UTR as well.
Methods
Animals and DNA
All dogs used in this study were examined by board-certified veterinary
ophthalmologists using indirect ophthalmoscopy and slit lamp biomicroscopy, after
mydriasis.  Whole blood was collected in EDTA anticoagulant tubes, and stored at
–70°C until analyzed.  Total genomic DNA (gDNA) was extracted from blood
lymphocytes using standard phenol:chloroform extraction protocols (44).  Limited
pedigree information made it impossible to perform genome wide scans, linkage or
association studies. Thus, to analyze the molecular basis of disease in these dogs, a
direct sequencing approach was used.  Three breeds with inherited ocular diseases
were examined including:
(a) Siberian huskies with inherited cataracts.  These cataracts occur
approximately between 8 months – 1.5 years of age, and affect the posterior cortex.
They form a characteristic large triangular plaque in the posterior cortex with a
prominent central inverted Y-suture.  Two unrelated, one-year-old male dogs (H-1,
and H–2) with bilateral, posterior cortical cataracts were selected for PAX6 sequence
analysis.
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(b) Basenjis with PPMs.  Two, 3 year-old, full sibling male dogs with
congenital, unilateral, iris-to-iris PPMs were selected for PAX6 analysis. B-1 was
affected in the left eye, and B-2, in the right eye.
(c) Soft-coated wheaten terriers (SCWT) with a congenital, autosomal
recessive syndrome characterized by PPMs, sclero-cornea, and choroidal hypoplasia.
Two, 4 month-old, full sibling SCWTs, one female (SCWT-1) and one male (SCWT-
2), with bilateral, iris-to-iris, PPMs were selected for PAX6 analysis.  Both dogs also
had ventral sclero-cornea such that the ventral margins of the normally transparent
cornea were invaded by opaque white scleral tissue.  SCWT-1 had mild, bilateral,
choroidal hypoplasia, while SCWT-2 had choroidal hypoplasia that was moderate and
localized in the right eye, and severe and localized in the left eye.
Exon scanning
Fourteen PAX6 exons along with their intron/exon boundaries, were sequenced
using PCR amplification of genomic DNA from two affected dogs from each breed,
and one non-affected, normal beagle as a control.  Exon 13 was sequenced through the
TAA stop codon only, as the exact end of this exon is unknown.  Primers used to
amplify each PAX6 exon were described in a previous study (27).  PCRs were run at
25ul reaction volume in triplicate, using Taq DNA polymerase (Invitrogen
Corporation, Carlsbad, CA).  PCR conditions were as follows: 2 min 94°C followed
by 30 cycles of 60 sec 94°C, 60 sec 58°C, 60 sec 72°C, and a final extension of 7 min
72°C.  However, an annealing temperature of 64° was used for exon 1 , and 56° for
exons 4, 5a, 9, 12 and 13.  PCRs were run on Amplitron II Thermolyne (Barnstead
Thermolyne Co., Dubuque, IA), and MJ Research Tetrad 2 (Global Medical
Instrumentation Inc., Ramsey, MN) thermocyclers, and PCR products were separated
by electrophoresis on 2% agarose gels (Invitrogen, Carlsbad, CA) with 1X TAE buffer
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(0.04 M Tris-acetate buffer, pH 8, 100 mM ethylenediaminetetra-acetic acid) at 60V.
Gels were stained with ethidium bromide, and visualized using an ultraviolet (UV)
transilluminator (Spectronics Corporation, Westbury, NY).  Digital images were
recorded of each gel.  PCR products were gel purified using the QIAquick Gel
Extraction kit (QIAGEN Inc., Valencia, CA) or the QIAquick PCR purification kit
(QIAGEN Inc., Valencia, CA).  Purified PCR products were then sequenced on the
Applied Biosystems Automated 3730 DNA Analyzer using Big Dye Terminator
chemistry and Ampli Taq-FS DNA Polymerase.
Sequencher™ software (Gene Codes Corporation, Ann Arbor, MI) was used
for sequence analysis.  Nucleotide changes in PAX6 identified in the study dogs were
compared with sequences from normal beagle, 1.5X canine (poodle) genomic
sequence (45) and 7.5X canine (boxer) genomic sequence (46).  However, the 7.5X
(boxer) sequence did not contain the PAX6 exon 2 microsatellite, or the exon 7 SNP.
Results
PAX6 sequences were analyzed in 6 dogs representing three breeds with
inherited ocular diseases.  These included; two Siberian huskies with cataracts, two
Basenjis with PPM, and two SCWTs with PPM, sclero-cornea, and choroidal
hypoplasia.  Fourteen PAX6 exons were examined for mutations, including
untranslated exons 1-3, and part of exon 4, translated exons 4-13, and alternatively
transcribed exon 5a.  Exon 13 sequences were analyzed through the TAA stop codon
(Figure 4.1).
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Siberian Huskies
3276        7029
Basenjis
3268     3269
SCWTs
9568        9573
1353bp
1078bp
872bp
603bp
310bp
271, 281bp
Figure 4.1.  Representative 2% agarose gels showing PCR products
amplified from genomic DNA using primers specific for PAX6 exon 13
(318bp) in Siberian huskies with cataracts (gel #1), Basenjis with PPM (gel
#2), and SCWTs with PPM, sclero-cornea, and choroidal hypoplasia (gel
#3). Individual dog identification numbers are indicated above wells.  Gels
#1 and #3 show PCRs run in triplicate while gel #2 shows PCRs run in
duplicate.  The first column of each gel contains a PhiX174 DNA marker.
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  Intron/exon boundaries (splice sites) were also examined including at least 13
intronic nucleotides before each exon, and at least 16 intronic nucleotides after each
exon.  Introns 5a (94bp), 9 (234bp), and 10 (99bp) were examined in their entirety in
all 6 dogs.  Canine PAX6(5a) cDNA was 1766bp from exon 1 through the TAA stop
codon in exon 13.  The PAX6(5a) coding sequence was 1311bp and began at the ATG
start codon in exon 4 (nucleotide 456), and ended at the TAA stop codon in exon 13
(nucleotide 1766).  This sequence coded for a 436 amino acid protein (27).
The results of PAX6 sequence analysis revealed 2 intronic SNPs, 2 exonic
SNPs, and 2 microsatellite expansions (Table 4.1).   At the 5’ end of intron 2 there was
a cytosine to guanine (C G) change at intronic nucleotide (+27), and a thymine to
cytosine (T  C) change at intronic nucleotide (+51).  The latter SNP (intron 2, +51),
was located at the 3’ end of a CTT microsatellite (5’-CTTCTTCTTCTTTTT-3’) such
that it expanded a microsatellite from four repeats (CTT)4, to five (CTT)5.  Thus, dogs
with a thymine (T) at this position had four microsatellite repeats (CTT)4, while dogs
with a cytosine (C) had 5 repeats (CTT)5.  Canine PAX6 exon 2 was 224 bp and
contained a 23bp poly-A region (nucleotides 229-251) followed by a (CCAA)7
microsatellite (nucleotides 259-286) which varied in repeat number in some subject
dogs.  This sequence was unavailable in the 7.5X canine (boxer) public genomic
sequence (46), but was present in the 1.5X canine (poodle) public genomic sequence
(45).  Exonic SNPs included a previously reported cytosine to thymine (CT) change
in exon 7 at nucleotide 956 (codon 167; ACC, ACT = threonine) (27), and a novel
guanine to adenine (GA) change in exon 12, at nucleotide 1631 (codon 392; CAG,
CAA = glutamine).  Both exonic SNPs occurred at the third position of the codon and
were synonymous changes which did not alter the amino acid coded.
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Table 4.1.  PAX6 sequence changes identified in Siberian huskies (cataract), Basenjis
(PPM), and Soft-coated wheaten terriers (SCWTs) with PPM, sclero-cornea, and
choroidal hypoplasia.  Changes were compared with normal controls taken from
beagle, the 1.5X canine (poodle) genomic sequence, and the 7.5X (boxer) genomic
sequence.  The latter sequence did not contain PAX6 exon 2 or exon 7; NA- not
applicable.
AFFECTED DOGS NORMAL CONTROLS
Siberian Husky
cataract
Basenji
PPM
SCWT
PPM, sclero-cornea
& choroidal
hypoplasia
1.5X Seq 7.5X
Seq.
PAX6
LOCA-
TION
H-1 H-2 B-1 B-2 SCWT-1 SCWT-2 BEAGLE POODLE BOXER
EXON 2
(CCAA)
repeat
(CCAA)
x8
(CCAA)
x7
(CCAA)
x8
(CCAA)
x8
(CCAA)
x7
(CCAA)
x7
(CCAA)
x7
(CCAA)
x7
NA
INTRON
2 (+27)
C/C C/C C/G C/C C/G C/G C/C C/C C/C
INTRON
2 (+51)
C/C
(CTT)5
T/C
(CTT)4
(CTT)5
T/C
(CTT)4
(CTT)5
C/C
(CTT)5
T/C
(CTT)4
(CTT)5
T/T
(CTT)4
T/C
(CTT)4
(CTT)5
T/T
(CTT)4
T/T
(CTT)4
EXON 7
(nt 956;
codon
167)
C/T C/C C/C C/C C/T T/T C/C C/C NA
EXON 12
(nt 1631;
codon
392)
G/G G/G G/G G/G A/G G/G G/G G/G G/G
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Siberian Husky - cataract
Within exon 2, H-1 was homozygous for eight microsatellite repeats (CCAA)8
while H-2 was homozygous for seven (CCAA)7 (Table 4.1).  Both were homozygous
C/C at intron 2 (+27). H-1 was also homozygous C/C at intron 2 (+51) resulting in
five microsatellite repeats (CTT)5, while H-2 was heterozygous C/T resulting in both
(CTT)4 and (CTT)5 alleles.  At the exon 7 SNP, H-1 was heterozygous C/T while H-2
was homozygous C/C. Both were homozygous G/G at the exon 12 SNP.
Basenji – persistent pupillary membrane
Both dogs were homozygous for eight microsatellite repeats (CCAA)8 in exon
2 (Table 4.1).  In intron 2 (+27), B-1 was heterozygous C/G while B-2 was
homozygous C/C. At intron 2 (+51), B-1 was heterozygous T/C resulting in both four
(CTT)4, and five (CTT)5 microsatellite repeats, while B-2 was homozygous C/C with
five (CTT)5 repeats.  Both were homozygous C/C and G/G for exon 7 and exon 12
SNPs, respectively.
Soft-coated wheaten terriers – PPM, sclero-cornea, and choroidal hypoplasia
Both dogs were homozygous for 7 microsatellite repeats (CCAA)7 in exon 2,
and were heterozygous C/G at intron 2 (+27) (Table 4.1).  SCWT-1 was heterozygous
T/C at intron 2 (+51), resulting in both (CTT)4 and (CTT)5 alleles, while SCWT-2
was homozygous T/T with (CTT)4 repeats.  SCWT-1 was heterozygous C/T at the
exon 7 SNP and A/G at the exon 12 SNP while SCWT-2 was homozygous T/T, and
G/G at the exon 7, and 12 SNPs, respectively.
Discussion
In an effort to identify missense mutations in PAX6 which are associated with
non-aniridia ocular phenotypes, exon scanning was used to evaluate PAX6 in three dog
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breeds with inherited ocular diseases.  These included, Siberian huskies with cataract,
Basenjis with PPM, and SCWTs with PPM, sclero-cornea, and choroidal hypoplasia.
Assuming autosomal recessive inheritance for each disease analyzed, a pathological
PAX6 mutation must be homozygous, and present in both affected dogs of each breed.
This criteria is only met for the exon 2, (CCAA)8 microsatellite which occurred in
both Basenji dogs.  All other sequence changes identified were either not present in
both affected dogs, or were not present in a homozygous state (Table 4.1).  Assuming
autosomal dominant inheritance for each disease, a pathological PAX6 mutation may
be heterozygous, or homozygous, but must occur in both affected dogs of each breed.
This criteria was fulfilled again in the exon 2, (CCAA)8 microsatellite in both
Basenjis.  In addition, both affected SCWTs had at least one “mutant” PAX6 allele for
the intron 2 (+21), and the exon 7 SNPs (Table 4.1).
However, none of the mutations identified in this study were expected to alter
PAX6 transcription or translation.  The (CCAA)7-8 microsatellite was located within
non-coding exon 2, and to date, there have been no pathological mutations identified
in human non-coding exons 1 or 2.  Nevertheless, pathological mutations have been
identified in the human PAX6 5’UTR from intron 2 through exon 4, and also within
introns 4-12 (The Human PAX6 Allelic Variant Database:http://PAX6.hgu.mrc.ac.uk).
Human PAX6 exon 2 is 188 bp (NM001604) compared to 224bp in the dog
(EF141017).  The 36 bp difference is partly composed of a 23 bp poly-A sequence in
the dog, from nucleotide 229-251 followed by the (CCAA)7 repeat from nucleotide
259-286.  Human exon 2 contains a smaller poly-A sequence, consisting of 6
adenosine residues from nucleotide 242-247, followed by two CCAA repeats from
nucleotide 250-257.  The mouse Pax6 sequence does not contain a poly-A, or a CCAA
repeat.  Microsatellite repeats are common in mammalian DNA, and are highly
polymorphic among individuals.
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Neither of the canine PAX6 intron 2 SNPs identified in this study (intron
2(+27), and intron 2(+51)), were associated with splice donor or acceptor sites, and
therefore should not affect post-transcriptional processing.  However, the intron
2(+51) SNP was associated with a CTT microsatellite, and intronic microsatellites can
be significant as in the case of Friedrich’s ataxia which involves a GAA repeat
expansion in intron 1 of the FRDA gene (47).  Nevertheless, the occurrence of this
SNP in a normal control (beagle) dog suggests that it is truly insignificant.  The
Human PAX6 Allelic Variant Database (http://PAX6.hgu.mrc.ac.uk/) contains one
unique mutation in intron 2 which involves a deletion of an invariant adenine (A)
residue at the 3’ end splice acceptor site (position –2) (48).  The effect of this mutation
on the corresponding RNA and amino acid products has not been determined, but it is
expected to alter the splicing of exon 3, and in fact segregates with aniridia in two
patients (48).
The exon 7 SNP located within the coding region was previously described in
a family of Catalan sheepdogs with inherited aniridia (27).  This SNP occured in the
Linker region of PAX6 between the paired and homeo domains, and created a
synonymous change at codon 167 (CT: ACC, ACT= threonine).  The Human PAX6
Allelic Variant database (http://PAX6.hgu.mrc.ac.uk/) contains 20 unique mutations in
exon 7 which include insertions, deletions, missense, and nonsense changes.  A
cytosine to thymine (CT) change in human exon 7, codon 140 creates a
synonymous change (GAC, GAT = Aspartic acid) associated with a normal phenotype
(49).  This SNP also occurs in the Linker region.
The canine exon 12 SNP (GA: CAG, CAA = glutamine) occurred at codon
392, in the proline-serine-threonine (PST) region, and represented the second
synonymous change identified in this study.  In man there are 17 unique mutations
described in exon 12 including  insertions, deletions, missense, and nonsense
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mutations, but no synonymous changes (http://PAX6.hgu.mrc.ac.uk/), hence, this
sequence change is considered non-pathogenic.
The four SNPs and 2 microsatellites identified here are not expected to alter
the PAX6 coding sequence or the corresponding amino acids. However, before PAX6
can be definitively excluded as a candidate gene for cataracts in Siberian huskies,
PPM in Basenjis, and PPM, sclero-cornea, and choroidal hypoplasia in SCWTs,
additional pedigree information is needed from each breed for association testing of
the disease phenotype with the PAX6 locus.  Tissue samples from normal and affected
dogs should also be obtained for PAX6 RNA and protein expression studies.  The lack
of pathological mutations in the 14 exons of the canine PAX6 gene, including both
coding, and non-coding exons, as well as intron/exon boundaries (splice sites),
however, suggests that PAX6 is not involved in the diseases examined.
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CHAPTER 5
CONCLUSION
Cataracts are the number one cause of blindness and low vision throughout the
world.  Over twenty-six million (22%) Americans greater than 40 years of age, have
cataracts, or have undergone cataract surgery (1).    Although cataracts can be
successfully treated surgically, many people do not have access to health care that
would provide this service.  As a result, there is a need to understand how and why
cataracts develop, with the hope of one day discovering a way to prevent, delay, or
even medically cure cataracts.  The study of congenital cataracts in man, as well as the
study of cataracts in animal models, has helped to identify genes involved in
cataractogenesis.  As the functions of these genes are elucidated, we will increase our
understanding of the mechanisms involved in cataract formation.  The purpose of my
thesis research was to facilitate the development of canine models of cataract, which
could contribute to our understanding of the genes and mechanisms involved in
cataract development.
When the Radiation Hybrid mapping project began (Chapter 2), the canine
genome was not yet publicly available.  The goal of the mapping project was to
establish the locations of cataract gene homologues on canine chromosomes in relation
to nearby markers.  Polymorphic markers located near cataract genes can be used in
association analysis to test for association of these genes with cataract phenotypes in
canine pedigrees.  This tool was created to facilitate association and linkage testing in
canine pedigrees with inherited cataracts, and to support the use of canine models to
study cataracts.  Once association is established between a cataract phenotype and a
candidate gene locus, the gene can be sequenced, and analyzed for the presence of
disease-causing mutations.
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Recently, mutations causing cataracts in three dog breeds were identified in
heat shock factor 4 (HSF4) (2), one of the candidate genes we mapped to canine
chromosome 5.  The markers on CFA5 , identified in the RH-mapping project may
also be useful in linking HSF4 to other cataract phenotypes in additional breeds.
Furthermore, single nucleotide polymorphism (SNP) databases now exists that provide
the locations of SNPs within the canine genome.  The genomic locations determined
for the cataract homologues in the RH-mapping project, can also be used to select
nearby SNPs from these databases for association analysis. This is especially useful in
cases where microsatellites are sparse or if the microsatellites identified are not
polymorphic in the pedigree of interest.
Although the canine genomic sequence is now publicly available, many genes
have not been annotated within the sequence.  In addition, there are gaps throughout
the genome where the sequence has not yet been determined, and these gaps may
contain genes or parts of genes.  For example, the cloning and characterization of the
cataract candidate gene PAX6 provided the annotated canine gene sequence, as well as
sequences for two large gaps in the canine genome (Chapter 3).  In addition, because
PAX6 is the primary aniridia gene in man, it was examined for mutations causing
aniridia in dogs.  However, no mutations were identified in the coding regions or
splice sites examined.  As a result, canine aniridia may be caused by a novel gene, and
may even involve alternate mechanisms of pathogenesis compared with human
aniridia.  However, it is also possible that dogs affected with aniridia have a PAX6
mutation in an area that was not examined, i.e. in an intron, a promoter, or other
regulatory element.  To rule out this possibility, additional pedigree information is
needed to first, confirm the mode of inheritance of canine aniridia, and second, to
definitively determine if an association exists between canine aniridia, and PAX6.  If
an association is established, then a search for mutations outside of the coding region
162
should be pursued.  As well, ocular tissue samples are needed for both gene (mRNA),
and protein expression analysis, to demonstrate potential differences in PAX6
expression in normal versus affected dogs.
PAX6 was also examined for mutations causing cataracts, PPM, sclero-cornea,
and choroidal hypoplasia in three dog breeds (Chapter 4).  Again, no pathological
mutations were identified by direct sequencing within the PAX6 coding regions, or
splice sites.   Unfortunately, sufficient pedigree information necessary to test for an
association between the phenotypes examined and the PAX6 locus, was not available
for the dogs used in this study.  However, by working with Siberian husky, Basenji,
and SCWT breeders, we may obtain additional pedigree information and DNA
samples from dogs which can be used to overcome this limitation.  If markers at the
PAX6 locus co-segregate with the phenotypes of any of the breeds examined, then the
non-coding regions of PAX6 should be examined in those breeds.   In addition, gene
(mRNA), and protein expression should be analyzed.
Today many tools exist which support the development and use of canine
models to study cataracts at the molecular level.  These include the canine genomic
sequence, gene maps, miscrosatellite and SNP markers, and Minimal Screening Sets
(MSS) for genome wide scans.  In addition, a large number of dog breeds are afflicted
with naturally-occurring cataract phenotypes.  Informative pedigrees from these
breeds, can be used to determine the mode of inheritance of the observed cataract
phenotypes.  As well, DNA samples from selected members of these pedigrees can be
used to test for linkage or association of the phenotype with cataract gene loci.  This
may be done using microsatellite or SNP markers from public databases, as well as
SNPs independently discovered within the gene sequence.  In addition, genome wide
scans performed with the Minimal Screening Sets now available, may help to identify
new cataract genes.  Once the genes responsible for canine cataracts are identified, the
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molecular mechanisms involved can be elucidated, creating new animal models which
can be used to study non-surgical therapeutic interventions, including pharmaceutical
and gene therapies.  Finally, the dog can serve as an intermediate mammalian species
model for assessing gene therapy interventions, after testing in rodents, and before
implementing in human patients.  The results of this research have taken initial steps
to show that the dog is indeed a viable model for molecular studies of cataracts.
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